

Understanding the tumor immune microenvironment (

Nature Medicine

24, 541-550

DOI: [10.1038/s41591-018-0014-x](https://doi.org/10.1038/s41591-018-0014-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Physical Activity and Colorectal Cancer Prognosis According to Tumor-Infiltrating T Cells. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky058.	1.4	10
2	Cancer/testis Antigen MAGEA3 Interacts with STAT1 and Remodels the Tumor Microenvironment. <i>International Journal of Medical Sciences</i> , 2018, 15, 1702-1712.	1.1	12
4	Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 3081.	2.2	116
5	Dissecting the Immune Landscape of Acute Myeloid Leukemia. <i>Biomedicines</i> , 2018, 6, 110.	1.4	32
6	Hypoxic Microenvironment and Metastatic Bone Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3523.	1.8	51
7	Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors. <i>Genes</i> , 2018, 9, 633.	1.0	26
8	Ex Vivo Tumor-on-a-Chip Platforms to Study Intercellular Interactions within the Tumor Microenvironment. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801198.	3.9	49
10	Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using ⁶⁴ Cu-Labeled Macrin. <i>ACS Nano</i> , 2018, 12, 12015-12029.	7.3	117
11	Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 1977.	2.2	123
12	The Multiple Layers of the Tumor Environment. <i>Trends in Cancer</i> , 2018, 4, 802-809.	3.8	55
13	Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology. <i>Frontiers in Oncology</i> , 2018, 8, 430.	1.3	57
14	Tim-3 expression and its role in hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 126.	6.9	89
15	The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one. <i>Cancer Treatment Reviews</i> , 2018, 70, 41-46.	3.4	21
16	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. <i>Advanced Functional Materials</i> , 2018, 28, 1802540.	7.8	92
17	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1878.	1.8	34
18	Tracking Cell Recruitment and Behavior within the Tumor Microenvironment Using Advanced Intravital Imaging Approaches. <i>Cells</i> , 2018, 7, 69.	1.8	11
19	CARs versus BiTEs: A Comparison between T Cell Redirection Strategies for Cancer Treatment. <i>Cancer Discovery</i> , 2018, 8, 924-934.	7.7	173
20	Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases. <i>British Journal of Cancer</i> , 2018, 119, 737-743.	2.9	41

#	ARTICLE	IF	CITATIONS
21	Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. <i>Pharmacological Research</i> , 2018, 136, 151-159.	3.1	85
22	The Neutrophil-Lymphocyte Ratio Is an Independent Prognostic Factor for Overall Survival in Hispanic Patients with Gastric Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 728-734.	0.6	6
23	The role of dendritic cells in cancer. <i>International Review of Cell and Molecular Biology</i> , 2019, 348, 123-178.	1.6	110
24	Sphingosine-1-Phosphate and Macrophage Biologyâ€”How the Sphinx Tames the Big Eater. <i>Frontiers in Immunology</i> , 2019, 10, 1706.	2.2	80
25	Carbon nanotube based dielectric spectroscopy of tumor secretion; electrochemical lipidomics for cancer diagnosis. <i>Biosensors and Bioelectronics</i> , 2019, 142, 111566.	5.3	11
26	Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy. <i>Scientific Reports</i> , 2019, 9, 11617.	1.6	35
27	Tuning the Tumor Myeloid Microenvironment to Fight Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1611.	2.2	96
28	The great debate at â€œImmunotherapy Bridge 2018â€, Naples, November 29th, 2018. , 2019, 7, 221.		4
29	Selfâ€Amplified Drug Delivery with Lightâ€Inducible Nanocargoes to Enhance Cancer Immunotherapy. <i>Advanced Materials</i> , 2019, 31, e1902960.	11.1	192
30	AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 5034-5047.	0.4	37
32	The Spatial and Genomic Hierarchy of Tumor Ecosystems Revealed by Single-Cell Technologies. <i>Trends in Cancer</i> , 2019, 5, 411-425.	3.8	44
33	Usefulness of the nCounter Analysis System to Monitor Immune-related Biomarkers in PBMCs During Anti-PD-1 Therapy. <i>Anticancer Research</i> , 2019, 39, 4517-4523.	0.5	1
34	Tissue Site and the Cancer Immunity Cycle. <i>Trends in Cancer</i> , 2019, 5, 593-603.	3.8	37
35	Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer. <i>Nature Communications</i> , 2019, 10, 3817.	5.8	61
36	The prognostic role of tumourâ€infiltrating lymphocytes in oral squamous cell carcinoma: A metaâ€analysis. <i>Journal of Oral Pathology and Medicine</i> , 2019, 48, 788-798.	1.4	35
37	Effects of pericytes and colon cancer stem cells in the tumor microenvironment. <i>Cancer Cell International</i> , 2019, 19, 173.	1.8	39
38	Inflammation and Cancer: Triggers, Mechanisms, and Consequences. <i>Immunity</i> , 2019, 51, 27-41.	6.6	1,946
39	HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 5482-5489.	0.4	86

#	ARTICLE	IF	CITATIONS
40	Correlation Analysis of Histopathology and Proteogenomics Data for Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2019, 18, S37-S51.	2.5	24
41	Intersection of the p63 and NF- κ B pathways in epithelial homeostasis and disease. <i>Molecular Carcinogenesis</i> , 2019, 58, 1571-1580.	1.3	13
42	Subtyping of microsatellite instability-high colorectal cancer. <i>Cell Communication and Signaling</i> , 2019, 17, 79.	2.7	42
43	Computational approaches for characterizing the tumor immune microenvironment. <i>Immunology</i> , 2019, 158, 70-84.	2.0	30
44	Association of two <i>BRM</i> promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. <i>Molecular Carcinogenesis</i> , 2019, 58, 1960-1973.	1.3	1
45	Plasma-Derived Reactive Species Shape a Differentiation Profile in Human Monocytes. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 2530.	1.3	22
46	Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy. <i>Cancer Science</i> , 2019, 110, 2620-2628.	1.7	27
47	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. <i>Cancers</i> , 2019, 11, 942.	1.7	66
48	Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. <i>Scientific Reports</i> , 2019, 9, 15099.	1.6	40
49	Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue. <i>Science Immunology</i> , 2019, 4, .	5.6	95
50	Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis. <i>Advanced Materials</i> , 2019, 31, e1904156.	11.1	120
51	The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5080.	1.8	39
52	MicroRNA delivery through nanoparticles. <i>Journal of Controlled Release</i> , 2019, 313, 80-95.	4.8	235
53	NK Cell-Fc Receptors Advance Tumor Immunotherapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1667.	1.0	17
54	Immune-Based Therapies in Acute Leukemia. <i>Trends in Cancer</i> , 2019, 5, 604-618.	3.8	32
55	Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy. <i>ACS Nano</i> , 2019, 13, 12671-12686.	7.3	86
56	The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1733-1745.	2.0	72
57	LncRNAs as Chromatin Regulators in Cancer: From Molecular Function to Clinical Potential. <i>Cancers</i> , 2019, 11, 1524.	1.7	59

#	ARTICLE	IF	CITATIONS
58	Noninvasive imaging in cancer immunotherapy: The way to precision medicine. <i>Cancer Letters</i> , 2019, 466, 13-22.	3.2	19
59	Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2019, 121, 819-826.	2.9	2
60	Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses. <i>Journal of Experimental Medicine</i> , 2019, 216, 2854-2868.	4.2	49
61	Comprehensive Benchmarking and Integration of Tumor Microenvironment Cell Estimation Methods. <i>Cancer Research</i> , 2019, 79, 6238-6246.	0.4	116
62	Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression. <i>Aging Cell</i> , 2019, 18, e13027.	3.0	79
63	Gastric Cancer in the Era of Immune Checkpoint Blockade. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	23
64	Imaging of T-cells and their responses during anti-cancer immunotherapy. <i>Theranostics</i> , 2019, 9, 7924-7947.	4.6	77
65	Theranostics in immuno-oncology using nanobody derivatives. <i>Theranostics</i> , 2019, 9, 7772-7791.	4.6	83
66	Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models. <i>Npj Breast Cancer</i> , 2019, 5, 39.	2.3	16
67	Smart cancer nanomedicine. <i>Nature Nanotechnology</i> , 2019, 14, 1007-1017.	15.6	776
68	Neutrophil activation causes tumor regression in Walker 256 tumor-bearing rats. <i>Scientific Reports</i> , 2019, 9, 16524.	1.6	13
69	Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity. <i>Cell Reports</i> , 2019, 29, 1236-1248.e7.	2.9	187
70	Studying immune to non-immune cell cross-talk using single-cell technologies. <i>Current Opinion in Systems Biology</i> , 2019, 18, 87-94.	1.3	5
71	Inflammation, Cancer and Immunity—Implication of TRPV1 Channel. <i>Frontiers in Oncology</i> , 2019, 9, 1087.	1.3	157
72	Sequential MR Image-Guided Local Immune Checkpoint Blockade Cancer Immunotherapy Using Ferumoxytol Capped Ultralarge Pore Mesoporous Silica Carriers after Standard Chemotherapy. <i>Small</i> , 2019, 15, e1904378.	5.2	36
73	Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. , 2019, 7, 288.		22
74	Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1782.	2.2	45
75	Linkage of CD8+ T cell exhaustion with high-fat diet-induced tumorigenesis. <i>Scientific Reports</i> , 2019, 9, 12284.	1.6	48

#	ARTICLE	IF	CITATIONS
76	Tumours pick the path to cancer inflammation. <i>Nature Cell Biology</i> , 2019, 21, 1055-1057.	4.6	4
78	Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma. <i>Journal of Receptor and Signal Transduction Research</i> , 2019, 39, 208-214.	1.3	57
79	Molecular profiling of transcription factors pinpoints MYC-estrogen related receptor regulatory factor X5 panel for characterizing the immune microenvironment and predicting the efficacy of immune checkpoint inhibitors in renal cell carcinoma. <i>Oncology Letters</i> , 2019, 18, 1895-1903.	0.8	1
80	siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion. <i>Translational Research</i> , 2019, 214, 105-120.	2.2	48
81	The Role of Circular RNA CDR1as/ciRS-7 in Regulating Tumor Microenvironment: A Pan-Cancer Analysis. <i>Biomolecules</i> , 2019, 9, 429.	1.8	87
82	Improving cancer immunotherapy through nanotechnology. <i>Nature Reviews Cancer</i> , 2019, 19, 587-602.	12.8	426
83	Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC. <i>Cancers</i> , 2019, 11, 1306.	1.7	52
84	Extracellular K ⁺ Dampens T Cell Functions: Implications for Immune Suppression in the Tumor Microenvironment. <i>Bioelectricity</i> , 2019, 1, 169-179.	0.6	17
85	In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?. <i>Frontiers in Immunology</i> , 2019, 10, 2303.	2.2	11
86	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. , 2019, 7, 255.		123
87	Cerenkov Luminescence-Induced NO Release from ³² P-Labeled ZnFe(CN) ₅ NO Nanosheets to Enhance Radioisotope-Immunotherapy. <i>Matter</i> , 2019, 1, 1061-1076.	5.0	70
88	Modulation of the inflammatory tumor microenvironment: a new approach for photothermal-synergized cancer immunotherapy. <i>Nanomedicine</i> , 2019, 14, 2101-2104.	1.7	5
89	Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	19
90	Controlling the Phenotype of Tumor-Infiltrating Macrophages via the PHD-HIF Axis Inhibits Tumor Growth in a Mouse Model. <i>IScience</i> , 2019, 19, 940-954.	1.9	24
91	Immunobiology of cholangiocarcinoma. <i>JHEP Reports</i> , 2019, 1, 297-311.	2.6	79
92	TCR-like antibodies in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 99.	6.9	39
93	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	1.0	41
94	IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells. <i>Cancer Immunology Research</i> , 2019, 7, 1944-1957.	1.6	61

#	ARTICLE	IF	CITATIONS
95	Tumors vs. Chronic Wounds: An Immune Cell's Perspective. <i>Frontiers in Immunology</i> , 2019, 10, 2178.	2.2	52
96	Iron chelated melanin-like nanoparticles for tumor-associated macrophage repolarization and cancer therapy. <i>Biomaterials</i> , 2019, 225, 119515.	5.7	118
97	Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. <i>Drug Resistance Updates</i> , 2019, 46, 100644.	6.5	133
98	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. <i>Cancer Microenvironment</i> , 2019, 12, 119-132.	3.1	46
99	Trends and Challenges in Tumor Anti-Angiogenic Therapies. <i>Cells</i> , 2019, 8, 1102.	1.8	150
100	Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. <i>Nature Nanotechnology</i> , 2019, 14, 269-278.	15.6	406
101	Delivery of 5â€²-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy. <i>Biomaterials Science</i> , 2019, 7, 547-559.	2.6	49
102	The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2019, 11, 140.	1.7	18
103	The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2018, 9, 3120.	2.2	28
104	3Dâ€œBioprinted Miniâ€œBrain: A Glioblastoma Model to Study Cellular Interactions and Therapeutics. <i>Advanced Materials</i> , 2019, 31, e1806590.	11.1	168
105	Tumor Microenvironment Modulates Immunological Outcomes of Myeloid Cells with mTORC1 Disruption. <i>Journal of Immunology</i> , 2019, 202, 1623-1634.	0.4	8
106	Quantifying Leukocyte Egress via Lymphatic Vessels from Murine Skin and Tumors. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	16
107	The innate immune architecture of lung tumors and its implication in disease progression. <i>Journal of Pathology</i> , 2019, 247, 589-605.	2.1	32
108	Adaptive Transcriptional Responses by CRTC Coactivators in Cancer. <i>Trends in Cancer</i> , 2019, 5, 111-127.	3.8	14
109	Saikosaponin A Inhibits Breast Cancer by Regulating Th1/Th2 Balance. <i>Frontiers in Pharmacology</i> , 2019, 10, 624.	1.6	103
110	Cell Type-Specific p38Î³ Targeting Reveals a Context-, Stage-, and Sex-Dependent Regulation of Skin Carcinogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1532.	1.8	10
111	Probing Single-Cell Mechanical Allostasis Using Ultrasound Tweezers. <i>Cellular and Molecular Bioengineering</i> , 2019, 12, 415-427.	1.0	10
112	Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2970.	1.8	53

#	ARTICLE	IF	CITATIONS
113	Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 193, 105415.	1.2	44
114	The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. <i>Cells</i> , 2019, 8, 613.	1.8	60
115	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 240-247.	1.3	13
116	Phage display screening of therapeutic peptide for cancer targeting and therapy. <i>Protein and Cell</i> , 2019, 10, 787-807.	4.8	163
117	Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. <i>Journal of Clinical Medicine</i> , 2019, 8, 762.	1.0	53
118	Unraveling the ECM-Immune Cell Crosstalk in Skin Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 68.	1.8	83
119	Tumour-associated neutrophils in patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 601-620.	12.5	558
120	Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion. <i>Cancer Research</i> , 2019, 79, 3903-3915.	0.4	68
121	Hypoxia and Cancer Metastasis. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	5
122	Hypoxia-Induced Resistance to Chemotherapy in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1136, 123-139.	0.8	58
123	Combining Nanomedicine and Immunotherapy. <i>Accounts of Chemical Research</i> , 2019, 52, 1543-1554.	7.6	310
124	Turning the Tide Against Regulatory T Cells. <i>Frontiers in Oncology</i> , 2019, 9, 279.	1.3	47
125	Current Status of Immunotherapies for Treating Pancreatic Cancer. <i>Current Oncology Reports</i> , 2019, 21, 60.	1.8	38
126	Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy. <i>AAPS Journal</i> , 2019, 21, 64.	2.2	21
127	Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model. <i>Journal of Bone Oncology</i> , 2019, 16, 100238.	1.0	9
128	Fast and robust deconvolution of tumor infiltrating lymphocyte from expression profiles using least trimmed squares. <i>PLoS Computational Biology</i> , 2019, 15, e1006976.	1.5	61
129	High-Throughput Microfluidic 3D Cytotoxicity Assay for Cancer Immunotherapy (CACI-IMPACT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 100	2.2	69
130	Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. <i>Cancer Cell</i> , 2019, 35, 767-781.e6.	7.7	91

#	ARTICLE	IF	CITATIONS
131	Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression. <i>Frontiers in Immunology</i> , 2019, 10, 771.	2.2	146
132	Targeting Delivery of Oligodeoxynucleotides to Macrophages by Mannosylated Cationic Albumin for Immune Stimulation in Cancer Treatment. <i>Molecular Pharmaceutics</i> , 2019, 16, 2616-2625.	2.3	14
133	Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments. <i>Journal of Controlled Release</i> , 2019, 305, 130-154.	4.8	40
134	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1903.	1.8	15
135	Beyond the tumour microenvironment. <i>International Journal of Cancer</i> , 2019, 145, 2611-2618.	2.3	71
136	Engineering Multidimensional Evolutionary Forces to Combat Cancer. <i>Cancer Discovery</i> , 2019, 9, 587-604.	7.7	13
137	Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 691.	2.2	63
138	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	6.9	58
139	CCL2/CCR2 Axis Promotes the Progression of Salivary Adenoid Cystic Carcinoma via Recruiting and Reprogramming the Tumor-Associated Macrophages. <i>Frontiers in Oncology</i> , 2019, 9, 231.	1.3	54
140	The Role of the Immune System in Cutaneous Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2009.	1.8	81
141	Prognostic significance of CD68+ and CD163+ tumor associated macrophages in head and neck squamous cell carcinoma: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2019, 93, 66-75.	0.8	115
142	3D models in the new era of immune oncology: focus on T cells, CAF and ECM. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 117.	3.5	78
143	miRNA-223 at the crossroads of inflammation and cancer. <i>Cancer Letters</i> , 2019, 451, 136-141.	3.2	66
144	Smart pH-Responsive Nanocube-Controlled Delivery of DNA Vaccine and Chemotherapeutic Drugs for Chemoimmunotherapy. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 13058-13068.	4.0	17
145	Genomic correlates of response to immune checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 389-402.	15.2	346
146	Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. <i>Cancers</i> , 2019, 11, 298.	1.7	10
147	The Immune Subtypes and Landscape of Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 3528-3537.	3.2	136
148	Pharmacodynamic Drug-Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1395-1406.	2.3	101

#	ARTICLE	IF	CITATIONS
149	Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects. <i>Engineering</i> , 2019, 5, 106-114.	3.2	30
150	Checkpoint Blockade Strategies in the Treatment of Breast Cancer: <i>Where We Are and Where We Are Heading</i> . <i>Current Treatment Options in Oncology</i> , 2019, 20, 35.	1.3	44
151	Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 123.	3.5	32
152	TLR3 Activation of Intratumoral CD103+ Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 503.	2.2	24
153	Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. <i>Immunity</i> , 2019, 50, 1317-1334.e10.	6.6	897
154	An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma. <i>Oncotarget</i> , 2019, 10, 1840-1849.	0.8	19
155	Pathogenesis of Nasopharyngeal Carcinoma. , 2019, , 45-64.		3
156	Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogeneic Bone Marrow Transplantation. <i>Cancer Research</i> , 2019, 79, 2709-2721.	0.4	7
157	Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. <i>Cell</i> , 2019, 177, 556-571.e16.	13.5	405
158	Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1. <i>Nano Letters</i> , 2019, 19, 2935-2944.	4.5	134
159	Podoplanin Positive Myeloid Cells Promote Glioma Development by Immune Suppression. <i>Frontiers in Oncology</i> , 2019, 9, 187.	1.3	12
160	Genome-Wide and Phenotypic Evaluation of Stem Cell Progenitors Derived From Gprc5a-Deficient Murine Lung Adenocarcinoma With Somatic Kras Mutations. <i>Frontiers in Oncology</i> , 2019, 9, 207.	1.3	11
161	Perspectives on immunotherapy via oncolytic viruses. <i>Infectious Agents and Cancer</i> , 2019, 14, 5.	1.2	24
162	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801320.	3.9	43
163	Targeting mTOR in Acute Lymphoblastic Leukemia. <i>Cells</i> , 2019, 8, 190.	1.8	44
164	Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans. <i>Cancers</i> , 2019, 11, 183.	1.7	21
165	Tumor-associated macrophages: a short compendium. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1447-1458.	2.4	71
166	Heterogeneity of neutrophils. <i>Nature Reviews Immunology</i> , 2019, 19, 255-265.	10.6	416

#	ARTICLE	IF	CITATIONS
167	Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade. <i>Advanced Materials</i> , 2019, 31, e1805888.	11.1	374
168	Kinetic Aspects of the Interplay of Cancer and the Immune System. <i>Biophysical Reviews and Letters</i> , 2019, 14, 101-114.	0.9	3
169	Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs. <i>Cancer Research</i> , 2019, 80, canres.1425.2019.	0.4	13
170	MicroRNA-155 coordinates the immunological landscape within murine melanoma and correlates with immunity in human cancers. <i>JCI Insight</i> , 2019, 4, .	2.3	31
171	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2019, 11, 1753.	1.7	16
172	TSLP: from allergy to cancer. <i>Nature Immunology</i> , 2019, 20, 1603-1609.	7.0	132
173	Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. <i>Genes and Development</i> , 2019, 33, 1641-1656.	2.7	9
174	Biodegradable hollow manganese/cobalt oxide nanoparticles for tumor theranostics. <i>Nanoscale</i> , 2019, 11, 23021-23026.	2.8	35
175	Enhanced Anti-melanoma Efficacy of a Pim-3-Targeting Bifunctional Small Hairpin RNA via Single-Stranded RNA-Mediated Activation of Plasmacytoid Dendritic Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2721.	2.2	9
176	Identification of a Subtype of Hepatocellular Carcinoma with Poor Prognosis Based on Expression of Genes within the Glucose Metabolic Pathway. <i>Cancers</i> , 2019, 11, 2023.	1.7	11
177	Immune receptor repertoires in pediatric and adult acute myeloid leukemia. <i>Genome Medicine</i> , 2019, 11, 73.	3.6	38
178	Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2019, 10, 2936.	2.2	97
179	Allies or Enemies? The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 2746.	2.2	41
180	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. <i>Cancer Cell</i> , 2019, 36, 613-629.e7.	7.7	99
181	Comparative Approach to the Temporo-Spatial Organization of the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2019, 9, 1185.	1.3	9
182	Immunology of Adenoviral Vectors in Cancer Therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 418-429.	1.8	54
183	Tissue-specific tumor microenvironments influence responses to immunotherapies. <i>Clinical and Translational Immunology</i> , 2019, 8, e1094.	1.7	20
184	XIAOPI Formula Inhibits Breast Cancer Stem Cells via Suppressing Tumor-Associated Macrophages/C-X-C Motif Chemokine Ligand 1 Pathway. <i>Frontiers in Pharmacology</i> , 2019, 10, 1371.	1.6	19

#	ARTICLE	IF	CITATIONS
185	BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design. <i>Frontiers in Immunology</i> , 2019, 10, 2806.	2.2	225
186	Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2928.	2.2	25
187	Enterotoxins can support CAR T cells against solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25229-25235.	3.3	16
188	Recruitment of CD103 dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. <i>Science Advances</i> , 2019, 5, eaay1357.	4.7	87
189	From cachexia to obesity: the role of host metabolism in cancer immunotherapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 305-310.	0.5	16
190	Immune Cell Infiltration in the Microenvironment of Liver Oligometastasis from Colorectal Cancer: Intratumoural CD8/CD3 Ratio Is a Valuable Prognostic Index for Patients Undergoing Liver Metastasectomy. <i>Cancers</i> , 2019, 11, 1922.	1.7	11
191	GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. <i>Science Immunology</i> , 2019, 4, .	5.6	85
192	Redirecting T cells to treat solid pediatric cancers. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 611-624.	2.7	3
193	Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction. <i>Frontiers in Oncology</i> , 2019, 9, 1408.	1.3	17
195	Rho GTPase signaling regulates tumor-microenvironment interactions. <i>Biochemical Society Transactions</i> , 2019, 47, 101-108.	1.6	35
196	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. <i>Cell</i> , 2019, 176, 775-789.e18.	13.5	760
197	Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. <i>Oncotarget</i> , 2019, 8, 1553477.	2.1	103
198	Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 510-524.	0.6	179
199	The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. <i>Lung Cancer</i> , 2019, 127, 153-163.	0.9	77
200	Progress in Tumor-Associated Macrophages: From Bench to Bedside. <i>Advanced Biology</i> , 2019, 3, e1800232.	3.0	12
201	Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder. <i>Histopathology</i> , 2019, 75, 354-364.	1.6	4
202	Delivery technologies for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 175-196.	21.5	1,562
203	The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 142-158.	2.9	218

#	ARTICLE	IF	CITATIONS
204	Comparing the effects of different cell death programs in tumor progression and immunotherapy. <i>Cell Death and Differentiation</i> , 2019, 26, 115-129.	5.0	74
205	The Ratio of Peripheral Regulatory T Cells to Lox-1 ⁺ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 243-246.	2.5	85
206	Tumor microenvironment: Interactions and therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 5700-5721.	2.0	144
207	Contribution of regulatory T cells to cancer: A review. <i>Journal of Cellular Physiology</i> , 2019, 234, 7983-7993.	2.0	136
208	Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?. <i>Bulletin Du Cancer</i> , 2019, 106, 105-113.	0.6	35
209	Nanomedicine and macroscale materials in immuno-oncology. <i>Chemical Society Reviews</i> , 2019, 48, 351-381.	18.7	118
210	Transforming growth factor- β signaling: Tumorigenesis and targeting for cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 12173-12187.	2.0	115
211	CD8 ⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review. <i>Journal of Cellular Physiology</i> , 2019, 234, 8509-8521.	2.0	1,012
212	Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. <i>Hepatology</i> , 2019, 69, 1803-1815.	3.6	195
213	Macrophage polarity in cancer: A review. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 2756-2765.	1.2	362
214	NOX2 in autoimmunity, tumor growth and metastasis. <i>Journal of Pathology</i> , 2019, 247, 151-154.	2.1	50
215	CRISPR technology for immuno-oncology applications. <i>Methods in Enzymology</i> , 2020, 635, 251-266.	0.4	1
216	The emerging role of epigenetic therapeutics in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 75-90.	12.5	260
217	Radiosensitive core/satellite ternary heteronanostructure for multimodal imaging-guided synergistic cancer radiotherapy. <i>Biomaterials</i> , 2020, 226, 119545.	5.7	55
218	Identification of non-cancer cells from cancer transcriptomic data. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2020, 1863, 194445.	0.9	7
219	At the bench: Engineering the next generation of cancer vaccines. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1435-1453.	1.5	22
220	Techniques for the generation of humanized mouse models for immuno-oncology. <i>Methods in Enzymology</i> , 2020, 636, 351-368.	0.4	5
221	Immunological and Clinicopathological Significance of MFG-E8 Expression in Patients with Oral Squamous Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 1263-1268.	0.9	3

#	ARTICLE	IF	CITATIONS
222	Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues. <i>Methods in Enzymology</i> , 2020, 635, 149-166.	0.4	4
223	Defining the "Metastosome": Perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences. <i>Seminars in Cancer Biology</i> , 2020, 60, 1-13.	4.3	20
224	Lactoferrin deficiency induces a pro-metastatic tumor microenvironment through recruiting myeloid-derived suppressor cells in mice. <i>Oncogene</i> , 2020, 39, 122-135.	2.6	18
225	Targeted cancer immunotherapy with genetically engineered oncolytic <i>Salmonella typhimurium</i> . <i>Cancer Letters</i> , 2020, 469, 102-110.	3.2	67
226	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2020, 206, 107438.		117
227	Metabolic reprogramming in tumors: Contributions of the tumor microenvironment. <i>Genes and Diseases</i> , 2020, 7, 185-198.	1.5	45
228	Cellular Plasticity during Metastasis: New Insights Provided by Intravital Microscopy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037267.	2.9	10
229	Metabolic Fitness and Plasticity in Cancer Progression. <i>Trends in Cancer</i> , 2020, 6, 49-61.	3.8	76
230	Ultrafast Low-Temperature Photothermal Therapy Activates Autophagy and Recovers Immunity for Efficient Antitumor Treatment. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 4265-4275.	4.0	48
231	Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. <i>Nanoscale</i> , 2020, 12, 413-436.	2.8	49
232	Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 140-154.	4.3	66
233	Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. <i>Cancers</i> , 2020, 12, 99.	1.7	23
235	Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. <i>Autophagy</i> , 2020, 16, 2069-2083.	4.3	319
237	Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy. <i>Biomaterials Science</i> , 2020, 8, 1045-1057.	2.6	20
238	A multi-functional drug delivery system based on polyphenols for efficient tumor inhibition and metastasis prevention. <i>Biomaterials Science</i> , 2020, 8, 702-711.	2.6	31
239	Polarization of tumor-associated macrophage phenotype <i>via</i> porous hollow iron nanoparticles for tumor immunotherapy <i>in vivo</i> . <i>Nanoscale</i> , 2020, 12, 130-144.	2.8	83
240	Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1302-1313.	3.3	55
241	The tumor organismal environment: Role in tumor development and cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 197-206.	4.3	26

#	ARTICLE	IF	CITATIONS
242	Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1119-1128.	3.3	140
243	Recent Advances in Microfluidic Platforms Applied in Cancer Metastasis: Circulating Tumor Cells' (CTCs) Isolation and Tumor-on-a-Chip. Small, 2020, 16, e1903899.	5.2	76
244	Programmed Cell Death-1/Ligand-1 PET Imaging. PET Clinics, 2020, 15, 35-43.	1.5	34
245	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. Seminars in Cancer Biology, 2020, 65, 114-122.	4.3	45
246	Mechanotactic Activation of TGF β 2 by PEDOT Artificial Microenvironments Triggers Epithelial to Mesenchymal Transition. Advanced Biology, 2020, 4, 1900165.	3.0	2
247	WNT and β -Catenin in Cancer: Genes and Therapy. Annual Review of Cancer Biology, 2020, 4, 177-196.	2.3	39
248	Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy. Pancreatology, 2020, 20, 229-238.	0.5	12
249	Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies. Seminars in Cancer Biology, 2020, 65, 28-37.	4.3	13
250	Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment. Frontiers in Oncology, 2019, 9, 1497.	1.3	38
251	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Review of Respiratory Medicine, 2020, 14, 125-136.	1.0	51
252	Synthetic 3D scaffolds for cancer immunotherapy. Current Opinion in Biotechnology, 2020, 65, 1-8.	3.3	6
253	Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatology International, 2020, 14, 80-95.	1.9	15
254	Expression of Indoleamine 2, 3-dioxygenase 1 (IDO1) and Tryptophanyl-tRNA Synthetase (WARS) in Gastric Cancer Molecular Subtypes. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 360-368.	0.6	26
255	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nature Reviews Clinical Oncology, 2020, 17, 108-123.	12.5	244
256	Sequential depletion of myeloid-derived suppressor cells and tumor cells with a dual-pH-sensitive conjugated micelle system for cancer chemoimmunotherapy. Journal of Controlled Release, 2020, 317, 43-56.	4.8	27
257	Sexual dimorphism in gastric cancer: tumor-associated neutrophils predict patient outcome only for women. Journal of Cancer Research and Clinical Oncology, 2020, 146, 53-66.	1.2	17
258	Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma. Journal of Immunological Methods, 2020, 478, 112714.	0.6	38
259	1,25-Dihydroxyvitamin D (1,25(OH)2D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC). Journal of Steroid Biochemistry and Molecular Biology, 2020, 198, 105557.	1.2	32

#	ARTICLE	IF	CITATIONS
260	Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma: Where does it come from?. <i>Surgery Today</i> , 2020, 50, 569-576.	0.7	3
261	Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6Chigh Myeloid Cells. <i>Journal of Immunology</i> , 2020, 204, 212-223.	0.4	42
262	Promising approaches in cancer immunotherapy. <i>Immunobiology</i> , 2020, 225, 151875.	0.8	49
263	Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response. <i>International Journal of Molecular Sciences</i> , 2020, 21, 157.	1.8	136
264	The effect of Tai Chi practice on immunological function in cancer survivors. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 58)</i> , 2020, 99, 1041.	0.4	1
265	Regulation of tumor growth by leukocyte-specific protein 1 in T cells. , 2020, 8, e001180.		5
266	<p>Digital Image Analysis of CD8+ and CD3+ Tumor-Infiltrating Lymphocytes in Tongue Squamous Cell Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 8275-8285.	0.9	13
267	Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 2105.	2.2	164
268	Multifunctional peptides for tumor therapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 160, 36-51.	6.6	40
269	Myeloid cells hold the master key for T-ALL spread. <i>Blood</i> , 2020, 136, 1799-1800.	0.6	1
270	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. <i>AAPS Journal</i> , 2020, 22, 132.	2.2	27
271	Probing the Superiority of Diselenium Bond on Docetaxel Dimeric Prodrug Nanoassemblies: Small Roles Taking Big Responsibilities. <i>Small</i> , 2020, 16, e2005039.	5.2	63
272	Challenges and Opportunities for Pancreatic Cancer Immunotherapy. <i>Cancer Cell</i> , 2020, 38, 788-802.	7.7	273
273	Antibody and antibody fragments for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2020, 328, 395-406.	4.8	63
274	CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?. <i>Molecular Therapy</i> , 2020, 28, 2320-2339.	3.7	194
275	Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. <i>Drug Resistance Updates</i> , 2020, 53, 100720.	6.5	107
276	Immunomodulatory activity of IR700-labelled affibody targeting HER2. <i>Cell Death and Disease</i> , 2020, 11, 886.	2.7	20
277	Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 5355-5366.	0.4	9

#	ARTICLE	IF	CITATIONS
278	Focused Ultrasound for Immunomodulation of the Tumor Microenvironment. <i>Journal of Immunology</i> , 2020, 205, 2327-2341.	0.4	37
279	Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 557638.	1.3	23
280	The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma. <i>Cancers</i> , 2020, 12, 2973.	1.7	39
281	Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. , 2020, 8, e001358.		44
282	Integrative analysis of genomic alteration, immune cells infiltration and prognosis of lung squamous cell carcinoma (LUSC) to identify smoking-related biomarkers. <i>International Immunopharmacology</i> , 2020, 89, 107053.	1.7	11
283	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. <i>Human Molecular Genetics</i> , 2020, 29, R214-R225.	1.4	3
284	Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-É signaling. <i>Experimental Cell Research</i> , 2020, 396, 112315.	1.2	74
285	Assessing Immunotherapy with Functional and Molecular Imaging and Radiomics. <i>Radiographics</i> , 2020, 40, 1987-2010.	1.4	22
286	Lymph-directed immunotherapy â€œ Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer. <i>Advanced Drug Delivery Reviews</i> , 2020, 160, 115-135.	6.6	18
287	Breast cancer cell debris diminishes therapeutic efficacy through heme oxygenase-1-mediated inactivation of M1-like tumor-associated macrophages. <i>Neoplasia</i> , 2020, 22, 606-616.	2.3	15
288	Portrait of a CAF: The story of cancer-associated fibroblasts in head and neck cancer. <i>Oral Oncology</i> , 2020, 110, 104972.	0.8	32
289	Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1050-1050.	0.7	31
290	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. <i>Cytotherapy</i> , 2020, 22, 204-213.	0.3	9
291	Selenium nanoparticles regulates selenoprotein to boost cytokine-induced killer cells-based cancer immunotherapy. <i>Nano Today</i> , 2020, 35, 100975.	6.2	72
292	Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation. <i>Science Advances</i> , 2020, 6, .	4.7	86
293	Acoustic-based chemical tools for profiling the tumor microenvironment. <i>Current Opinion in Chemical Biology</i> , 2020, 57, 114-121.	2.8	19
294	Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages â€œ A promising cancer immunotherapy. <i>International Journal of Pharmaceutics</i> , 2020, 590, 119929.	2.6	31
295	Do free radical NETwork and oxidative stress disparities in African Americans enhance their vulnerability to SARS-CoV-2 infection and COVID-19 severity?. <i>Redox Biology</i> , 2020, 37, 101721.	3.9	19

#	ARTICLE	IF	CITATIONS
296	Polymer-loaded hydrogels serve as depots for lactate and mimic "cold" tumor microenvironments. <i>Biomaterials Science</i> , 2020, 8, 6056-6068.	2.6	8
297	Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. <i>Oncogene</i> , 2020, 39, 5553-5569.	2.6	20
298	Tumor microenvironment and future targets of immunotherapy in breast cancer. <i>Translational Breast Cancer Research</i> , 0, 1, 6-6.	0.4	2
299	Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment. <i>Cancers</i> , 2020, 12, 1850.	1.7	70
300	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1875.	1.7	19
301	Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. <i>EBioMedicine</i> , 2020, 57, 102860.	2.7	31
302	Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials. <i>Journal of Controlled Release</i> , 2020, 326, 203-221.	4.8	33
303	Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour. <i>EBioMedicine</i> , 2020, 57, 102850.	2.7	20
304	The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5034.	1.8	30
305	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. <i>Drug Resistance Updates</i> , 2020, 53, 100718.	6.5	103
306	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner. <i>Cancer Immunology Research</i> , 2020, 8, 1180-1192.	1.6	19
307	The Development and Homing of Myeloid-Derived Suppressor Cells: From a Two-Stage Model to a Multistep Narrative. <i>Frontiers in Immunology</i> , 2020, 11, 557586.	2.2	32
308	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. <i>Oncimmunology</i> , 2020, 9, 1841948.	2.1	3
309	Immune Microenvironment Related Competitive Endogenous RNA Network as Powerful Predictors for Melanoma Prognosis Based on WGCNA Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 577072.	1.3	21
310	Trends in biomaterials for three-dimensional cancer modeling. , 2020, , 3-41.		3
311	Metastatic Colonization: Escaping Immune Surveillance. <i>Cancers</i> , 2020, 12, 3385.	1.7	28
312	Engineering Living Bacteria for Cancer Therapy. <i>ACS Applied Bio Materials</i> , 2020, 3, 8136-8145.	2.3	18
313	Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. <i>Immunity</i> , 2020, 53, 1215-1229.e8.	6.6	131

#	ARTICLE	IF	CITATIONS
314	Identification of Tumor Microenvironment-Related Prognostic Biomarkers in Luminal Breast Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 555865.	1.1	16
315	Pan-Cancer Analyses Reveal Prognostic Value of Osteomimicry Across 20 Solid Cancer Types. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 576269.	1.6	3
316	Technical Advancements for Studying Immune Regulation of Disseminated Dormant Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 594514.	1.3	10
317	<p>Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11645-11658.	1.0	21
318	Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. , 2020, 8, e001558.		85
319	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. <i>Frontiers in Genetics</i> , 2020, 11, 548719.	1.1	18
320	The evolving landscape of predictive biomarkers in immuno–oncology with a focus on spatial technologies. <i>Clinical and Translational Immunology</i> , 2020, 9, e1215.	1.7	23
321	Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages. <i>Cancers</i> , 2020, 12, 3526.	1.7	28
322	Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2054-2074.	5.7	65
323	Manipulation of immune–vascular crosstalk: new strategies towards cancer treatment. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2018-2036.	5.7	42
324	CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. <i>Nature Communications</i> , 2020, 11, 6171.	5.8	20
325	The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 569202.	1.3	22
326	Mathematical and Computational Oncology. <i>Lecture Notes in Computer Science</i> , 2020, , .	1.0	0
327	Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors. <i>Vaccines</i> , 2020, 8, 733.	2.1	10
328	Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. <i>Scientific Reports</i> , 2020, 10, 19296.	1.6	39
329	Prognostic value of tumor infiltrating lymphocytes combined with PD-L1 expression for patients with solitary colorectal cancer liver metastasis. <i>Annals of Translational Medicine</i> , 2020, 8, 1221-1221.	0.7	14
330	The Role of Chemokines in the Development of Gastric Cancer–Diagnostic and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8456.	1.8	16
331	Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 582884.	1.3	23

#	ARTICLE	IF	CITATIONS
332	Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. <i>Lung Cancer</i> , 2020, 148, 1-11.	0.9	68
333	Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1047-1059.	1.5	11
334	Cellular metabolism dictates T cell effector function in health and disease. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12956.	1.3	12
335	Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel. <i>Nature Biomedical Engineering</i> , 2020, 4, 1090-1101.	11.6	168
336	The non-linearity of RAF-MEK signaling in dendritic cells. <i>Cell Cycle</i> , 2020, 19, 2249-2259.	1.3	5
337	<p>Past, Present, and Future of Anticancer Nanomedicine</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5719-5743.	3.3	23
338	Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy. <i>Small Structures</i> , 2020, 1, 2000026.	6.9	54
339	Network Approaches for Dissecting the Immune System. <i>IScience</i> , 2020, 23, 101354.	1.9	28
340	Hypoxia-driven intratumor heterogeneity and immune evasion. <i>Cancer Letters</i> , 2020, 492, 1-10.	3.2	39
341	Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 4774-4798.	2.6	23
342	Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study. <i>Breast Cancer Research</i> , 2020, 22, 78.	2.2	9
343	Tracking leukemic Tâ€cell transcriptional dynamics in vivo with a bloodâ€based reporter assay. <i>FEBS Open Bio</i> , 2020, 10, 1868-1879.	1.0	3
344	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. <i>Cancer Treatment Reviews</i> , 2020, 89, 102085.	3.4	41
345	Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. , 2020, 8, e000588.		38
346	Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 960.	1.6	15
347	Exosomes in Tumor Immunotherapy: Mediator, Drug Carrier, and Prognostic Biomarker. <i>Advanced Biology</i> , 2020, 4, 2000061.	3.0	6
348	Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines. <i>ACS Nano</i> , 2020, 14, 9904-9916.	7.3	97
349	Immune Landscape of the Tumor Microenvironment Identifies Prognostic Gene Signature CD4/CD68/CSF1R in Osteosarcoma. <i>Frontiers in Oncology</i> , 2020, 10, 1198.	1.3	25

#	ARTICLE	IF	CITATIONS
350	The Role of GSK3 β in T Lymphocytes in the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 1221.	1.3	7
351	Unraveling the Complexity of the Cancer Microenvironment With Multidimensional Genomic and Cytometric Technologies. <i>Frontiers in Oncology</i> , 2020, 10, 1254.	1.3	45
352	Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN- γ Production and Tumor Control. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5085.	1.8	2
353	The CCL20-CCR6 Axis in Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5186.	1.8	124
354	Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 550.	1.8	14
355	Leveraging Public Single-Cell and Bulk Transcriptomic Datasets to Delineate MAIT Cell Roles and Phenotypic Characteristics in Human Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 1691.	2.2	27
356	Immune cells as tumor drug delivery vehicles. <i>Journal of Controlled Release</i> , 2020, 327, 70-87.	4.8	53
357	Anti-angiogenesis: Opening a new window for immunotherapy. <i>Life Sciences</i> , 2020, 258, 118163.	2.0	33
358	Immune signature of tumor-infiltrating immune cells predicts the prognosis and therapeutic effects in squamous cell carcinoma. <i>International Immunopharmacology</i> , 2020, 87, 106802.	1.7	8
359	Prognostic Value of CXCR2 in Breast Cancer. <i>Cancers</i> , 2020, 12, 2076.	1.7	19
360	Controlling TIME: How MNK Kinases Function to Shape Tumor Immunity. <i>Cancers</i> , 2020, 12, 2096.	1.7	9
361	Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. <i>Cell</i> , 2020, 182, 1341-1359.e19.	13.5	464
362	Multi-omics Data Analyses Construct TME and Identify the Immune-Related Prognosis Signatures in Human LUAD. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 860-873.	2.3	40
363	Stromal regulation of tumor-associated lymphatics. <i>Advanced Drug Delivery Reviews</i> , 2020, 161-162, 75-89.	6.6	6
364	<i>In vivo</i> anti-V α 19 TCR antibody treatment delays ovarian tumor growth by increasing antitumor immune responses. <i>Molecular Oncology</i> , 2020, 14, 2436-2454.	2.1	8
365	Germline genomes have a dominant heritable contribution to cancer immune evasion and immunotherapy response. <i>Quantitative Biology</i> , 2020, 8, 216-227.	0.3	2
366	Therapeutic Time-restricted Feeding Reduces Renal Tumor Bioluminescence in Mice but Fails to Improve Anti-CTLA-4 Efficacy. <i>Anticancer Research</i> , 2020, 40, 5445-5456.	0.5	10
367	Therapy Resistance, Cancer Stem Cells and ECM in Cancer: The Matrix Reloaded. <i>Cancers</i> , 2020, 12, 3067.	1.7	40

#	ARTICLE	IF	CITATIONS
368	The Tumor Microenvironment of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3076.	1.7	17
369	Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2020, 8, 1542-1553.	1.6	19
370	Role of CD4- and CD8-Positive T Cells in Breast Cancer Progression and Outcome: A Pilot Study of 47 Cases in Central India Region. <i>Indian Journal of Gynecologic Oncology</i> , 2020, 18, 1.	0.1	2
371	A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	37
372	Editorial: Metabolism Meets Function: Untangling the Cross-Talk Between Signaling and Metabolism. <i>Frontiers in Oncology</i> , 2020, 10, 607511.	1.3	3
374	Eosinophils in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 1-28.	0.8	20
375	Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer. <i>Cancer Cell</i> , 2020, 38, 818-828.e5.	7.7	146
376	The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation against Cancer. <i>Cancers</i> , 2020, 12, 3158.	1.7	29
377	IgE Antibodies against Cancer: Efficacy and Safety. <i>Antibodies</i> , 2020, 9, 55.	1.2	17
378	Tailoring precision immunotherapy: coming to a clinic soon?. <i>ESMO Open</i> , 2020, 5, e000631.	2.0	8
379	Modular design of Bi-specific nanoplatform engaged in malignant lymphoma immunotherapy. <i>Nanoscale</i> , 2020, 12, 18418-18428.	2.8	6
380	GSH depletion liposome adjuvant for augmenting the photothermal immunotherapy of breast cancer. <i>Science Advances</i> , 2020, 6, .	4.7	124
381	Study and analysis of antitumor resistance mechanism of PD1/PD-1 immune checkpoint blocker. <i>Cancer Medicine</i> , 2020, 9, 8086-8121.	1.3	95
382	Targeting Obesity-Induced Macrophages during Preneoplastic Growth Promotes Mammary Epithelial Stem/Progenitor Activity, DNA Damage, and Tumor Formation. <i>Cancer Research</i> , 2020, 80, 4465-4475.	0.4	14
383	Deciphering the Immune Microenvironment on A Single Archival Formalin-Fixed Paraffin-Embedded Tissue Section by An Immediately Implementable Multiplex Fluorescence Immunostaining Protocol. <i>Cancers</i> , 2020, 12, 2449.	1.7	22
384	Exploiting Manipulated Small Extracellular Vesicles to Subvert Immunosuppression at the Tumor Microenvironment through Mannose Receptor/CD206 Targeting. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6318.	1.8	17
385	Organoids in Translational Oncology. <i>Journal of Clinical Medicine</i> , 2020, 9, 2774.	1.0	18
386	Leukotrienes in Tumor-Associated Inflammation. <i>Frontiers in Pharmacology</i> , 2020, 11, 1289.	1.6	45

#	ARTICLE	IF	CITATIONS
387	Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology. <i>Personalized Medicine</i> , 2020, 17, 399-420.	0.8	7
388	Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 2020, 11, 1842.	2.2	28
389	Helios Expression in Tumor-Infiltrating Lymphocytes Correlates with Overall Survival of Advanced Gastric Cancer Patients. <i>Life</i> , 2020, 10, 189.	1.1	2
390	Development of an IFN γ response-related signature for predicting the survival of cutaneous melanoma. <i>Cancer Medicine</i> , 2020, 9, 8186-8201.	1.3	17
391	Beyond CAR T cells: Engineered V β 9V α 2 T cells to fight solid tumors. <i>Immunological Reviews</i> , 2020, 298, 117-133.	2.8	9
392	Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6885.	1.8	156
393	Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy. <i>Journal of Immunology Research</i> , 2020, 2020, 1-8.	0.9	8
394	Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. <i>Nature</i> , 2020, 586, 120-126.	13.7	249
395	Targeting TANK-binding kinase 1 (TBK1) in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1065-1078.	1.5	26
396	Tumor-derived microparticles in tumor immunology and immunotherapy. <i>European Journal of Immunology</i> , 2020, 50, 1653-1662.	1.6	29
397	Schwann cells promote lung cancer proliferation by promoting the M2 polarization of macrophages. <i>Cellular Immunology</i> , 2020, 357, 104211.	1.4	15
398	Oncolytic Immunotherapy: Can't Start a Fire Without a Spark. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 94-101.	3.2	9
399	Biological roles of Yin Yang 2: Its implications in physiological and pathological events. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12886-12899.	1.6	8
400	Post translational modification-assisted cancer immunotherapy for effective breast cancer treatment. <i>Chemical Science</i> , 2020, 11, 10421-10430.	3.7	14
401	Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. <i>Cells</i> , 2020, 9, 2102.	1.8	56
402	Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies. <i>Cancer Research</i> , 2020, 80, 5147-5154.	0.4	11
403	Single-cell Proteomics: Progress and Prospects. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 1739-1748.	2.5	220
404	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , 2020, 11, 4324.	5.8	75

#	ARTICLE	IF	CITATIONS
405	Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients. <i>BMC Cancer</i> , 2020, 20, 814.	1.1	19
406	Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment. <i>Journal of Translational Medicine</i> , 2020, 18, 324.	1.8	48
407	Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise. <i>Cancers</i> , 2020, 12, 2572.	1.7	38
408	Single-cell transcriptomics in cancer: computational challenges and opportunities. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1452-1465.	3.2	108
409	Tumor Immune Microenvironments (TIMEs): Responsive Nanoplatfoms for Antitumor Immunotherapy. <i>Frontiers in Chemistry</i> , 2020, 8, 804.	1.8	6
410	A novel scoring method based on RNA-seq immunograms describing individual cancer-immunity interactions. <i>Cancer Science</i> , 2020, 111, 4031-4040.	1.7	32
411	Tumor-Derived cGAMP Regulates Activation of the Vasculature. <i>Frontiers in Immunology</i> , 2020, 11, 2090.	2.2	37
412	Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors. <i>ACS Nano</i> , 2020, 14, 13343-13366.	7.3	91
413	EZH2 inhibition: a promising strategy to prevent cancer immune editing. <i>Epigenomics</i> , 2020, 12, 1457-1476.	1.0	37
414	The function and mechanism of ferroptosis in cancer. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 786-798.	2.2	119
415	PD-L1 Positivity Associated With Presence of Tertiary Lymphoid Structures and High-Stage Disease in Upper Tract Urothelial Carcinoma. <i>American Journal of Clinical Pathology</i> , 2020, 154, 802-810.	0.4	6
416	Tackling TAMs for Cancer Immunotherapy: It's Nano Time. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 701-714.	4.0	60
417	TRPV1 acts as a Tumor Suppressor and is associated with Immune Cell Infiltration in Clear Cell Renal Cell Carcinoma: evidence from integrated analysis. <i>Journal of Cancer</i> , 2020, 11, 5678-5688.	1.2	8
418	Mitochondria as a target in cancer treatment. <i>MedComm</i> , 2020, 1, 129-139.	3.1	57
419	Tumoral and paratumoral NK cells and CD8+ T cells of esophageal carcinoma patients express high levels of CD47. <i>Scientific Reports</i> , 2020, 10, 13936.	1.6	11
420	Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy. <i>Accounts of Chemical Research</i> , 2020, 53, 1761-1772.	7.6	64
421	The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1400.	1.3	11
422	Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 2274.	1.7	71

#	ARTICLE	IF	CITATIONS
423	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. <i>Cancers</i> , 2020, 12, 2317.	1.7	37
424	Targeting the Calcium Signalling Machinery in Cancer. <i>Cancers</i> , 2020, 12, 2351.	1.7	37
425	Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5845.	1.8	51
426	The updated landscape of tumor microenvironment and drug repurposing. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 166.	7.1	563
427	CD8+ T-cell lymphocytes infiltration predict clinical outcomes in Wilms's tumor. <i>Tumor Biology</i> , 2020, 42, 101042832097597.	0.8	19
428	Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 3801.	1.7	28
429	Quality of CD8 T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context. <i>Science Advances</i> , 2020, 6, .	4.7	24
430	Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9705.	1.8	12
431	MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. <i>Oncotarget</i> , 2020, 9, 1846915.	2.1	42
432	Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. <i>Cell Discovery</i> , 2020, 6, 90.	3.1	84
433	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. <i>Npj Precision Oncology</i> , 2020, 4, 29.	2.3	11
434	Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer. <i>BMC Cancer</i> , 2020, 20, 1205.	1.1	17
435	The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. <i>Frontiers in Endocrinology</i> , 2020, 11, 608422.	1.5	37
436	Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 586580.	1.3	42
437	Apigenin Increases SHIP-1 Expression, Promotes Tumoricidal Macrophages and Anti-Tumor Immune Responses in Murine Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3631.	1.7	23
438	Gremlin-1 Promotes Metastasis of Breast Cancer Cells by Activating STAT3-MMP13 Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9227.	1.8	35
439	Injectable Porous Microchips with Oxygen Reservoirs and an Immune-Niche Enhance the Efficacy of CAR T Cell Therapy in Solid Tumors. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 56712-56722.	4.0	17
440	Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101584.	1.9	15

#	ARTICLE	IF	CITATIONS
441	Cell Softness Prevents Cytolytic T-cell Killing of Tumor-Repopulating Cells. <i>Cancer Research</i> , 2021, 81, 476-488.	0.4	54
442	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
443	Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis. <i>Scientific Reports</i> , 2020, 10, 19037.	1.6	4
444	Application of microfluidic technology in cancer research and therapy. <i>Advances in Clinical Chemistry</i> , 2020, 99, 193-235.	1.8	8
445	Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. <i>Cell Reports</i> , 2020, 31, 107522.	2.9	50
446	Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 986-994.	2.8	93
447	Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. <i>Nature Cell Biology</i> , 2020, 22, 716-727.	4.6	70
448	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. <i>Drug Resistance Updates</i> , 2020, 51, 100702.	6.5	53
449	11 β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 61-71.	2.9	6
450	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1221.	1.7	46
451	Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 89.	3.5	157
452	Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 246-256.	1.3	17
453	Shaping Up the Tumor Microenvironment With Cellular Fibronectin. <i>Frontiers in Oncology</i> , 2020, 10, 641.	1.3	85
454	HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. <i>Journal of Cancer</i> , 2020, 11, 4059-4072.	1.2	65
455	A Nitric Oxide (NO) Nanoreporter for Noninvasive Real-Time Imaging of Macrophage Immunotherapy. <i>Advanced Materials</i> , 2020, 32, e2000648.	11.1	67
456	Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. <i>Nature Communications</i> , 2020, 11, 2285.	5.8	565
457	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1736-1752.	1.1	10
458	Adoptive cellular immunotherapy of tumors via effective CpG delivery to dendritic cells using dendrimer-entrapped gold nanoparticles as a gene vector. <i>Journal of Materials Chemistry B</i> , 2020, 8, 5052-5063.	2.9	30

#	ARTICLE	IF	CITATIONS
459	Novel Forms of Immunomodulation for Cancer Therapy. <i>Trends in Cancer</i> , 2020, 6, 518-532.	3.8	17
460	Cold to Hot: Binary Cooperative Microneedle Array-Amplified Photoimmunotherapy for Eliciting Antitumor Immunity and the Abscopal Effect. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 32259-32269.	4.0	65
461	Turning Cold into Hot: Firing up the Tumor Microenvironment. <i>Trends in Cancer</i> , 2020, 6, 605-618.	3.8	562
462	Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer. <i>Science Advances</i> , 2020, 6, eaba1590.	4.7	142
463	A paracrine activin A- α 2 axis promotes squamous carcinogenesis via fibroblast reprogramming. <i>EMBO Molecular Medicine</i> , 2020, 12, e11466.	3.3	40
464	The immunoregulatory function of polyphenols: implications in cancer immunity. <i>Journal of Nutritional Biochemistry</i> , 2020, 85, 108428.	1.9	20
465	Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12288-12294.	3.3	65
466	Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 597.	1.3	24
467	Emerging functions and clinical prospects of connexins and pannexins in melanoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188380.	3.3	14
468	Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes. <i>Cell</i> , 2020, 181, 1626-1642.e20.	13.5	388
469	Engineering Polymeric Prodrug Nanoplatfor for Vaccination Immunotherapy of Cancer. <i>Nano Letters</i> , 2020, 20, 4393-4402.	4.5	93
470	Immune checkpoint signaling and cancer immunotherapy. <i>Cell Research</i> , 2020, 30, 660-669.	5.7	617
471	Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient. <i>Cellular and Molecular Immunology</i> , 2020, 17, 684-692.	4.8	12
472	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
473	Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. <i>Genome Medicine</i> , 2020, 12, 47.	3.6	107
474	HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression. , 2020, 8, e000258.		9
475	Immunodeficiency-Related Lymphoid Proliferations: New Insights With Relevance to Practice. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 360-371.	1.2	5
476	Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188386.	3.3	67

#	ARTICLE	IF	CITATIONS
477	Early stratification of radiotherapy response by activatable inflammation magnetic resonance imaging. <i>Nature Communications</i> , 2020, 11, 3032.	5.8	62
478	Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine based-nanocarriers. <i>Biomaterials</i> , 2020, 255, 120208.	5.7	66
479	Delineating the evolutionary dynamics of cancer from theory to reality. <i>Nature Cancer</i> , 2020, 1, 580-588.	5.7	29
480	Advances in the discovery and development of selective heme-displacing IDO1 inhibitors. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1223-1232.	2.5	8
481	Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 3345-3354.	0.5	11
482	Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer. <i>Data in Brief</i> , 2020, 31, 105781.	0.5	6
483	Immunostimulant Complexed With Polylysine Limits Transport and Maintains Immune Cell Activation. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2836-2846.	1.6	5
484	Reply to Boland and Bennett. <i>Pain</i> , 2020, 161, 875-876.	2.0	0
485	Bronchoscopic intratumoural therapies for non-small cell lung cancer. <i>European Respiratory Review</i> , 2020, 29, 200028.	3.0	17
486	Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	117
487	Heme Oxygenase 1â€Targeted Hybrid Nanoparticle for Chemoâ€and Immunoâ€Combination Therapy in Acute Myelogenous Leukemia. <i>Advanced Science</i> , 2020, 7, 2000487.	5.6	15
488	Landscape of immune cell gene expression is unique in predominantly WHO grade 1 skull base meningiomas when compared to convexity. <i>Scientific Reports</i> , 2020, 10, 9065.	1.6	10
489	Cancer nanomedicine meets immunotherapy: opportunities and challenges. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 954-958.	2.8	33
490	<p>Superior Antitumor Efficacy of IFN-Î±2b-Incorporated Photo-Cross-Linked Hydrogels Combined with T Cell Transfer and Low-Dose Irradiation Against Gastric Cancer</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 3669-3680.	3.3	18
491	Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy. <i>Cells</i> , 2020, 9, 1485.	1.8	48
492	Cancer Immunotherapeutic Potential of NKT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4317.	1.8	7
493	Tumour dormancy in inflammatory microenvironment: A promising therapeutic strategy for cancer-related bone metastasis. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 5149-5169.	2.4	15
494	Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1673-1697.	2.0	38

#	ARTICLE	IF	CITATIONS
495	Targeting focal adhesion kinase in cancer cells and the tumor microenvironment. <i>Experimental and Molecular Medicine</i> , 2020, 52, 877-886.	3.2	105
496	Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice. <i>Immunopharmacology and Immunotoxicology</i> , 2020, 42, 346-357.	1.1	7
497	Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 348.	2.0	4
498	CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. <i>Frontiers in Immunology</i> , 2020, 11, 976.	2.2	133
499	Generation of Myeloid Cells in Cancer: The Spleen Matters. <i>Frontiers in Immunology</i> , 2020, 11, 1126.	2.2	41
500	An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. <i>Nature Communications</i> , 2020, 11, 1395.	5.8	124
501	The coadministration of trehalose dibehenate and monosodium urate crystals promotes an antitumor phenotype in human-derived myeloid cells. <i>Immunology and Cell Biology</i> , 2020, 98, 411-422.	1.0	6
502	IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model. <i>Biomedicine and Pharmacotherapy</i> , 2020, 126, 110062.	2.5	11
503	Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes. <i>Annals of Translational Medicine</i> , 2020, 8, 141-141.	0.7	44
504	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 364.	2.2	50
505	Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology. <i>Annual Review of Cancer Biology</i> , 2020, 4, 121-139.	2.3	13
506	Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes. <i>Immunological Reviews</i> , 2020, 295, 203-219.	2.8	25
507	Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3616-3628.	3.2	31
508	Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression. <i>Cell</i> , 2020, 180, 1098-1114.e16.	13.5	140
509	Regulatory Mechanism of MicroRNA Expression in Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1723.	1.8	525
510	Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 21-21.	1.5	2
511	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 490.	2.2	38
512	Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database. <i>Frontiers in Medicine</i> , 2020, 7, 64.	1.2	53

#	ARTICLE	IF	CITATIONS
513	Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. <i>Theranostics</i> , 2020, 10, 3099-3117.	4.6	70
514	Overexpression of Murine Rnaset2 in a Colon Syngeneic Mouse Carcinoma Model Leads to Rebalance of Intra-Tumor M1/M2 Macrophage Ratio, Activation of T Cells, Delayed Tumor Growth, and Rejection. <i>Cancers</i> , 2020, 12, 717.	1.7	16
515	Computational methods in tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, 209-259.	0.4	3
516	Tumour Cell Secretome in Chemoresistance and Tumour Recurrence. <i>Trends in Cancer</i> , 2020, 6, 489-505.	3.8	101
517	In silico analyses of the tumor microenvironment highlight tumoral inflammation, a Th2 cytokine shift and a mesenchymal stem cell-like phenotype in advanced basal cell carcinomas. <i>Journal of Cell Communication and Signaling</i> , 2020, 14, 245-254.	1.8	18
518	Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090750.	1.4	94
519	Designing Stimuli-Responsive Upconversion Nanoparticles that Exploit the Tumor Microenvironment. <i>Advanced Materials</i> , 2020, 32, e2000055.	11.1	143
520	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
521	Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response. <i>British Journal of Cancer</i> , 2020, 122, 1649-1660.	2.9	17
522	m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. <i>Molecular Cancer</i> , 2020, 19, 53.	7.9	704
523	Targets and Antibody Formats for Immunotherapy of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1836-1848.	0.8	74
524	Prognostic significance of neutrophil-to-lymphocyte ratio in several malignancies: where do we stand?. <i>Biomarkers in Medicine</i> , 2020, 14, 169-172.	0.6	9
525	Pleiotropic Role and Bidirectional Immunomodulation of Innate Lymphoid Cells in Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 3111.	2.2	24
526	Mapping cell phenotypes in breast cancer. <i>Nature Cancer</i> , 2020, 1, 156-157.	5.7	5
527	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 223.	2.2	54
528	An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia. <i>British Journal of Cancer</i> , 2020, 123, 919-931.	2.9	0
529	The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites. <i>Current Oncology Reports</i> , 2020, 22, 81.	1.8	51
530	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155

#	ARTICLE	IF	CITATIONS
531	Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2020, 11, 1218.	2.2	124
532	Lymphatic Vessels in Tumor Dissemination versus Immunotherapy. <i>Cancer Research</i> , 2020, 80, 3463-3465.	0.4	42
533	Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 950.	1.3	15
534	Toward Systems Biomarkers of Response to Immune Checkpoint Blockers. <i>Frontiers in Oncology</i> , 2020, 10, 1027.	1.3	16
535	Systematic profiling of alternative splicing in <i>Helicobacter pylori</i> -negative gastric cancer and their clinical significance. <i>Cancer Cell International</i> , 2020, 20, 279.	1.8	8
536	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. <i>Nanomaterials</i> , 2020, 10, 1274.	1.9	26
537	Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. <i>Integrative Biology (United Kingdom)</i> , 2020, 12, 188-197.	0.6	25
538	Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2319-2331.	2.0	20
539	IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. , 2020, 8, e000285.		95
540	Exploring TCGA database for identification of potential prognostic genes in stomach adenocarcinoma. <i>Cancer Cell International</i> , 2020, 20, 264.	1.8	27
541	Integrating the Tumor Microenvironment into Cancer Therapy. <i>Cancers</i> , 2020, 12, 1677.	1.7	24
542	Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4921-4932.	3.2	86
543	Tumor-associated myeloid cells provide critical support for T-ALL. <i>Blood</i> , 2020, 136, 1837-1850.	0.6	16
544	Breathing fresh air into respiratory research with single-cell RNA sequencing. <i>European Respiratory Review</i> , 2020, 29, 200060.	3.0	11
545	Converting Immune Cold into Hot by Biosynthetic Functional Vesicles to Boost Systematic Antitumor Immunity. <i>IScience</i> , 2020, 23, 101341.	1.9	34
546	Dynamics in protein translation sustaining T cell preparedness. <i>Nature Immunology</i> , 2020, 21, 927-937.	7.0	120
547	The growth of non-solid neoplastic lung nodules is associated with low PD L1 expression, irrespective of sampling technique. <i>Journal of Translational Medicine</i> , 2020, 18, 54.	1.8	3
548	The Multifaceted Effects of Autophagy on the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1225, 99-114.	0.8	18

#	ARTICLE	IF	CITATIONS
549	Lipid droplets: platforms with multiple functions in cancer hallmarks. <i>Cell Death and Disease</i> , 2020, 11, 105.	2.7	273
550	The role of the innate immune system in the development and treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2020, 7, HEP17.	4.2	46
551	The Impact of Focused Ultrasound in Two Tumor Models: Temporal Alterations in the Natural History on Tumor Microenvironment and Immune Cell Response. <i>Cancers</i> , 2020, 12, 350.	1.7	11
552	Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments. <i>Molecules</i> , 2020, 25, 715.	1.7	52
553	Biological mechanisms linked to inflammation in cancer: Discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. <i>International Journal of Biological Markers</i> , 2020, 35, 8-11.	0.7	15
554	Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets. <i>Frontiers in Immunology</i> , 2020, 11, 140.	2.2	69
555	An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC). <i>Cancer Medicine</i> , 2020, 9, 2774-2790.	1.3	63
556	Molecularly Imprinted Synthetic Antibodies: From Chemical Design to Biomedical Applications. <i>Small</i> , 2020, 16, e1906644.	5.2	94
557	Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1057-1069.	2.0	31
558	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. <i>Lung Cancer</i> , 2020, 142, 70-79.	0.9	17
559	CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. <i>Molecular Cancer</i> , 2020, 19, 41.	7.9	200
560	Biology and therapeutic targeting of tumour-associated macrophages. <i>Journal of Pathology</i> , 2020, 250, 573-592.	2.1	56
561	Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. <i>Science Immunology</i> , 2020, 5, .	5.6	296
562	Immunoactivating the tumor microenvironment enhances immunotherapy as predicted by integrative computational model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4447-4449.	3.3	21
563	Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1612.	3.3	33
564	Bioinformatics for Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, , .	0.4	1
565	Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment. <i>Trends in Immunology</i> , 2020, 41, 274-285.	2.9	130
566	Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	1

#	ARTICLE	IF	CITATIONS
567	Hollow Porous Carbon Coated FeS ₂ -Based Nanocatalysts for Multimodal Imaging-Guided Photothermal, Starvation, and Triple-Enhanced Chemodynamic Therapy of Cancer. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 10142-10155.	4.0	73
569	Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens. <i>Biomaterials</i> , 2020, 241, 119852.	5.7	32
570	PD-1/PD-L1-dependent immune response in colorectal cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 5461-5475.	2.0	86
571	Updates on mechanistic insights and targeting of tumour metastasis. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2076-2086.	1.6	9
572	Astrocytic trans-Differentiation Completes a Multicellular Paracrine Feedback Loop Required for Medulloblastoma Tumor Growth. <i>Cell</i> , 2020, 180, 502-520.e19.	13.5	99
573	Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer. <i>Journal of Controlled Release</i> , 2020, 320, 105-111.	4.8	27
574	Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment. <i>Cell Reports</i> , 2020, 30, 525-540.e7.	2.9	61
575	Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links. <i>Heliyon</i> , 2020, 6, e03077.	1.4	18
576	Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma). <i>International Immunopharmacology</i> , 2020, 80, 106198.	1.7	64
577	Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment. <i>Advanced Therapeutics</i> , 2020, 3, 1900136.	1.6	23
578	SNHG3 Functions as miRNA Sponge to Promote Breast Cancer Cells Growth Through the Metabolic Reprogramming. <i>Applied Biochemistry and Biotechnology</i> , 2020, 191, 1084-1099.	1.4	82
579	Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 643.	1.6	124
580	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. <i>Immunity</i> , 2020, 52, 36-54.	6.6	127
581	Characterization of the tumor immune infiltrate by multiparametric flow cytometry and unbiased high-dimensional data analysis. <i>Methods in Enzymology</i> , 2020, 632, 309-337.	0.4	6
582	From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. <i>Cells</i> , 2020, 9, 309.	1.8	23
583	Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation. <i>Chonnam Medical Journal</i> , 2020, 56, 6.	0.5	1
584	Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 629-640.	2.0	11
585	Photodynamic therapy produces enhanced efficacy of antitumor immunotherapy by simultaneously inducing intratumoral release of sorafenib. <i>Biomaterials</i> , 2020, 240, 119845.	5.7	62

#	ARTICLE	IF	CITATIONS
586	The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3125.	1.8	76
587	CD30L/CD30 signaling regulates the formation of the tumor immune microenvironment and inhibits intestinal tumor development of colitis-associated colon cancer in mice. <i>International Immunopharmacology</i> , 2020, 84, 106531.	1.7	7
588	Novel pH-sensitive drug-loaded electrospun nanofibers based on regenerated keratin for local tumor chemotherapy. <i>Textile Reseach Journal</i> , 2020, 90, 2336-2349.	1.1	9
589	Ex Vivo Exposure of Human Melanoma Tissue to Cold Physical Plasma Elicits Apoptosis and Modulates Inflammation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 1971.	1.3	23
590	Tumor Milieu Controlled by RB Tumor Suppressor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2450.	1.8	17
591	The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. <i>Journal of Leukocyte Biology</i> , 2020, 108, 363-376.	1.5	40
592	Development and functional analysis of an anticancer Tâ€cell medicine with immune checkpoint inhibitory ability. <i>IUBMB Life</i> , 2020, 72, 1649-1658.	1.5	2
593	Immunogenic clearance-mediated cancer vaccination. , 2020, , 549-568.		1
594	Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer. <i>Annals of Oncology</i> , 2020, 31, 760-768.	0.6	101
595	Genomics and precision surgery for head and neck squamous cell carcinoma. <i>Cancer Letters</i> , 2020, 481, 45-54.	3.2	10
596	Tumor-associated macrophages. <i>Current Biology</i> , 2020, 30, R246-R248.	1.8	136
597	Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures. <i>International Immunopharmacology</i> , 2020, 83, 106477.	1.7	19
598	TGFÎ² suppresses CD8+ T cell expression of CXCR3 and tumor trafficking. <i>Nature Communications</i> , 2020, 11, 1749.	5.8	110
599	Zebrafish patient avatars in cancer biology and precision cancer therapy. <i>Nature Reviews Cancer</i> , 2020, 20, 263-273.	12.8	137
600	Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 619-628.	0.6	14
601	Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma. , 2020, 8, e000282.		95
602	Dual Pro- and Anti-Inflammatory Features of Monocyte-Derived Dendritic Cells. <i>Frontiers in Immunology</i> , 2020, 11, 438.	2.2	15
603	Pan-Cancer Analysis of Radiotherapy Benefits and Immune Infiltration in Multiple Human Cancers. <i>Cancers</i> , 2020, 12, 957.	1.7	10

#	ARTICLE	IF	CITATIONS
604	Reprogramming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma. <i>Cancer Science</i> , 2020, 111, 1899-1909.	1.7	54
605	Profiling of immune-cancer interactions at the single-cell level using a microfluidic well array. <i>Analyst</i> , The, 2020, 145, 4138-4147.	1.7	17
606	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020, 181, 236-249.	13.5	334
607	Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC. <i>Lung Cancer</i> , 2020, 144, 30-39.	0.9	23
608	A gene signature for immune subtyping of desert, excluded, and inflamed ovarian tumors. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13244.	1.2	18
609	Improving Cancer Immunotherapy Outcomes Using Biomaterials. <i>Angewandte Chemie</i> , 2020, 132, 17484-17495.	1.6	12
610	Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. <i>Cell</i> , 2020, 181, 728-744.e21.	13.5	131
611	Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. <i>Cell</i> , 2020, 181, 442-459.e29.	13.5	741
612	Dissecting the Tumor Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. <i>Clinical Cancer Research</i> , 2020, 26, 3505-3513.	3.2	18
613	Improving Cancer Immunotherapy Outcomes Using Biomaterials. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 17332-17343.	7.2	48
614	Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1003-1007.	1.1	9
615	Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1083-1097.	1.4	15
616	Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies. <i>Cancer Immunology Research</i> , 2020, 8, 161-166.	1.6	48
617	Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix. <i>Journal of Immunology Research</i> , 2020, 2020, 1-7.	0.9	16
618	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 487-504.	3.2	355
619	Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma. <i>BMC Medical Genomics</i> , 2020, 13, 57.	0.7	21
620	Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival. <i>PLoS ONE</i> , 2020, 15, e0231003.	1.1	33
621	Revisiting Cancer Stem Cells as the Origin of Cancer-Associated Cells in the Tumor Microenvironment: A Hypothetical View from the Potential of iPSCs. <i>Cancers</i> , 2020, 12, 879.	1.7	44

#	ARTICLE	IF	CITATIONS
622	TNF α and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling. <i>Cells</i> , 2020, 9, 798.	1.8	26
623	Visualization, Quantification, and Mapping of Immune Cell Populations in the Tumor Microenvironment. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	7
624	The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases. <i>Journal of Cancer</i> , 2020, 11, 3207-3215.	1.2	49
625	Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival. <i>Journal of Medical Genetics</i> , 2021, 58, 12-19.	1.5	22
626	Epigenetic modulation of immunotherapy cofactors to enhance tumor response in lung cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 51-54.	1.4	7
627	Computational principles and practice for decoding immune contexture in the tumor microenvironment. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	33
628	The unique immune microenvironment of liver metastases: Challenges and opportunities. <i>Seminars in Cancer Biology</i> , 2021, 71, 143-156.	4.3	35
629	Liver Cancer Immunity. <i>Hepatology</i> , 2021, 73, 86-103.	3.6	52
630	Dietary fat and male sex increase histopathological changes in a mouse model of oral cancer. <i>Oral Diseases</i> , 2021, 27, 215-225.	1.5	5
631	Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers. <i>Urology</i> , 2021, 147, 119-126.	0.5	19
632	Mesenchymal stem cells induce PD α L1 expression through the secretion of CCL5 in breast cancer cells. <i>Journal of Cellular Physiology</i> , 2021, 236, 3918-3928.	2.0	25
633	Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. <i>Cancer Discovery</i> , 2021, 11, 736-753.	7.7	73
634	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. <i>Cancer Discovery</i> , 2021, 11, 362-383.	7.7	50
635	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. <i>Molecular Therapy</i> , 2021, 29, 505-520.	3.7	48
636	Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer. <i>Journal of Drug Targeting</i> , 2021, 29, 1-11.	2.1	12
637	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 221-232.	2.0	12
638	Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2021, 219, 107694.		79
639	Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. <i>Trends in Molecular Medicine</i> , 2021, 27, 75-90.	3.5	5

#	ARTICLE	IF	CITATIONS
640	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021, 137, 216-231.	0.6	40
641	TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2021, 32, 97-102.	0.6	42
642	Expression profiles of metallothionein-I/II and megalin/LRP-2 in uterine cervical squamous lesions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 735-746.	1.4	4
643	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. <i>British Journal of Cancer</i> , 2021, 124, 414-424.	2.9	38
645	A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 923-933.	2.0	52
646	Î electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer. <i>Biomaterials</i> , 2021, 266, 120432.	5.7	31
647	Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery. <i>Journal of Controlled Release</i> , 2021, 329, 882-893.	4.8	22
648	Targeting the tumor immune microenvironment with œnutraceuticalsœ From bench to clinical trials. , 2021, 219, 107700.		14
649	¹⁸F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 802-807.	2.8	15
650	Intravital molecular imaging reveals the restrained capacity of CTLs in the killing of tumor cells in the liver. <i>Theranostics</i> , 2021, 11, 194-208.	4.6	9
651	Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. <i>Cancer Letters</i> , 2021, 499, 279-289.	3.2	7
652	The fibrotic and immune microenvironments as targetable drivers of metastasis. <i>British Journal of Cancer</i> , 2021, 124, 27-36.	2.9	47
653	The presence of TIMœ3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. <i>Brain Pathology</i> , 2021, 31, e12921.	2.1	5
654	Bioengineering of nano metal-organic frameworks for cancer immunotherapy. <i>Nano Research</i> , 2021, 14, 1244-1259.	5.8	37
655	StimuliœResponsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001044.	3.9	27
656	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 112-127.	4.8	159
657	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1069-1081.	3.2	75
658	Single nanosheet can sustainably generate oxygen and inhibit respiration simultaneously in cancer cells. <i>Materials Horizons</i> , 2021, 8, 597-605.	6.4	10

#	ARTICLE	IF	CITATIONS
659	Understanding the tumor microenvironment for effective immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 1474-1498.	5.0	130
660	Activatable Polymer Nanoenzymes for Photodynamic Immunometabolic Cancer Therapy. <i>Advanced Materials</i> , 2021, 33, e2007247.	11.1	194
661	Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model. <i>Journal of Virology</i> , 2021, 95, .	1.5	13
662	Pathological angiogenesis and inflammation in tissues. <i>Archives of Pharmacal Research</i> , 2021, 44, 1-15.	2.7	65
663	Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 694-707.	5.7	56
664	Recent advances of immunotherapy for biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 527-536.	1.4	85
665	NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2021, 14, 100930.	1.7	95
666	3D In Vitro Model (R)evolution: Unveiling Tumor Stroma Interactions. <i>Trends in Cancer</i> , 2021, 7, 249-264.	3.8	209
667	A seven-nuclear receptor-based prognostic signature in breast cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 1292-1303.	1.2	15
668	Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. <i>Nature Biomedical Engineering</i> , 2021, 5, 441-454.	11.6	57
669	Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. <i>Journal of Controlled Release</i> , 2021, 330, 1118-1129.	4.8	58
670	Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor tyrosine kinase inhibitor resistance acquisition in lung adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 718-727.	1.3	11
671	EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures. <i>British Journal of Cancer</i> , 2021, 124, 259-269.	2.9	115
672	The Multifaceted Role of Regulatory T Cells in Breast Cancer. <i>Annual Review of Cancer Biology</i> , 2021, 5, 291-310.	2.3	24
673	Immunogenomic landscape of gynecologic carcinosarcoma. <i>Gynecologic Oncology</i> , 2021, 160, 547-556.	0.6	8
674	Tumor-permeated bioinspired theranostic nanovehicle remodels tumor immunosuppression for cancer therapy. <i>Biomaterials</i> , 2021, 269, 120609.	5.7	23
675	ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1564-1572.e4.	0.3	20
676	Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. <i>Brain Pathology</i> , 2021, 31, 365-380.	2.1	27

#	ARTICLE	IF	CITATIONS
677	Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1135-1148.	1.4	5
678	Organ-on-a-Chip: A New Paradigm for Drug Development. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 119-133.	4.0	232
679	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 429-438.	1.9	13
680	Heterogeneous tumor-immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti-PD-L1 antibody therapy. <i>Thoracic Cancer</i> , 2021, 12, 397-401.	0.8	4
681	Imaging the Immune Tumor Microenvironment to Monitor and Improve Therapy. <i>Radiology</i> , 2021, 298, 133-134.	3.6	3
682	Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. <i>Pathology</i> , 2021, 53, 56-66.	0.3	22
683	Immunotherapy in prostate cancer: new horizon of hurdles and hopes. <i>World Journal of Urology</i> , 2021, 39, 1387-1403.	1.2	17
684	At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer. <i>Journal of Leukocyte Biology</i> , 2021, 109, 969-989.	1.5	28
685	Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma. <i>Laryngoscope</i> , 2021, 131, E1481-E1488.	1.1	15
686	Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumor. <i>Bioactive Materials</i> , 2021, 6, 951-962.	8.6	20
687	Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images. <i>Translational Oncology</i> , 2021, 14, 100921.	1.7	34
688	Atomic force microscopy for revealing micro/nanoscale mechanics in tumor metastasis: from single cells to microenvironmental cues. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 323-339.	2.8	43
689	Brief review on the roles of neutrophils in cancer development. <i>Journal of Leukocyte Biology</i> , 2021, 109, 407-413.	1.5	17
690	Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid- β^2 accumulation and improves cognition in APP/PS1 mice. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 128-141.	2.0	16
691	Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment. <i>Cell Death and Differentiation</i> , 2021, 28, 715-729.	5.0	52
692	Reinvigorating exhausted CD8 ⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56
693	Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer. <i>Carcinogenesis</i> , 2021, 42, 38-47.	1.3	46
694	Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets. <i>Seminars in Cancer Biology</i> , 2021, 68, 59-74.	4.3	64

#	ARTICLE	IF	CITATIONS
695	Nano-immunotherapy: Overcoming tumour immune evasion. <i>Seminars in Cancer Biology</i> , 2021, 69, 238-248.	4.3	47
696	Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling. <i>Journal of Cancer</i> , 2021, 12, 2359-2370.	1.2	3
697	Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs. <i>Oncoimmunology</i> , 2021, 10, 1898753.	2.1	28
698	Molecular approaches toward targeted cancer therapy with some food plant products: On the role of antioxidants and immune microenvironment. , 2021, , 191-202.		1
699	Synthetic promoters to induce immune-effectors into the tumor microenvironment. <i>Communications Biology</i> , 2021, 4, 143.	2.0	11
700	Comprehensive assessments of germline deletion structural variants reveal the association between prognostic MUC4 and CEP72 deletions and immune response gene expression in colorectal cancer patients. <i>Human Genomics</i> , 2021, 15, 3.	1.4	4
701	Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 607349.	1.3	22
703	Multiregion single-cell sequencing reveals the transcriptional landscape of the immune microenvironment of colorectal cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e253.	1.7	48
704	YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer. <i>Oncoimmunology</i> , 2021, 10, 1962656.	2.1	51
705	Radiation Response in the Tumour Microenvironment: Predictive Biomarkers and Future Perspectives. <i>Journal of Personalized Medicine</i> , 2021, 11, 53.	1.1	17
706	Spatial proteomics for understanding the tissue microenvironment. <i>Analyst, The</i> , 2021, 146, 3777-3798.	1.7	21
707	Role of Exosomes for Delivery of Chemotherapeutic Drugs. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2021, 38, 53-97.	1.2	35
708	Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy. <i>Immune Network</i> , 2021, 21, e23.	1.6	7
709	Nanoparticle-Mediated Lipid Metabolic Reprogramming of T Cells in Tumor Microenvironments for Immunometabolic Therapy. <i>Nano-Micro Letters</i> , 2021, 13, 31.	14.4	31
710	Deep learning quantified mucus-tumor ratio predicting survival of patients with colorectal cancer using whole-slide images. <i>Precision Clinical Medicine</i> , 2021, 4, 17-24.	1.3	8
711	Glutamine Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1311, 17-38.	0.8	43
712	Gut Microbiota in Tumor Microenvironment: A Critical Regulator in Cancer Initiation and Development as Potential Targets for Chinese Medicine. <i>The American Journal of Chinese Medicine</i> , 2021, 49, 609-626.	1.5	18
713	Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. <i>Gastroenterology Report</i> , 2021, 9, 560-570.	0.6	10

#	ARTICLE	IF	CITATIONS
714	The influence of TNF- α on the expression profile of key enzymes of steroidogenesis in H295R cells. <i>Postepy Dermatologii i Alergologii</i> , 2021, 38, 404-411.	0.4	1
715	Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. , 2021, 9, e001341.		102
716	SEC23A Inhibit Melanoma Metastatic through Secretory PF4 Cooperation with SPARC to Inhibit MAPK Signaling Pathway. <i>International Journal of Biological Sciences</i> , 2021, 17, 3000-3012.	2.6	7
717	<i>Cancer Immunology</i> . , 2021, , .		0
718	The Tumor Microenvironment Impairs Th1 IFN γ Secretion through Alternative Splicing Modifications of <i>IRF1</i> Pre-mRNA. <i>Cancer Immunology Research</i> , 2021, 9, 324-336.	1.6	8
719	Protein arginine methyltransferase 5: a potential cancer therapeutic target. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 33-44.	2.1	26
720	Relationship between Tertiary Lymphoid Structure and the Prognosis and Clinicopathologic Characteristics in Solid Tumors. <i>International Journal of Medical Sciences</i> , 2021, 18, 2327-2338.	1.1	13
721	Successes and challenges of NKT cell immunotherapy: Breaking tolerance to cancer resistance. , 2021, , 63-80.		0
722	m ⁶ A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer. <i>Theranostics</i> , 2021, 11, 2201-2217.	4.6	148
723	Patient-Derived Xenograft Models in Breast Cancer Research. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 283-301.	0.8	3
724	Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 612202.	2.2	66
725	Immune-Related lncRNA Predicts the Prognosis of Colon Adenocarcinoma. <i>Advances in Clinical Medicine</i> , 2021, 11, 2288-2295.	0.0	0
726	Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 18.	0.1	0
727	Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1036-1043.	3.0	50
728	A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance. <i>Cancers</i> , 2021, 13, 227.	1.7	48
729	Anti-proliferative and anti-migratory properties of coffee diterpenes kahweol acetate and cafestol in human renal cancer cells. <i>Scientific Reports</i> , 2021, 11, 675.	1.6	16
730	Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy. <i>Theranostics</i> , 2021, 11, 6033-6043.	4.6	22
731	Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 574778.	1.3	4

#	ARTICLE	IF	CITATIONS
732	The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. <i>BMC Cancer</i> , 2021, 21, 19.	1.1	24
733	MicroRNA-Mediated Metabolic Shaping of the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 127.	1.7	11
734	Innovative strategies of hydrogen peroxide-involving tumor therapeutics. <i>Materials Chemistry Frontiers</i> , 2021, 5, 4474-4501.	3.2	16
735	Circulating Endothelial Cells: Characteristics and Clinical Relevance. , 2021, , 163-168.		0
736	Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 4.	7.1	51
737	Prognostic Value of PLXND1 and TGF- β 1 Coexpression and Its Correlation With Immune Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 604131.	1.3	13
738	Reactive oxygen species, proinflammatory and immunosuppressive mediators induced in COVID-19: overlapping biology with cancer. <i>RSC Chemical Biology</i> , 2021, 2, 1402-1414.	2.0	9
739	CAR T cells in solid tumors: challenges and opportunities. <i>Stem Cell Research and Therapy</i> , 2021, 12, 81.	2.4	312
740	Transcriptional Profiling of Macrophages <i>in situ</i> in Metastatic Melanoma Reveals Localization-Dependent Phenotypes and Function. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
741	Integrated analyses of m ¹ A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer. <i>Oncolmunology</i> , 2021, 10, 1936758.	2.1	38
742	The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. <i>Journal of Hematology and Oncology</i> , 2021, 14, 13.	6.9	49
743	Chronic stress promotes acute myeloid leukemia progression through HMGB1/NLRP3/IL-1 β signaling pathway. <i>Journal of Molecular Medicine</i> , 2021, 99, 403-414.	1.7	18
744	Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors. <i>Frontiers in Immunology</i> , 2020, 11, 586126.	2.2	40
745	Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. <i>Oncolmunology</i> , 2021, 10, 1900635.	2.1	73
746	Construction of co-expression modules related to survival by WGCNA and identification of potential prognostic biomarkers in glioblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1633-1644.	1.6	29
747	Biological bases of cancer immunotherapy. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e3.	1.6	14
748	CFP is a prognostic biomarker and correlated with immune infiltrates in Gastric Cancer and Lung Cancer. <i>Journal of Cancer</i> , 2021, 12, 3378-3390.	1.2	7
749	Revisiting immunogenic cell death to improve treatment response in cancer. , 2021, , 65-90.		4

#	ARTICLE	IF	CITATIONS
750	Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors. <i>Oncotarget</i> , 2021, 12, 1-3.	0.8	2
751	SGK1 in Human Cancer: Emerging Roles and Mechanisms. <i>Frontiers in Oncology</i> , 2020, 10, 608722.	1.3	39
752	An integrative microenvironment approach for laryngeal carcinoma: the role of immune/methylation/autophagy signatures on disease clinical prognosis and single-cell genotypes. <i>Journal of Cancer</i> , 2021, 12, 4148-4171.	1.2	19
753	Systems biology analysis identifies TNFRSF9 as a functional marker of tumor-infiltrating regulatory T-cell enabling clinical outcome prediction in lung cancer. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 860-868.	1.9	12
754	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. <i>Onc Immunology</i> , 2021, 10, 1860586.	2.1	40
755	Tumor microenvironment characterization in stage IV gastric cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	2
756	A multilayered blood vessel/tumor tissue chip to investigate T cell infiltration into solid tumor tissues. <i>Lab on A Chip</i> , 2021, 21, 2142-2152.	3.1	32
757	Beyond DNA-targeting in Cancer Chemotherapy. <i>Emerging Frontiers - A Review. Current Topics in Medicinal Chemistry</i> , 2021, 21, 28-47.	1.0	6
758	Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1995-2008.	2.0	25
759	Engineered Multifunctional Nano€and Biological Materials for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001680.	3.9	17
760	PAFAH1B3 Expression Is Correlated With Gastric Cancer Cell Proliferation and Immune Infiltration. <i>Frontiers in Oncology</i> , 2021, 11, 591545.	1.3	12
761	Gastric Carcinomas with Stromal B7-H3 Expression Have Lower Intratumoural CD8+ T Cell Density. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2129.	1.8	14
762	Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 586760.	2.2	21
763	Neoantigen€based vaccines as a promising strategy in cancer immunotherapeutics. <i>Immunomedicine</i> , 2021, 1, e1021.	0.7	1
764	Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancers</i> , 2021, 13, 781.	1.7	62
765	Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 94.	7.1	406
766	Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. <i>Nature Communications</i> , 2021, 12, 1151.	5.8	187
767	CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration. <i>Journal of Immunology Research</i> , 2021, 2021, 1-14.	0.9	10

#	ARTICLE	IF	CITATIONS
768	Intratumoral heterogeneity in cancer progression and response to immunotherapy. <i>Nature Medicine</i> , 2021, 27, 212-224.	15.2	376
769	The Natural Killer–Dendritic Cell Immune Axis in Anti-Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 621254.	2.2	33
770	Multi-Modal Multi-Spectral Intravital Microscopic Imaging of Signaling Dynamics in Real-Time during Tumor–Immune Interactions. <i>Cells</i> , 2021, 10, 499.	1.8	7
771	Targeting NR4A Nuclear Receptors to Control Stromal Cell Inflammation, Metabolism, Angiogenesis, and Tumorigenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 589770.	1.8	36
772	Multi-Modal Multi-Spectral Intravital Macroscopic Imaging of Signaling Dynamics in Real Time during Tumor–Immune Interactions. <i>Cells</i> , 2021, 10, 489.	1.8	7
773	ADAMTS proteases and the tumor immune microenvironment: Lessons from substrates and pathologies. <i>Matrix Biology Plus</i> , 2021, 9, 100054.	1.9	11
774	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. , 2021, 9, e001167.		11
775	<i>In Situ</i> Self-Assembly Nanomicelle Microneedles for Enhanced Photoimmunotherapy <i>via</i> Autophagy Regulation Strategy. <i>ACS Nano</i> , 2021, 15, 3387-3401.	7.3	84
776	m ⁶ A modification patterns and tumor immune landscape in clear cell renal carcinoma. , 2021, 9, e001646.		42
777	Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. , 2021, 9, e001691.		34
778	Bacteria–Based Cancer Immunotherapy. <i>Advanced Science</i> , 2021, 8, 2003572.	5.6	115
779	Cutting edge: Metabolic immune reprogramming, reactive oxygen species, and cancer. <i>Journal of Cellular Physiology</i> , 2021, 236, 6168-6189.	2.0	8
781	Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2142.	1.8	6
783	Identification and Validation of a Prognostic Gene Signature for Diffuse Large B-Cell Lymphoma Based on Tumor Microenvironment-Related Genes. <i>Frontiers in Oncology</i> , 2021, 11, 614211.	1.3	11
784	Advances in Modeling the Immune Microenvironment of Colorectal Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 614300.	2.2	16
785	Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 631067.	1.6	14
786	Inhibition of Arginase 1 Liberates Potent T Cell Immunostimulatory Activity of Human Neutrophil Granulocytes. <i>Frontiers in Immunology</i> , 2020, 11, 617699.	2.2	19
787	Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2067.	1.8	14

#	ARTICLE	IF	CITATIONS
788	Determinants, mechanisms, and functional outcomes of myeloid cell diversity in cancer. <i>Immunological Reviews</i> , 2021, 300, 220-236.	2.8	5
789	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 153-162.	1.5	11
790	Unexpected PD-1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies. <i>EMBO Molecular Medicine</i> , 2021, 13, e12716.	3.3	12
791	Application of Bionanomaterials in Tumor Immune Microenvironment Therapy. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	0.9	3
792	Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation. <i>Cancer Research</i> , 2021, 81, 2171-2183.	0.4	14
794	Warburg Effect Is a Cancer Immune Evasion Mechanism Against Macrophage Immunosurveillance. <i>Frontiers in Immunology</i> , 2020, 11, 621757.	2.2	24
795	Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. <i>Science</i> , 2021, 371, .	6.0	166
796	Immune checkpoint blockade in renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 739-750.	0.8	13
797	Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics. <i>Frontiers in Immunology</i> , 2021, 12, 597651.	2.2	9
798	Cracking the Breast Cancer Glyco-Code through Glycan-Lectin Interactions: Targeting Immunosuppressive Macrophages. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1972.	1.8	8
799	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	7.1	191
800	Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 73.	3.5	24
801	RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 632934.	1.3	22
802	Recent Advances in Cell Membrane-Derived Biomimetic Nanotechnology for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002081.	3.9	78
803	Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors. <i>Advanced Functional Materials</i> , 2021, 31, 2009489.	7.8	29
804	Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 442-450.	1.8	4
805	Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. <i>Pharmaceutics</i> , 2021, 13, 422.	2.0	16
806	Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 38.	1.3	24

#	ARTICLE	IF	CITATIONS
807	An Extracellular Matrix-Based Signature Associated With Immune Microenvironment Predicts the Prognosis and Therapeutic Responses of Patients With Oesophageal Squamous Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 598427.	1.6	8
808	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. <i>Cancers</i> , 2021, 13, 1374.	1.7	18
809	High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder. <i>International Journal of Hematology</i> , 2021, 114, 53-64.	0.7	1
810	The role of myeloid-derived suppressor cells in rheumatoid arthritis: An update. <i>Life Sciences</i> , 2021, 269, 119083.	2.0	15
811	The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. <i>Journal of Controlled Release</i> , 2021, 331, 321-334.	4.8	35
812	Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy. <i>Frontiers in Immunology</i> , 2021, 12, 643291.	2.2	52
813	Nanobiomaterial-based vaccination immunotherapy of cancer. <i>Biomaterials</i> , 2021, 270, 120709.	5.7	77
814	Cytosolic Delivery of Thiolated Mn ²⁺ GAMP Nanovaccine to Enhance the Antitumor Immune Responses. <i>Small</i> , 2021, 17, e2006970.	5.2	38
815	Oncolytic Adenoviruses for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2517.	1.8	18
816	Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 343-350.	1.9	75
817	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. <i>Cancer Discovery</i> , 2021, 11, 2014-2031.	7.7	79
819	BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma. <i>Oncology Letters</i> , 2021, 21, 391.	0.8	8
820	A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. <i>Heliyon</i> , 2021, 7, e06438.	1.4	16
821	Delivery of cancer therapies by synthetic and bio-inspired nanovectors. <i>Molecular Cancer</i> , 2021, 20, 55.	7.9	57
822	PLCG2 as a potential indicator of tumor microenvironment remodeling in soft tissue sarcoma. <i>Medicine (United States)</i> , 2021, 100, e25008.	0.4	10
823	Pulsed-Focused Ultrasound Slows B16 Melanoma and 4T1 Breast Tumor Growth through Differential Tumor Microenvironmental Changes. <i>Cancers</i> , 2021, 13, 1546.	1.7	7
824	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	2.9	113
825	Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2021, 74, 625-634.	1.0	18

#	ARTICLE	IF	CITATIONS
826	Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality. <i>Cell Reports</i> , 2021, 34, 108917.	2.9	27
827	Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	5
828	Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies. <i>Genes</i> , 2021, 12, 445.	1.0	43
829	Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 1162.	1.7	16
830	The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering. <i>Future Microbiology</i> , 2021, 16, 341-368.	1.0	5
831	An expanded universe of cancer targets. <i>Cell</i> , 2021, 184, 1142-1155.	13.5	135
832	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	0.8	34
833	Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression: A retrospective cohort study. <i>Annals of Medicine and Surgery</i> , 2021, 63, 102144.	0.5	4
834	A Unique Anti-Cancer 3-Styrylchromone Suppresses Inflammatory Response via HMGB1-RAGE Signaling. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 17.	0.7	5
835	Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 042001.	1.7	6
836	Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2021, 9, 651-664.	1.6	43
837	Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status. <i>PeerJ</i> , 2021, 9, e11133.	0.9	1
838	Hot and Cold Tumors: Is Endoglin (CD105) a Potential Target for Vessel Normalization?. <i>Cancers</i> , 2021, 13, 1552.	1.7	20
839	A comprehensive analysis of tumor microenvironment-related genes in colon cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 1769-1781.	1.2	4
840	Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review). <i>Oncology Reports</i> , 2021, 45, .	1.2	9
841	Harnessing metabolic dependencies in pancreatic cancers. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 482-492.	8.2	81
842	Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. <i>Nature Communications</i> , 2021, 12, 1540.	5.8	88
843	Correlation Between Dual-Time-Point FDG PET and Tumor Microenvironment Immune Types in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 559623.	1.3	9

#	ARTICLE	IF	CITATIONS
844	The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy. <i>Biomedicines</i> , 2021, 9, 361.	1.4	7
845	Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. , 2021, 9, e001813.		57
846	Establishment and characterization of HXWMF-1: the first mouse fibroblastic tumor cell line derived from leukemia-associated fibroblasts. <i>Cancer Cell International</i> , 2021, 21, 177.	1.8	5
847	Oxidized Phospholipids in Tumor Microenvironment Stimulate Tumor Metastasis via Regulation of Autophagy. <i>Cells</i> , 2021, 10, 558.	1.8	9
848	Leveraging microenvironmental synthetic lethality to treat cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
849	Renal cell carcinoma pathology in 2021: â€˜new need for renal cancer immune profilingâ€™. <i>Current Opinion in Urology</i> , 2021, 31, 228-235.	0.9	5
850	Synthetic Receptor-Based Targeting Strategies to Improve Tumor Drug Delivery. <i>AAPS PharmSciTech</i> , 2021, 22, 93.	1.5	6
851	CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 495-523.	2.1	32
852	Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry. <i>Journal of Clinical Pathology</i> , 2022, 75, 452-458.	1.0	2
853	A Nano â€œImmuneâ€Guideâ€Recruiting Lymphocytes and Modulating the Ratio of Macrophages from Different Origins to Enhance Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 209116.	7.8	24
854	Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors. <i>Frontiers in Chemistry</i> , 2020, 8, 572471.	1.8	9
855	Contribution of Genomics to the Surgical Management and Study of Oral Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 5842-5854.	0.7	9
856	A novel tumor-immune microenvironment (TIME)-on-Chip mimics three dimensional neutrophil-tumor dynamics and neutrophil extracellular traps (NETs)-mediated collective tumor invasion. <i>Biofabrication</i> , 2021, 13, 035029.	3.7	47
857	Aliphatic Polyesterâ€Based Materials for Enhanced Cancer Immunotherapy. <i>Macromolecular Bioscience</i> , 2021, 21, e2100087.	2.1	7
858	Exosomes: Powerful weapon for cancer nano-immunoengineering. <i>Biochemical Pharmacology</i> , 2021, 186, 114487.	2.0	20
859	Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 679117.	2.2	22
860	Translation of single-cell transcriptomic analysis of uveal melanomas to clinical oncology. <i>Progress in Retinal and Eye Research</i> , 2021, 85, 100968.	7.3	13
861	Tumor Immune Microenvironment during Epithelialâ€Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2021, 27, 4669-4679.	3.2	138

#	ARTICLE	IF	CITATIONS
862	Cervical Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2021, 27, 4953-4973.	3.2	129
863	High-density lipoprotein modulates tumor-associated macrophage for chemoimmunotherapy of hepatocellular carcinoma. <i>Nano Today</i> , 2021, 37, 101064.	6.2	20
864	Proteomic approaches to assist in diagnosis and prognosis of oral cancer. <i>Expert Review of Proteomics</i> , 2021, 18, 261-284.	1.3	8
865	Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy. <i>Cancers</i> , 2021, 13, 1863.	1.7	6
866	Tissues and Tumor Microenvironment (TME) in 3D: Models to Shed Light on Immunosuppression in Cancer. <i>Cells</i> , 2021, 10, 831.	1.8	12
868	Gene expression patterns associated with tumor-infiltrating CD4+ and CD8+ T cells in invasive breast carcinomas. <i>Human Immunology</i> , 2021, 82, 279-287.	1.2	5
869	Extracellular Vesicles from <i>Akkermansia muciniphila</i> Elicit Antitumor Immunity Against Prostate Cancer via Modulation of CD8+ T Cells and Macrophages. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2949-2963.	3.3	48
870	Trials and tribulations of pancreatic cancer immunotherapy. <i>Cancer Letters</i> , 2021, 504, 1-14.	3.2	37
872	The synergistic strategies for the immuno-oncotherapy with photothermal nanoagents. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1717.	3.3	9
873	CAR T cell therapy in solid tumors: a short review. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 143-149.	0.3	17
874	The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. <i>Biomedicines</i> , 2021, 9, 389.	1.4	21
876	Interaction Networks Converging on Immunosuppressive Roles of Granzyme B: Special Niches Within the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 670324.	2.2	9
877	Cell competition between anaplastic thyroid cancer and normal thyroid follicular cells exerts reciprocal stress response defining tumor suppressive effects of normal epithelial tissue. <i>PLoS ONE</i> , 2021, 16, e0249059.	1.1	0
878	Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	66
879	CD244 ⁺ polymorphonuclear myeloid-derived suppressor cells reflect the status of peritoneal dissemination in a colon cancer mouse model. <i>Oncology Reports</i> , 2021, 45, .	1.2	6
880	Identification of Novel Prognostic Risk Signatures of Soft Tissue Sarcoma Based on Ferroptosis-Related Genes. <i>Frontiers in Oncology</i> , 2021, 11, 629868.	1.3	13
881	Biodegradable Nanosensitizers with the Multiple Modulation of Tumor Microenvironment for Enhanced Sonodynamic Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2633-2646.	3.3	10
882	Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. <i>Cancer Cell International</i> , 2021, 21, 196.	1.8	18

#	ARTICLE	IF	CITATIONS
883	Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. , 2021, 9, e001875.		34
885	Pattern of Tumor-Infiltrating Lymphocytes in Mixed Epithelial and Stromal Tumor of the Kidney: A Review of Five Cases. <i>Cells</i> , 2021, 10, 917.	1.8	0
886	CD8+ T cells inhibit metastasis and CXCL4 regulates its function. <i>British Journal of Cancer</i> , 2021, 125, 176-189.	2.9	21
887	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. <i>Nature Cancer</i> , 2021, 2, 400-413.	5.7	41
888	Endogenous Stimuli-Activatable Nanomedicine for Immune Theranostics for Cancer. <i>Advanced Functional Materials</i> , 2021, 31, 2100386.	7.8	36
889	Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 640369.	2.2	26
890	Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3775.	1.8	41
891	Bioinformatic analysis of differentially expressed genes as prognostic markers in pheochromocytoma and paraganglioma tumors. <i>Genes and Genetic Systems</i> , 2021, 96, 55-69.	0.2	5
892	CSF1R is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in the Gastric Cancer Microenvironment. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 445-457.	0.4	3
893	Emerging Trends in Immunomodulatory Nanomaterials Toward Cancer Therapy. <i>Synthesis Lectures on Biomedical Engineering</i> , 2021, 16, i-84.	0.1	0
894	Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 551-551.	0.7	5
895	Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. <i>Journal of Controlled Release</i> , 2021, 332, 109-126.	4.8	33
896	Effect of physicochemical properties on in vivo fate of nanoparticle-based cancer immunotherapies. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 886-902.	5.7	42
898	Boosting innate and adaptive antitumor immunity via a biocompatible and carrier-free nanovaccine engineered by the bisphosphonates-metal coordination. <i>Nano Today</i> , 2021, 37, 101097.	6.2	11
899	High Dimensional Imaging Mass Cytometry Panel to Visualize the Tumor Immune Microenvironment Contexture. <i>Frontiers in Immunology</i> , 2021, 12, 666233.	2.2	35
900	The Hallmarks of Cancer as Ecologically Driven Phenotypes. <i>Frontiers in Ecology and Evolution</i> , 2021, 9, .	1.1	24
901	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4159.	1.8	41
902	Therapeutic Targeting of the Tumor Microenvironment. <i>Cancer Discovery</i> , 2021, 11, 933-959.	7.7	646

#	ARTICLE	IF	CITATIONS
903	The role of N6-methyladenosine mRNA in the tumor microenvironment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188522.	3.3	69
905	Expression of Lipid-Metabolism Genes Is Correlated With Immune Microenvironment and Predicts Prognosis in Osteosarcoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 673827.	1.8	40
906	Prognostic Value of Tumor-Associated Macrophages in Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 657318.	1.3	28
907	Are radiomics features universally applicable to different organs?. <i>Cancer Imaging</i> , 2021, 21, 31.	1.2	7
908	Myeloid cell-derived HOCl is a paracrine effector that trans-inhibits IKK/NF- κ B in melanoma cells and limits early tumor progression. <i>Science Signaling</i> , 2021, 14, .	1.6	17
909	Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 672158.	2.2	26
910	Tumor-Associated Neutrophils Drive B-cell Recruitment and Their Differentiation to Plasma Cells. <i>Cancer Immunology Research</i> , 2021, 9, 811-824.	1.6	17
911	Diet-Induced Obesity Impairs Outcomes and Induces Multi-Factorial Deficiencies in Effector T Cell Responses Following Anti-CTLA-4 Combinatorial Immunotherapy in Renal Tumor-Bearing Mice. <i>Cancers</i> , 2021, 13, 2295.	1.7	2
912	Natural Killer-Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy. <i>Cancers</i> , 2021, 13, 2184.	1.7	14
913	Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 663495.	2.2	30
914	Deciphering the nexus between the tumor immune microenvironment and DNA methylation in subgrouping estrogen receptor-positive breast cancer. <i>Breast Cancer</i> , 2021, 28, 1252-1260.	1.3	1
915	Role of circular RNAs in colorectal tumor microenvironment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111351.	2.5	10
916	Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives. <i>Cancers</i> , 2021, 13, 2418.	1.7	36
917	Defucosylation of Tumor-Specific Humanized Anti-MUC1 Monoclonal Antibody Enhances NK Cell-Mediated Anti-Tumor Cell Cytotoxicity. <i>Cancers</i> , 2021, 13, 2579.	1.7	12
918	Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer. <i>Investigational New Drugs</i> , 2021, 39, 1469-1483.	1.2	10
919	Chemokines and the immune response to cancer. <i>Immunity</i> , 2021, 54, 859-874.	6.6	254
920	Polysaccharide-rich extract from <i>Polygonatum sibiricum</i> protects hematopoiesis in bone marrow suppressed by triple negative breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111338.	2.5	21
921	A polyamidoamine (PAMAM) derivative dendrimer with high loading capacity of TLR7/8 agonist for improved cancer immunotherapy. <i>Nano Research</i> , 2022, 15, 510-518.	5.8	12

#	ARTICLE	IF	CITATIONS
922	A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets. <i>Life Sciences</i> , 2021, 273, 119307.	2.0	8
923	SENP3 loss promotes M2 macrophage polarization and breast cancer progression. <i>Molecular Oncology</i> , 2022, 16, 1026-1044.	2.1	29
924	The Role of GPNMB in Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 674739.	2.2	78
926	Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy. <i>Nano Letters</i> , 2021, 21, 4371-4380.	4.5	39
927	Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2007576.	11.1	42
928	Multimomics characteristics of neurogenesis-related gene are dysregulated in tumor immune microenvironment. <i>Npj Genomic Medicine</i> , 2021, 6, 37.	1.7	7
930	Role of Metabolic Syndrome in Prostate Cancer Development. <i>European Urology Focus</i> , 2021, 7, 508-512.	1.6	5
931	Spatiotemporal Analysis of B Cell- and Antibody Secreting Cell-Subsets in Human Melanoma Reveals Metastasis-, Tumor Stage-, and Age-Associated Dynamics. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 677944.	1.8	3
932	Construction of an immune-related signature with prognostic value for colon cancer. <i>PeerJ</i> , 2021, 9, e10812.	0.9	2
933	Imaging of T-cell Responses in the Context of Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 490-502.	1.6	8
934	Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. <i>EBioMedicine</i> , 2021, 67, 103375.	2.7	33
935	Identification of a prognostic signature based on immune-related genes in bladder cancer. <i>Genomics</i> , 2021, 113, 1203-1218.	1.3	5
936	Development of Toll-like Receptor Agonist-Loaded Nanoparticles as Precision Immunotherapy for Reprogramming Tumor-Associated Macrophages. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 24442-24452.	4.0	26
937	Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 2540.	5.8	295
938	Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment. <i>Cancer Discovery</i> , 2021, 11, 1886-1895.	7.7	12
939	Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 633205.	2.2	42
940	Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs-Targeting Immunotherapy of Colon Cancer. <i>Advanced Science</i> , 2021, 8, e2100712.	5.6	59
941	Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity. <i>Cancers</i> , 2021, 13, 2735.	1.7	21

#	ARTICLE	IF	CITATIONS
942	Translational Applications of Hydrogels. <i>Chemical Reviews</i> , 2021, 121, 11385-11457.	23.0	438
943	Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment. <i>Experimental Hematology and Oncology</i> , 2021, 10, 31.	2.0	25
944	MATISSE: a method for improved single cell segmentation in imaging mass cytometry. <i>BMC Biology</i> , 2021, 19, 99.	1.7	21
945	Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression. <i>Cancer Immunology Research</i> , 2021, 9, 862-876.	1.6	15
946	Tristetraprolin, a Potential Safeguard Against Carcinoma: Role in the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 632189.	1.3	6
947	Pivotal Role for Cxcr2 in Regulating Tumor-Associated Neutrophil in Breast Cancer. <i>Cancers</i> , 2021, 13, 2584.	1.7	22
948	A century of BCG: Impact on tuberculosis control and beyond. <i>Immunological Reviews</i> , 2021, 301, 98-121.	2.8	37
949	A brand new era of cancer immunotherapy: breakthroughs and challenges. <i>Chinese Medical Journal</i> , 2021, 134, 1267-1275.	0.9	15
950	Signal-transducing innate receptors in tumor immunity. <i>Cancer Science</i> , 2021, 112, 2578-2591.	1.7	8
951	Navigating CAR-T cells through the solid-tumour microenvironment. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 531-550.	21.5	236
952	Pyroptosis: a new paradigm of cell death for fighting against cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 153.	3.5	224
953	Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23810.	0.9	20
954	Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5158.	1.8	3
955	Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer. <i>Immunity</i> , 2021, 54, 903-915.	6.6	147
956	Hypermutated tumours across 11 cancer types show three distinct immune subtypes. <i>European Journal of Cancer</i> , 2021, 148, 230-238.	1.3	1
957	Laryngopharyngeal Reflux Alters Macrophage Polarization in Human Papilloma Virus-Negative Squamous Cell Carcinoma of the Larynx in Males. <i>Clinical and Experimental Otorhinolaryngology</i> , 2021, 14, 240-243.	1.1	2
958	Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance. <i>Drug Resistance Updates</i> , 2021, 56, 100752.	6.5	35
959	ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 675104.	1.3	17

#	ARTICLE	IF	CITATIONS
960	CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers. <i>Cancers</i> , 2021, 13, 2328.	1.7	20
961	The Immunology of Hormone Receptor Positive Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 674192.	2.2	68
962	Exploiting a New Approach to Destroy the Barrier of Tumor Microenvironment: Nano-Architecture Delivery Systems. <i>Molecules</i> , 2021, 26, 2703.	1.7	12
963	Intravital Imaging Identifies the VEGF-TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion. <i>Cancer Research</i> , 2021, 81, 4124-4132.	0.4	16
964	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	7.7	230
965	Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. <i>Cancer Cell International</i> , 2021, 21, 262.	1.8	31
966	Charge convertible biomimetic micellar nanoparticles for enhanced melanoma-targeted therapy through tumor cells and tumor-associated macrophages dual chemotherapy with IDO immunotherapy. <i>Chemical Engineering Journal</i> , 2021, 412, 128659.	6.6	19
967	Comprehensive Analysis of the Relationship Between Metabolic Reprogramming and Immune Function in Prostate Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3251-3266.	1.0	6
968	Engineering Breast Cancer On-chip—Moving Toward Subtype Specific Models. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 694218.	2.0	18
969	Nanomedicine-mediated optimization of immunotherapeutic approaches in cervical cancer. <i>Nanomedicine</i> , 2021, 16, 1311-1328.	1.7	10
970	IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation. <i>Nature Communications</i> , 2021, 12, 3651.	5.8	89
971	Metastasis-associated fibroblasts: an emerging target for metastatic cancer. <i>Biomarker Research</i> , 2021, 9, 47.	2.8	24
972	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4599-4609.	3.2	26
973	Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 3684.	5.8	136
974	Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	111
975	Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 685065.	1.3	4
976	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. <i>Current Drug Targets</i> , 2021, 22, 1021-1033.	1.0	6
977	Down-Regulation of an Autophagy-Related Gene SERPINA1 as a Superior Prognosis Biomarker Associates with Relapse and Distant Metastasis in Colon Adenocarcinoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3861-3872.	1.0	5

#	ARTICLE	IF	CITATIONS
979	Neoantigens elicit T cell responses in breast cancer. <i>Scientific Reports</i> , 2021, 11, 13590.	1.6	17
980	Applications of Single-Cell Omics in Tumor Immunology. <i>Frontiers in Immunology</i> , 2021, 12, 697412.	2.2	21
981	Optical Control of CD8+ T Cell Metabolism and Effector Functions. <i>Frontiers in Immunology</i> , 2021, 12, 666231.	2.2	21
982	Targeting cancer testis antigens in synovial sarcoma. , 2021, 9, e002072.		16
983	Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction. <i>ELife</i> , 2021, 10, .	2.8	40
984	Correlation between tumor infiltrating immune cells and peripheral regulatory T cell determined using methylation analyses and its prognostic significance in resected gastric cancer. <i>PLoS ONE</i> , 2021, 16, e0252480.	1.1	7
985	Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. <i>Cancer Letters</i> , 2021, 507, 55-69.	3.2	53
986	Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 288-302.	2.0	25
987	Chemodivergent manganese-catalyzed C-H activation: modular synthesis of fluorogenic probes. <i>Nature Communications</i> , 2021, 12, 3389.	5.8	50
989	SeqStain is an efficient method for multiplexed, spatialomic profiling of human and murine tissues. <i>Cell Reports Methods</i> , 2021, 1, 100006.	1.4	7
990	Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. <i>Journal of Hematology and Oncology</i> , 2021, 14, 98.	6.9	173
991	Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. <i>Current Opinion in Chemical Biology</i> , 2021, 62, 1-12.	2.8	83
992	Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 2985.	1.7	10
993	Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 2837-2860.	1.1	4
994	Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. <i>IScience</i> , 2021, 24, 102619.	1.9	33
995	Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. <i>Immunological Reviews</i> , 2021, 302, 241-258.	2.8	87
996	Role of differentiated embryo-chondrocyte expressed gene 1 (DEC1) in immunity. <i>International Immunopharmacology</i> , 2022, 102, 107892.	1.7	2
997	Multifaceted Role of the Transforming Growth Factor β^2 on Effector T Cells and the Implication for CAR-T Cell Therapy. <i>Immuno</i> , 2021, 1, 160-173.	0.6	4

#	ARTICLE	IF	CITATIONS
998	HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells. <i>Cancers</i> , 2021, 13, 2857.	1.7	11
999	Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal. <i>Cancer Reports</i> , 2022, 5, e1484.	0.6	2
1000	SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 399-415.	2.0	11
1001	Role of intravital imaging in nanomedicine-assisted anti-cancer therapy. <i>Current Opinion in Biotechnology</i> , 2021, 69, 153-161.	3.3	5
1002	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision. <i>International Journal of Biological Macromolecules</i> , 2021, 180, 739-752.	3.6	39
1003	Hyperbaric Oxygen Boosts PD-1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid Tumors. <i>Advanced Science</i> , 2021, 8, e2100233.	5.6	42
1004	Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e422.	1.7	47
1005	A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system. <i>Drug Discovery Today</i> , 2021, 26, 1482-1489.	3.2	12
1006	Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study. <i>Frontiers in Immunology</i> , 2021, 12, 685370.	2.2	32
1007	Pan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypes. <i>Npj Genomic Medicine</i> , 2021, 6, 52.	1.7	15
1008	Immune landscape and subtypes in primary resectable oral squamous cell carcinoma: prognostic significance and predictive of therapeutic response. , 2021, 9, e002434.		19
1009	SOX factors as cell-state regulators in the mammary gland and breast cancer. <i>Seminars in Cell and Developmental Biology</i> , 2021, 114, 126-133.	2.3	14
1012	Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 281-305.	6.6	38
1013	A Comprehensive Analysis of the Downregulation of miRNA-1827 and Its Prognostic Significance by Targeting SPTBN2 and BCL2L1 in Ovarian Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 687576.	1.6	6
1014	Type 17 immunity promotes the exhaustion of CD8 ⁺ T cells in cancer. , 2021, 9, e002603.		20
1015	A Nanoradiomics Approach for Differentiation of Tumors Based on Tumor-Associated Macrophage Burden. <i>Contrast Media and Molecular Imaging</i> , 2021, 2021, 1-9.	0.4	7
1016	SIRT2 promotes murine melanoma progression through natural killer cell inhibition. <i>Scientific Reports</i> , 2021, 11, 12988.	1.6	8
1017	Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 678562.	1.3	15

#	ARTICLE	IF	CITATIONS
1018	A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. <i>Oncogene</i> , 2021, 40, 4413-4424.	2.6	138
1019	Protein citrullination as a source of cancer neoantigens. , 2021, 9, e002549.		24
1020	Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. <i>Cell</i> , 2021, 184, 3998-4015.e19.	13.5	92
1021	Biomimetic sonodynamic therapy-nanovaccine integration platform potentiates Anti-PD-1 therapy in hypoxic tumors. <i>Nano Today</i> , 2021, 38, 101195.	6.2	65
1023	Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and scTIME Portal. <i>Cancer Immunology Research</i> , 2021, 9, 939-951.	1.6	35
1024	Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies. <i>Seminars in Cancer Biology</i> , 2022, 82, 3-10.	4.3	23
1025	Antibody-activated trans-endothelial delivery of mesoporous organosilica nanomedicine augments tumor extravasation and anti-cancer immunotherapy. <i>Bioactive Materials</i> , 2021, 6, 2158-2172.	8.6	12
1026	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. <i>Cancers</i> , 2021, 13, 3415.	1.7	15
1027	Neutrophil Extracellular Traps: A New Player in Cancer Metastasis and Therapeutic Target. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 233.	3.5	35
1028	Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network. <i>Bioscience Reports</i> , 2021, 41, .	1.1	3
1029	Green synthesis of gold nanoparticles for immune response regulation: Mechanisms, applications, and perspectives. <i>Journal of Biomedical Materials Research - Part A</i> , 2022, 110, 424-442.	2.1	22
1030	Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 709210.	1.3	54
1031	Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 693234.	1.3	18
1032	Sexual Dimorphism in Outcomes of Non-muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint. <i>European Urology Open Science</i> , 2021, 29, 50-58.	0.2	15
1033	Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 950-961.	5.7	13
1034	Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2073-2084.	1.0	4
1035	Tumor-infiltrating FoxP3+ T cells are associated with poor prognosis in oral squamous cell carcinoma. <i>Clinical and Experimental Dental Research</i> , 2022, 8, 152-159.	0.8	6
1036	In Situ biomimetic Nanof ormulation for metastatic cancer immunotherapy. <i>Acta Biomaterialia</i> , 2021, 134, 633-648.	4.1	5

#	ARTICLE	IF	CITATIONS
1037	Synergies between therapeutic ultrasound, gene therapy and immunotherapy in cancer treatment. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113906.	6.6	20
1038	Neutrophil extracellular traps in cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 91-104.	4.3	75
1039	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	10.6	345
1040	Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 688953.	1.8	11
1041	Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis. <i>PLoS ONE</i> , 2021, 16, e0254829.	1.1	1
1043	Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 651622.	1.3	17
1044	Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 692142.	1.3	123
1045	Cell Fate Reprogramming in the Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 714822.	2.2	27
1046	Collective metastasis: coordinating the multicellular voyage. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 373-399.	1.7	24
1047	Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions. <i>Medical Oncology</i> , 2021, 38, 106.	1.2	8
1048	Amine oxidase, copper containing 3 exerts anti-mesenchymal transformation and enhances CD4 ⁺ cell recruitment to prolong survival in lung cancer. <i>Oncology Reports</i> , 2021, 46, .	1.2	9
1049	A Bionanozyme with Ultrahigh Activity Enables Spatiotemporally Controlled Reactive Oxygen Species Generation for Cancer Therapy. <i>Advanced Functional Materials</i> , 2021, 31, 2104100.	7.8	18
1050	Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 671736.	1.8	6
1051	Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential. <i>Frontiers in Immunology</i> , 2021, 12, 697083.	2.2	33
1052	Shuttle-Shape Carrier-Free Platinum-Coordinated Nanoreactors with O ₂ Self-Supply and ROS Augment for Enhanced Phototherapy of Hypoxic Tumor. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 32690-32702.	4.0	19
1053	The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8036.	1.8	11
1054	Identification and Validation of a Four-Long Non-coding RNA Signature Associated With Immune Infiltration and Prognosis in Colon Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 671128.	1.1	10
1055	Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4 ⁺ T Cells That Subvert Immunosuppression. <i>Cancer Discovery</i> , 2021, 11, 3178-3197.	7.7	7

#	ARTICLE	IF	CITATIONS
1056	MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. , 2021, 9, e002528.		45
1057	GNRH1 and LTB4R might be novel immune-related prognostic biomarkers in clear cell renal cell carcinoma (ccRCC). <i>Cancer Cell International</i> , 2021, 21, 354.	1.8	11
1058	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. <i>Modern Pathology</i> , 2021, 34, 2229-2241.	2.9	25
1059	S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. <i>Clinical and Translational Medicine</i> , 2021, 11, e459.	1.7	26
1060	Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells. <i>Nature Immunology</i> , 2021, 22, 947-957.	7.0	37
1061	Emerging mechanisms and targeted therapy of ferroptosis in cancer. <i>Molecular Therapy</i> , 2021, 29, 2185-2208.	3.7	134
1063	Revealing consensus gene pathways associated with respiratory functions and disrupted by PM2.5 nitrate exposure at bulk tissue and single cell resolution. <i>Environmental Pollution</i> , 2021, 280, 116951.	3.7	12
1064	HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity. <i>Cancers</i> , 2021, 13, 3575.	1.7	35
1065	The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response. <i>Cells</i> , 2021, 10, 1668.	1.8	26
1066	Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy. <i>Acta Biomaterialia</i> , 2021, 134, 702-715.	4.1	28
1067	Follistatin-Like 3 Enhances Invasion and Metastasis via β -Catenin-Mediated EMT and Aerobic Glycolysis in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 660159.	1.8	18
1068	Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 265-293.	6.6	53
1069	Reinforcing the Combinational Immuno-Oncotherapy of Switching "Cold" Tumor to "Hot" by Responsive Penetrating Nanogels. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 36824-36838.	4.0	24
1070	Different co-culture models reveal the pivotal role of TBBPA-promoted M2 macrophage polarization in the deterioration of endometrial cancer. <i>Journal of Hazardous Materials</i> , 2021, 413, 125337.	6.5	13
1071	Overcoming physical stromal barriers to cancer immunotherapy. <i>Drug Delivery and Translational Research</i> , 2021, 11, 2430-2447.	3.0	5
1072	CD47 blockade enhances therapeutic efficacy of cisplatin against lung carcinoma in a murine model. <i>Experimental Cell Research</i> , 2021, 405, 112677.	1.2	8
1073	Neutrophil in the Pancreatic Tumor Microenvironment. <i>Biomolecules</i> , 2021, 11, 1170.	1.8	28
1074	Integrated Analysis Of Immunotherapy Treated Clear Cell Renal Cell Carcinomas: An Exploratory Study. <i>Journal of Immunotherapy</i> , 2022, 45, 35-42.	1.2	3

#	ARTICLE	IF	CITATIONS
1075	Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 152-161.	0.6	4
1076	Cancer biology deciphered by single-cell transcriptomic sequencing. <i>Protein and Cell</i> , 2022, 13, 167-179.	4.8	17
1077	Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review. <i>Immunotherapy</i> , 2021, 13, 989-1000.	1.0	7
1078	Early-phenotype CAR-T cells for the treatment of pediatric cancers. <i>Annals of Oncology</i> , 2021, 32, 1366-1380.	0.6	14
1079	Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9401.	1.8	16
1080	Myeloid cell-based delivery of IFN γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses. <i>EMBO Molecular Medicine</i> , 2021, 13, e13598.	3.3	13
1081	Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations. <i>Genes</i> , 2021, 12, 1274.	1.0	3
1082	Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9133.	1.8	4
1083	Roles and Regulation of Growth differentiation factor-15 in the Immune and tumor microenvironment. <i>Human Immunology</i> , 2021, 82, 937-944.	1.2	13
1084	Targeting cancer stem cells via integrin $\alpha 2 \beta 4$. <i>Oncotarget</i> , 2021, 12, 1850-1858.	0.8	6
1085	Oxygen Vacancy-Driven Reversible Free Radical Catalysis for Environment-Adaptive Cancer Chemodynamic Therapy. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 20943-20951.	7.2	44
1086	Overcoming Chemoimmunotherapy-Induced Immunosuppression by Assemblable and Depot Forming Immune Modulating Nanosuspension. <i>Advanced Science</i> , 2021, 8, e2102043.	5.6	23
1087	Avances en citometría de masas y aplicabilidad en patología digital para estudios clínico-traslacionales en oncología. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2022, 3, 17-29.	0.1	0
1088	Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy. <i>Biomaterials</i> , 2021, 275, 120970.	5.7	52
1089	Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2100010.	1.7	5
1090	Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC. <i>Cancers</i> , 2021, 13, 4091.	1.7	14
1091	M2 macrophage-targeted iron oxide nanoparticles for magnetic resonance image-guided magnetic hyperthermia therapy. <i>Journal of Materials Science and Technology</i> , 2021, 81, 77-87.	5.6	26
1092	Tumour-host interactions through the lens of <i>Drosophila</i> . <i>Nature Reviews Cancer</i> , 2021, 21, 687-700.	12.8	39

#	ARTICLE	IF	CITATIONS
1093	Fusobacterium nucleatum Acts as a Pro-carcinogenic Bacterium in Colorectal Cancer: From Association to Causality. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 710165.	1.8	52
1094	Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 717038.	1.6	2
1095	The Role of Bacteria in KSHV Infection and KSHV-Induced Cancers. <i>Cancers</i> , 2021, 13, 4269.	1.7	6
1096	Pyroptosis, a new bridge to tumor immunity. <i>Cancer Science</i> , 2021, 112, 3979-3994.	1.7	113
1098	Upregulation of C/EBP β Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5961-5978.	3.2	47
1099	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5878-5890.	3.2	30
1100	An Engineered Patientâ€Derived Tumor Organoid Model That Can Be Disassembled to Study Cellular Responses in a Graded 3D Microenvironment. <i>Advanced Functional Materials</i> , 2021, 31, 2105349.	7.8	15
1101	Immunotherapy for Dogs: Still Running Behind Humans. <i>Frontiers in Immunology</i> , 2021, 12, 665784.	2.2	14
1102	<i>Enterococcus</i> peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. <i>Science</i> , 2021, 373, 1040-1046.	6.0	158
1103	Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy. <i>Nano Today</i> , 2021, 39, 101225.	6.2	45
1104	Antiâ€PD-1 and Antiâ€PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 705096.	2.2	47
1105	Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 726492.	2.2	17
1106	Engineering Endogenous Tumorâ€Associated Macrophageâ€Targeted Biomimetic Nanoâ€RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemoâ€Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2103497.	11.1	73
1107	Influencing factors and strategies of enhancing nanoparticles into tumors inâ€vivo. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2265-2285.	5.7	94
1108	Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancerâ€May Cold Tumors Simply Be Too Hot?. <i>Frontiers in Immunology</i> , 2021, 12, 716342.	2.2	11
1109	Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies. <i>Seminars in Cancer Biology</i> , 2022, 86, 1076-1085.	4.3	20
1110	Single cell analyses to understand the immune continuum in atherosclerosis. <i>Atherosclerosis</i> , 2021, 330, 85-94.	0.4	18
1111	Identification of a circRNA-miRNA-mRNA regulatory network for exploring novel therapeutic options for glioma. <i>PeerJ</i> , 2021, 9, e11894.	0.9	5

#	ARTICLE	IF	CITATIONS
1112	Upregulation of THBS1 is Related to Immunity and Chemotherapy Resistance in Gastric Cancer. International Journal of General Medicine, 2021, Volume 14, 4945-4957.	0.8	26
1113	RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance. Medical Science Monitor, 2021, 27, e930994.	0.5	4
1114	Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC. Pharmacological Research, 2021, 170, 105734.	3.1	7
1115	Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 8530.	1.8	50
1116	Combined DNA Methylation and Transcriptomic Assessments to Determine a Prognostic Model for PD-1-Negative Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 708819.	1.8	4
1117	Balance and modulation of immunoediting for cancer treatment using synergistic nano-photo-immuno effects. Nanophotonics, 2021, 10, 3383-3389.	2.9	1
1118	Histological differentiation impacts the tumor immune microenvironment in gastric carcinoma: Relation to the immune cycle. World Journal of Gastroenterology, 2021, 27, 5259-5271.	1.4	6
1119	Increased CD3+, CD8+, or FoxP3+ T Lymphocyte Infiltrations Are Associated with the Pathogenesis of Colorectal Cancer but Not with the Overall Survival of Patients. Biology, 2021, 10, 808.	1.3	6
1120	Exploring the longitudinal glioma microenvironment landscape uncovers reprogrammed pro-tumorigenic neutrophils in the bone marrow. Cell Reports, 2021, 36, 109480.	2.9	30
1121	Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. Nano Today, 2021, 39, 101163.	6.2	18
1122	Decoding the Roles of Astrocytes and Hedgehog Signaling in Medulloblastoma. Current Oncology, 2021, 28, 3058-3070.	0.9	2
1123	Characterization of <i>in vitro</i> 3D cultures. Apmis, 2021, 129, 1-30.	0.9	3
1124	Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. Signal Transduction and Targeted Therapy, 2021, 6, 312.	7.1	50
1125	Role of Immune Cell-Specific Hypermethylation Signatures in Classification and Risk Stratification of Breast Cancer. Frontiers in Medicine, 2021, 8, 674338.	1.2	0
1126	Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. Cancers, 2021, 13, 4364.	1.7	5
1127	Oxygen Vacancy-Driven Reversible Free Radical Catalysis for Environment-Adaptive Cancer Chemodynamic Therapy. Angewandte Chemie, 2021, 133, 21111-21119.	1.6	3
1128	Antidiabetic DPP-4 Inhibitors Reprogram Tumor Microenvironment That Facilitates Murine Breast Cancer Metastasis Through Interaction With Cancer Cells via a ROS ⁺ NF- κ B ⁺ NLRP3 Axis. Frontiers in Oncology, 2021, 11, 728047.	1.3	8
1129	The Pandora's box of novel technologies that may revolutionize lung cancer. Lung Cancer, 2021, 159, 34-41.	0.9	12

#	ARTICLE	IF	CITATIONS
1130	Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. <i>Cell Metabolism</i> , 2021, 33, 2040-2058.e10.	7.2	200
1131	Engineered Attenuated <i>Salmonella typhimurium</i> Expressing Neoantigen Has Anticancer Effects. <i>ACS Synthetic Biology</i> , 2021, 10, 2478-2487.	1.9	13
1132	Cancer derived exosomes induce macrophages immunosuppressive polarization to promote bladder cancer progression. <i>Cell Communication and Signaling</i> , 2021, 19, 93.	2.7	23
1133	In situ functional cell phenotyping reveals microdomain networks in colorectal cancer recurrence. <i>Cell Reports Methods</i> , 2021, 1, 100072.	1.4	3
1134	Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy. <i>Scientific Reports</i> , 2021, 11, 19432.	1.6	6
1135	Potential Therapeutic and Prognostic Values of LSM Family Genes in Breast Cancer. <i>Cancers</i> , 2021, 13, 4902.	1.7	26
1136	Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1180-1192.	2.5	37
1137	Polysome Nanoreactor-Mediated Combination Chemodynamic-Immunotherapy via ROS Production and Enhanced STING Activation. <i>Advanced Therapeutics</i> , 2021, 4, 2100130.	1.6	15
1139	The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 744889.	1.3	19
1140	Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 96.	1.3	5
1141	Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. <i>Cancer Cell</i> , 2021, 39, 1202-1213.e6.	7.7	124
1142	IRF4 is Correlated with the Conversion to a Th17-Like Phenotype in Regulatory T Cells from the Malignant Pleural Effusion. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6009-6019.	0.8	7
1143	Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy. <i>Coordination Chemistry Reviews</i> , 2021, 442, 214009.	9.5	29
1144	Molecular Characterization of Prostate Cancers in the Precision Medicine Era. <i>Cancers</i> , 2021, 13, 4771.	1.7	10
1145	TCF4 enhances hepatic metastasis of colorectal cancer by regulating tumor-associated macrophage via CCL2/CCR2 signaling. <i>Cell Death and Disease</i> , 2021, 12, 882.	2.7	34
1146	ARIC: accurate and robust inference of cell type proportions from bulk gene expression or DNA methylation data. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	6
1147	Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance. <i>Cancers</i> , 2021, 13, 4515.	1.7	6
1148	Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures. <i>Immunity, Inflammation and Disease</i> , 2022, 10, 43-59.	1.3	4

#	ARTICLE	IF	CITATIONS
1150	N6-Methyladenosine RNA Modification: An Emerging Immunotherapeutic Approach to Turning Up Cold Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 736298.	1.8	7
1151	PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma. <i>Histopathology</i> , 2021, 79, 861-871.	1.6	6
1152	CCL2 produced by pancreatic ductal adenocarcinoma is essential for the accumulation and activation of monocytic myeloid-derived suppressor cells. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1686-1695.	1.3	14
1153	Trending topics of SIRT1 in tumorigenicity. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129952.	1.1	34
1154	Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. <i>Trends in Molecular Medicine</i> , 2021, 27, 856-867.	3.5	141
1155	Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4734.	1.7	13
1156	DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2021, 19, 274.	0.8	10
1157	Considerations for the delivery of STING ligands in cancer immunotherapy. <i>Journal of Controlled Release</i> , 2021, 339, 235-247.	4.8	18
1158	Efficient production of human neutrophils from iPSCs that prevent murine lethal infection with immune cell recruitment. <i>Blood</i> , 2021, 138, 2555-2569.	0.6	10
1159	Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer. <i>Modern Pathology</i> , 2022, 35, 218-227.	2.9	8
1160	The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication. <i>Frontiers in Immunology</i> , 2021, 12, 618367.	2.2	14
1161	The role of sialic acid-binding immunoglobulin-like-lectin-1 (siglec-1) in immunology and infectious disease. <i>International Reviews of Immunology</i> , 2023, 42, 113-138.	1.5	7
1162	Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 52, 128373.	1.0	3
1163	Mapping genomic and epigenomic evolution in cancer ecosystems. <i>Science</i> , 2021, 373, 1474-1479.	6.0	38
1164	Towards precision oncology in angiosarcomas using next generation genomic technologies. <i>Oncotarget</i> , 2021, 12, 1953-1955.	0.8	2
1165	RNA N ⁶ -methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential. <i>Clinical and Translational Medicine</i> , 2021, 11, e525.	1.7	18
1166	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunotherapy. <i>Cell</i> , 2021, 184, 4753-4771.e27.	13.5	99
1167	Atlas of clinically distinct cell states and ecosystems across human solid tumors. <i>Cell</i> , 2021, 184, 5482-5496.e28.	13.5	116

#	ARTICLE	IF	CITATIONS
1168	Lipidomic Typing of Colorectal Cancer Tissue Containing Tumour-Infiltrating Lymphocytes by MALDI Mass Spectrometry Imaging. <i>Metabolites</i> , 2021, 11, 599.	1.3	13
1169	Comprehensive Analysis of the Immune Infiltrates of Pyroptosis in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 716854.	1.3	17
1170	Cholangiocarcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 65.	18.1	270
1171	Identifying GPSM Family Members as Potential Biomarkers in Breast Cancer: A Comprehensive Bioinformatics Analysis. <i>Biomedicines</i> , 2021, 9, 1144.	1.4	18
1172	Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 953-966.	2.0	8
1173	Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer. <i>EBioMedicine</i> , 2021, 71, 103547.	2.7	4
1174	Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. , 2021, 9, e003032.		20
1175	The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 745859.	1.8	14
1176	A Review of Artificial Intelligence in Precise Assessment of Programmed Cell Death-ligand 1 and Tumor-infiltrating Lymphocytes in Non-small Cell Lung Cancer. <i>Advances in Anatomic Pathology</i> , 2021, 28, 439-445.	2.4	7
1177	High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments. <i>Biomedicines</i> , 2021, 9, 1132.	1.4	7
1178	Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 889-903.	2.0	8
1179	Engineered in vitro tumor models for cell-based immunotherapy. <i>Acta Biomaterialia</i> , 2021, 132, 345-359.	4.1	13
1180	The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9550.	1.8	15
1181	Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9890.	1.8	14
1182	Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors. <i>JCI Insight</i> , 2021, 6, .	2.3	21
1183	Epigenetic mechanisms of liver tumor resistance to immunotherapy. <i>World Journal of Hepatology</i> , 2021, 13, 979-1002.	0.8	5
1184	Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 732841.	1.3	1
1185	Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1694-1704.	0.5	12

#	ARTICLE	IF	CITATIONS
1186	Immunotherapy for HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 361-370.	1.0	5
1187	Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 37, 102415.	1.7	16
1188	Dynamic nanoassemblies of nanomaterials for cancer photomedicine. <i>Advanced Drug Delivery Reviews</i> , 2021, 177, 113954.	6.6	35
1189	Advances in spatial transcriptomic data analysis. <i>Genome Research</i> , 2021, 31, 1706-1718.	2.4	102
1190	Development and Verification of an Immune-Related Gene Pairs Prognostic Signature in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 715728.	1.6	4
1191	Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment. <i>Nano Today</i> , 2021, 40, 101244.	6.2	16
1192	Characteristics of macrophages from myelodysplastic syndrome microenvironment. <i>Experimental Cell Research</i> , 2021, 408, 112837.	1.2	3
1193	The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 41, 101134.	3.2	147
1194	Biomembrane-based nanostructures for cancer targeting and therapy: From synthetic liposomes to natural biomembranes and membrane-vesicles. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113974.	6.6	65
1195	Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 160, 121-127.	0.9	6
1196	Advance of nano anticancer therapies targeted on tumor-associated macrophages. <i>Coordination Chemistry Reviews</i> , 2021, 446, 214126.	9.5	6
1197	Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1-10.	2.3	11
1198	Preparation and evaluation of dabrafenib-loaded, CD47-conjugated human serum albumin-based nanoconstructs for chemoimmunomodulation. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 208, 112093.	2.5	6
1199	Spatial mapping of the tumor immune microenvironment. , 2022, , 293-329.		0
1200	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
1201	Targeting cancer-associated fibroblasts in immunotherapy. , 2022, , 163-209.		2
1202	Challenges and opportunities of nanotechnology in cancer immunotherapy. , 2022, , 197-239.		1
1203	Inflammation and cancer. , 2022, , 63-82.		2

#	ARTICLE	IF	CITATIONS
1204	Acid-responsive endosomolytic polymeric nanoparticles with amplification of intracellular oxidative stress for prodrug delivery and activation. <i>Biomaterials Science</i> , 2021, 9, 4613-4629.	2.6	10
1205	Underlying metastasis mechanism and clinical application of exosomal circular RNA in tumors (Review). <i>International Journal of Oncology</i> , 2021, 58, 289-297.	1.4	22
1206	Mutational Signatures Driven by Epigenetic Determinants Enable the Stratification of Patients with Gastric Cancer for Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 490.	1.7	5
1207	Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review. <i>Current Challenges in Thoracic Surgery</i> , 0, .	0.2	2
1208	Correction: Single nanosheet can sustainably generate oxygen and inhibit respiration simultaneously in cancer cells. <i>Materials Horizons</i> , 2021, 8, 645-645.	6.4	5
1209	Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. <i>Theranostics</i> , 2021, 11, 7029-7044.	4.6	37
1210	B-cell clusters at the invasive margin associate with longer survival in early-stage oral-tongue cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1882743.	2.1	11
1211	Multi-omics Analysis of Ferroptosis Regulation Patterns and Characterization of Tumor Microenvironment in Patients with Oral Squamous Cell Carcinoma. <i>International Journal of Biological Sciences</i> , 2021, 17, 3476-3492.	2.6	21
1213	Potential prognostic biomarkers related to immunity in clear cell renal cell carcinoma using bioinformatic strategy. <i>Bioengineered</i> , 2021, 12, 1773-1790.	1.4	15
1214	Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. <i>Nature Communications</i> , 2021, 12, 440.	5.8	175
1215	Typical Tumor Immune Microenvironment Status Determine Prognosis in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1216	Targeting metastatic cancer. <i>Nature Medicine</i> , 2021, 27, 34-44.	15.2	447
1217	Analysis of RNA m ⁶ A methylation regulators and tumour immune cell infiltration characterization in prostate cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2021, 49, 407-435.	1.9	15
1218	Overview: Lipid Metabolism in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1316, 41-47.	0.8	18
1219	Expression of programmed death-ligand 1 and programmed death-1 in patients with extramammary paget's disease. <i>Indian Journal of Dermatology</i> , 2021, 66, 169.	0.1	4
1220	CXCL12 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1302, 51-70.	0.8	26
1221	A novel cancer immunotherapy using tumor-infiltrating B cells in the APCmin/+ mouse model. <i>PLoS ONE</i> , 2021, 16, e0245608.	1.1	6
1222	A Universal Model for the Log-Normal Distribution of Elasticity in Polymeric Gels and Its Relevance to Mechanical Signature of Biological Tissues. <i>Biology</i> , 2021, 10, 64.	1.3	2

#	ARTICLE	IF	CITATIONS
1223	A Vaccination with Boosted Cross Presentation by ER α -Targeted Antigen Delivery for Anti-Tumor Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001934.	3.9	19
1224	Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy. <i>Journal of Materials Chemistry B</i> , 2021, 9, 3983-4001.	2.9	28
1225	Engineering nanomedicine for glutathione depletion-augmented cancer therapy. <i>Chemical Society Reviews</i> , 2021, 50, 6013-6041.	18.7	342
1226	PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 843-856.	2.0	18
1227	Quiescent Cancer Cells Resist T Cell Attack by Forming an Immunosuppressive Niche. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
1228	Identification of an Immune Gene Signature Based on Tumor Microenvironment Characteristics in Colon Adenocarcinoma. <i>Cell Transplantation</i> , 2021, 30, 096368972110013.	1.2	10
1229	Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages. <i>Nanoscale</i> , 2021, 13, 4705-4727.	2.8	33
1230	Leveraging Immunotherapy with Nanomedicine. <i>Advanced Therapeutics</i> , 2020, 3, 2000134.	1.6	2
1231	Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis. <i>International Journal of Cancer</i> , 2020, 147, 2279-2292.	2.3	10
1232	Computational Deconvolution of Tumor-Infiltrating Immune Components with Bulk Tumor Gene Expression Data. <i>Methods in Molecular Biology</i> , 2020, 2120, 249-262.	0.4	18
1233	Cell-Type Enrichment Analysis of Bulk Transcriptomes Using xCell. <i>Methods in Molecular Biology</i> , 2020, 2120, 263-276.	0.4	86
1234	Single-Cell Multiplexed Proteomics on the IsoLight Resolves Cellular Functional Heterogeneity to Reveal Clinical Responses of Cancer Patients to Immunotherapies. <i>Methods in Molecular Biology</i> , 2020, 2055, 413-431.	0.4	30
1235	Immunomodulation in Oncolytic Measles Virotherapy. <i>Methods in Molecular Biology</i> , 2020, 2058, 111-126.	0.4	10
1236	Tumor Microenvironment "Selective Pressures Boosting Cancer Progression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1219, 35-49.	0.8	16
1237	Rho-ROCK Signaling in Normal Physiology and as a Key Player in Shaping the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1223, 99-127.	0.8	17
1238	CCL20 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1231, 53-65.	0.8	38
1239	Interleukin-8 in the Tumor Immune Niche: Lessons from Comparative Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1240, 25-33.	0.8	19
1240	CAR T Cell Therapy Progress and Challenges for Solid Tumors. <i>Cancer Treatment and Research</i> , 2020, 180, 297-326.	0.2	23

#	ARTICLE	IF	CITATIONS
1241	Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1277, 143-158.	0.8	12
1242	Notch Signaling and the Breast Cancer Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1287, 183-200.	0.8	24
1243	Weakly Supervised Multiple Instance Learning Histopathological Tumor Segmentation. <i>Lecture Notes in Computer Science</i> , 2020, , 470-479.	1.0	33
1244	Flow cytometry-based isolation of tumor-associated regulatory T cells and assessment of their suppressive potential. <i>Methods in Enzymology</i> , 2020, 632, 259-281.	0.4	6
1245	Membrane-core nanoparticles for cancer nanomedicine. <i>Advanced Drug Delivery Reviews</i> , 2020, 156, 23-39.	6.6	53
1246	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. <i>Cell Reports</i> , 2020, 33, 108571.	2.9	99
1247	Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression. <i>EBioMedicine</i> , 2019, 40, 118-134.	2.7	50
1249	Chemo-physical Strategies to Advance the <i>in Vivo</i> Functionality of Targeted Nanomedicine: The Next Generation. <i>Journal of the American Chemical Society</i> , 2021, 143, 538-559.	6.6	148
1250	Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors. <i>Nature Communications</i> , 2020, 11, 622.	5.8	82
1251	Transcriptional effects of copy number alterations in a large set of human cancers. <i>Nature Communications</i> , 2020, 11, 715.	5.8	53
1252	Immune crosstalk in cancer progression and metastatic spread: a complex conversation. <i>Nature Reviews Immunology</i> , 2020, 20, 483-497.	10.6	241
1253	Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. <i>Nature Genetics</i> , 2020, 52, 594-603.	9.4	380
1254	Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis. <i>Seminars in Liver Disease</i> , 2020, 40, 307-320.	1.8	76
1255	Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32005-32016.	3.3	89
1256	<i>In situ</i> vaccination with nanoparticles for cancer immunotherapy: understanding the immunology. <i>International Journal of Hyperthermia</i> , 2020, 37, 4-17.	1.1	12
1257	SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	138
1258	Transplant Oncology in Primary and Metastatic Liver Tumors. <i>Annals of Surgery</i> , 2021, 273, 483-493.	2.1	33
1276	Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. <i>Cancer Science</i> , 2020, 111, 1943-1957.	1.7	24

#	ARTICLE	IF	CITATIONS
1277	Regulatory B cells in cancer. <i>Immunological Reviews</i> , 2021, 299, 74-92.	2.8	75
1278	Enhanced tumor immune surveillance through neutrophil reprogramming due to Tollip deficiency. <i>JCI Insight</i> , 2019, 4, .	2.3	23
1279	IFN regulatory factor α 8 expression in macrophages governs an antimetastatic program. <i>JCI Insight</i> , 2019, 4, .	2.3	30
1280	Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. <i>JCI Insight</i> , 2018, 3, .	2.3	216
1281	Primary tumors induce neutrophil extracellular traps with targetable metastasis-promoting effects. <i>JCI Insight</i> , 2019, 4, .	2.3	155
1282	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. <i>JCI Insight</i> , 2019, 4, .	2.3	113
1283	IL-32 β potentiates tumor immunity in melanoma. <i>JCI Insight</i> , 2020, 5, .	2.3	20
1284	A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. <i>Journal of Clinical Investigation</i> , 2020, 130, 1405-1416.	3.9	64
1285	Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 2081-2096.	3.9	108
1286	Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 3865-3884.	3.9	230
1287	Selective SIRP α blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 6109-6123.	3.9	53
1288	Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5380-5396.	3.9	185
1289	Immune profiling of pediatric solid tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 3391-3402.	3.9	27
1290	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1785-1800.	3.9	266
1292	Host deficiency in ephrin-A1 inhibits breast cancer metastasis. <i>F1000Research</i> , 2020, 9, 217.	0.8	13
1293	CRI iAtlas: an interactive portal for immuno-oncology research. <i>F1000Research</i> , 2020, 9, 1028.	0.8	39
1294	Density of CD3+ and CD8+ cells in gingivo-buccal oral squamous cell carcinoma is associated with lymph node metastases and survival. <i>PLoS ONE</i> , 2020, 15, e0242058.	1.1	17
1295	Classifying the Linkage between Adipose Tissue Inflammation and Tumor Growth through Cancer-Associated Adipocytes. <i>Molecules and Cells</i> , 2020, 43, 763-773.	1.0	4

#	ARTICLE	IF	CITATIONS
1296	The actin modulator <i>hMENA</i> regulates <i>GAS</i> β - <i>AXL</i> axis and promotes tumor cancer/stromal cell cooperation. <i>EMBO Reports</i> , 2020, 21, e50078.	2.0	20
1297	Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages. <i>EMBO Molecular Medicine</i> , 2020, 12, e11210.	3.3	29
1298	A single cell atlas of the human liver tumor microenvironment. <i>Molecular Systems Biology</i> , 2020, 16, e9682.	3.2	99
1299	The roles of homologous recombination and the immune system in the genomic evolution of cancer. <i>Journal of Translational Science</i> , 2018, 5, .	0.2	16
1300	Identification of prognostic genes in the acute myeloid leukemia microenvironment. <i>Aging</i> , 2019, 11, 10557-10580.	1.4	34
1301	Construction of immune-related and prognostic lncRNA clusters and identification of their immune and genomic alterations characteristics in lung adenocarcinoma samples. <i>Aging</i> , 2020, 12, 9868-9881.	1.4	9
1302	Long noncoding RNA <i>KCNQ1OT1</i> promotes colorectal carcinogenesis by enhancing aerobic glycolysis via hexokinase-2. <i>Aging</i> , 2020, 12, 11685-11697.	1.4	32
1303	Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 19641-19659.	1.4	4
1304	Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment. <i>Aging</i> , 2020, 12, 22152-22173.	1.4	15
1305	Emerging approaches to study cell-cell interactions in tumor microenvironment. <i>Oncotarget</i> , 2019, 10, 785-797.	0.8	51
1306	The multifaceted anti-cancer effects of BRAF-inhibitors. <i>Oncotarget</i> , 2019, 10, 6623-6640.	0.8	48
1307	TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades. <i>Oncotarget</i> , 2020, 11, 1961-1970.	0.8	8
1308	The dark side of immunotherapy: pancreatic cancer. , 2020, 3, 491-520.		15
1309	Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. <i>Annals of Translational Medicine</i> , 2019, 7, 645-645.	0.7	26
1310	Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses. <i>Journal of Thoracic Disease</i> , 2020, 12, 4504-4509.	0.6	3
1311	Harnessing Tumor Immune Ecosystem Dynamics to Personalize Radiation Therapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
1312	Tumor in 3D: In Vitro Complex Cellular Models to Improve Nanodrugs Cancer Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 7234-7255.	1.2	7
1313	Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 815-825.	0.5	73

#	ARTICLE	IF	CITATIONS
1314	Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00142.	0.6	3
1315	Engineering Targeting Materials for Therapeutic Cancer Vaccines. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 19.	2.0	23
1316	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
1317	Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images. <i>Journal of Clinical Medicine</i> , 2021, 10, 118.	1.0	14
1318	Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment. <i>Endocrinology and Metabolism</i> , 2020, 35, 443-455.	1.3	14
1319	Identification and validation of tumor microenvironment-related genes of prognostic value in lung adenocarcinoma. <i>Oncology Letters</i> , 2020, 20, 1772-1780.	0.8	12
1320	Comprehensive analysis of prognostic immune-related genes associated with the tumor microenvironment of pancreatic ductal adenocarcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	1
1321	Inhibition of Indoleamine 2,3-Dioxygenase Enhances the Therapeutic Efficacy of Immunogenic Chemotherapeutics in Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 196.	0.8	26
1322	Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 149-166.	1.3	28
1323	CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. <i>ELife</i> , 2019, 8, .	2.8	131
1324	Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. <i>ELife</i> , 2020, 9, .	2.8	81
1325	Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing. <i>ELife</i> , 2020, 9, .	2.8	44
1326	Cancer systems immunology. <i>ELife</i> , 2020, 9, .	2.8	14
1327	Tracking cells in epithelial acini by light sheet microscopy reveals proximity effects in breast cancer initiation. <i>ELife</i> , 2020, 9, .	2.8	30
1328	The Adrenergic Nerve Network in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 271-294.	0.8	5
1329	Design of Nanostructure Materials to Modulate Immunosuppressive Tumour Microenvironments and Enhance Cancer Immunotherapy. <i>Bioanalysis</i> , 2021, , 143-172.	0.1	0
1330	Progranulin/GP88, A Complex and Multifaceted Player of Tumor Growth by Direct Action and via the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 475-498.	0.8	7
1331	Spatiotemporal Co-Dependency between Macrophages and Exhausted CD8 ⁺ T Cells in Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1332	Intratumoral cancer immunotherapy exploiting anti-viral immunity. <i>Journal of Clinical and Experimental Hematopathology</i> : JCEH, 2022, 62, 1-8.	0.3	4
1333	Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer. <i>Cancer Research</i> , 2021, 81, 5963-5976.	0.4	10
1335	Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. <i>Cell</i> , 2021, 184, 5338-5356.e21.	13.5	229
1336	Tissue schematics map the specialization of immune tissue motifs and their appropriation by tumors. <i>Cell Systems</i> , 2022, 13, 109-130.e6.	2.9	38
1337	Metabolic Molecule PLA2G2D Is a Potential Prognostic Biomarker Correlating With Immune Cell Infiltration and the Expression of Immune Checkpoint Genes in Cervical Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 755668.	1.3	11
1338	Immune cell infiltration signatures identified molecular subtypes and underlying mechanisms in gastric cancer. <i>Npj Genomic Medicine</i> , 2021, 6, 83.	1.7	20
1339	Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 328.	4.2	14
1340	Pan-Cancer Analysis of the Associations of TGFBI Expression With Prognosis and Immune Characteristics. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 745649.	1.6	12
1341	Spatiotemporally Controllable Distribution of Combination Therapeutics in Solid Tumors by Dually Modified Bacteria. <i>Advanced Materials</i> , 2022, 34, e2106669.	11.1	53
1342	Senescence and Immunoregulation in the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 754069.	1.8	18
1343	Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 89-102.	0.5	16
1344	The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 327.	3.5	47
1345	Alloantigen-activated (AAA) CD4+ T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 314.	3.5	1
1347	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021, 12, 6071.	5.8	44
1348	Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749369.	2.2	7
1349	Impact of Epithelialâ€“Mesenchymal Transition on the Immune Landscape in Breast Cancer. <i>Cancers</i> , 2021, 13, 5099.	1.7	7
1350	mTORâ€“dependent immunometabolism as Achillesâ€™ heel of anticancer therapy. <i>European Journal of Immunology</i> , 2021, , .	1.6	7
1351	Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	4

#	ARTICLE	IF	CITATIONS
1352	Novel 3D Âtissues Mimicking the Fibrotic Stroma in Pancreatic Cancer to Study Cellular Interactions and Stroma-Modulating Therapeutics. <i>Cancers</i> , 2021, 13, 5006.	1.7	5
1353	Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 22802-22829.	1.4	8
1354	Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	3
1355	Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 326.	3.5	19
1356	The tumor immune microenvironments of <sc>HPV</sc> ⁺ and <sc>HPV</sc> ^â head and neck cancers. <i>WIREs Mechanisms of Disease</i> , 2022, 14, e1539.	1.5	13
1357	Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis. <i>Nature Cancer</i> , 2021, 2, 1086-1101.	5.7	39
1358	Nanotechnology-enhanced immunotherapy for metastatic cancer. <i>Innovation(China)</i> , 2021, 2, 100174.	5.2	29
1359	Impact of human papillomavirus on the tumor microenvironment in oropharyngeal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2022, 150, 521-531.	2.3	6
1360	The TNF-Î±/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 725473.	1.8	21
1362	Identification and validation of an immune-associated RNA-binding proteins signature to predict clinical outcomes and therapeutic responses in colon cancer patients. <i>World Journal of Surgical Oncology</i> , 2021, 19, 314.	0.8	7
1363	Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. <i>Neoplasia</i> , 2021, 23, 1110-1122.	2.3	15
1364	Identification of immune infiltration-related LncRNA FAM83C-AS1 for predicting prognosis and immunotherapy response in colon cancer. <i>Transplant Immunology</i> , 2021, 69, 101481.	0.6	2
1365	Wrapping Porphyromonas gingivalis for tumor microenvironment immunomodulation and photothermal immunotherapy. <i>Nano Today</i> , 2021, 41, 101311.	6.2	19
1366	Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1/miR-142-5p/ PD-L1 axis. <i>Molecular Immunology</i> , 2021, 140, 47-58.	1.0	25
1367	A bioluminescence reporter mouse strain for inÂvivo imaging of CD8+ T cell localization and function. <i>Biochemical and Biophysical Research Communications</i> , 2021, 581, 12-19.	1.0	4
1368	Cell Softness Prevents Cytolytic T Cell Killing of Tumor-Repopulating Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1370	A Multifunctional Envelope-Type Nano Device for Cancer Therapy. , 2019, , 217-251.		0
1372	Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity. , 2019, , 265-276.		0

#	ARTICLE	IF	CITATIONS
1374	Checkmate with Checkpoint Inhibitors: Hope and Hype. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 159-162.	0.1	0
1375	Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. Journal of Immunotherapy and Precision Oncology, 2019, 2, 23-35.	0.6	1
1381	Herausforderungen einer Anthroposophischen Onkologie. Der Merkurstab, 2020, 73, 382-393.	0.0	1
1383	Host deficiency in ephrin-A1 inhibits breast cancer metastasis. F1000Research, 2020, 9, 217.	0.8	11
1385	Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1. Korean Journal of Clinical Oncology, 2020, 16, 57-62.	0.1	0
1388	Tumour-associated CD204 ⁺ microglia/macrophages accumulate in perivascular and perinecrotic niches and correlate with an interleukin-6-enriched inflammatory profile in glioblastoma. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	12
1389	m6A-Mediated Tumor Invasion and Methylation Modification in Breast Cancer Microenvironment. Journal of Oncology, 2021, 2021, 1-17.	0.6	10
1390	Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma. Frontiers in Immunology, 2021, 12, 769534.	2.2	12
1391	Self-Organizing Maps for Cellular In Silico Staining and Cell Substate Classification. Frontiers in Immunology, 2021, 12, 765923.	2.2	5
1392	The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?. Cancers, 2021, 13, 5412.	1.7	11
1393	Immune Evasion Mechanism and AXL. Frontiers in Oncology, 2021, 11, 756225.	1.3	21
1394	Angiogenesis Pathway in Kidney Renal Clear Cell Carcinoma and Its Prognostic Value for Cancer Risk Prediction. Frontiers in Medicine, 2021, 8, 731214.	1.2	4
1395	Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer. Annals of Translational Medicine, 2021, 9, 1591-1591.	0.7	4
1396	Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nature Biomedical Engineering, 2021, 5, 1261-1273.	11.6	32
1397	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	9.4	110
1398	Ferroptosis-mediated Crosstalk in the Tumor Microenvironment Implicated in Cancer Progression and Therapy. Frontiers in Cell and Developmental Biology, 2021, 9, 739392.	1.8	17
1399	Tumor Environment of Retinoblastoma, Intraocular Cancer. Advances in Experimental Medicine and Biology, 2020, 1296, 349-358.	0.8	4
1400	Nanoformulations in Human Health Conditions: The Paradigm Shift. , 2020, , 13-42.		0

#	ARTICLE	IF	CITATIONS
1401	Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis. <i>Bioscience Reports</i> , 2020, 40, .	1.1	10
1402	E3 ligase FBXW7 restricts M2-like tumor-associated macrophage polarization by targeting c-Myc. <i>Aging</i> , 2020, 12, 24394-24423.	1.4	17
1404	Fighting microbial pathogens by integrating host ecosystem interactions and evolution. <i>BioEssays</i> , 2021, 43, 2000272.	1.2	5
1405	Tumor immune microenvironment lncRNAs. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	77
1406	Nucleic-Acid Scavengers Mitigate Breast Cancer Induced Inflammation, Invasion, and Metastasis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
1408	Dynamic label-free in vivo imaging of tumor-immune microenvironment (TiME) and microvasculature features in skin cancers with reflectance confocal microscopy (RCM). , 2020, , .		0
1409	Activation vs. Organization: Prognostic Implications of T and B Cell Features of the PDAC Microenvironment. <i>Lecture Notes in Computer Science</i> , 2020, , 44-55.	1.0	0
1411	Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2020, 20, 1-16.	0.3	3
1416	FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 758648.	2.2	12
1417	Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 692079.	2.2	7
1418	Target-Based Radiosensitization Strategies: Concepts and Companion Animal Model Outlook. <i>Frontiers in Oncology</i> , 2021, 11, 768692.	1.3	5
1419	Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 743724.	1.8	2
1420	m5C Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Papillary Thyroid Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 729887.	1.3	7
1421	The Immune Infiltration in HNSCC and Its Clinical Value: A Comprehensive Study Based on the TCGA and GEO Databases. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-11.	0.7	9
1422	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. <i>Nature Medicine</i> , 2021, 27, 1910-1920.	15.2	62
1423	Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases. <i>Cancer Letters</i> , 2022, 525, 170-178.	3.2	6
1424	Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1. <i>Cancers</i> , 2021, 13, 5508.	1.7	9
1425	Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer. <i>EBioMedicine</i> , 2021, 73, 103664.	2.7	5

#	ARTICLE	IF	CITATIONS
1426	Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12015.	1.8	9
1427	Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5586.	1.7	13
1428	The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy. <i>BMC Cancer</i> , 2021, 21, 1183.	1.1	5
1429	Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence. <i>Frontiers in Immunology</i> , 2021, 12, 750046.	2.2	27
1434	Antibody-drug conjugates: an evolving approach for melanoma treatment. <i>Melanoma Research</i> , 2021, 31, 1-17.	0.6	4
1436	Oncostatin M expression and TP53 mutation status regulate tumor-infiltration of immune cells and survival outcomes in cholangiocarcinoma. <i>Aging</i> , 2020, 12, 21518-21543.	1.4	5
1437	High RPS3A expression correlates with low tumor immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patients. <i>American Journal of Cancer Research</i> , 2020, 10, 2768-2784.	1.4	6
1439	Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?. <i>Annals of Translational Medicine</i> , 2020, 8, 1112.	0.7	0
1440	Multi-omics analysis reveals the genetics and immune landscape of dexamethasone responsive genes in cancer microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1416.	0.7	1
1441	Cyclooxygenase-2 expressed hepatocellular carcinoma induces cytotoxic T lymphocytes exhaustion through M2 macrophage polarization. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 4360-4375.	0.0	5
1442	Roles of long noncoding RNAs on tumor immune escape by regulating immune cells differentiation and function. <i>American Journal of Cancer Research</i> , 2021, 11, 2369-2385.	1.4	5
1443	Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator. <i>American Journal of Cancer Research</i> , 2021, 11, 3445-3460.	1.4	2
1444	Twelve unanswered questions in cancer inspired by the life and work of Leland Chung: "if this is true, what does it imply?". <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 254-260.	0.4	0
1445	The Art of Oncoimmunovaccinomics. <i>World Journal of Vaccines</i> , 2021, 11, 50-66.	0.8	1
1446	BiTEs Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1447	Exposure to Tobacco Smoking Induces a subset of Activated Tumor-resident Tregs in Non-Small Cell Lung Cancer. <i>Translational Oncology</i> , 2022, 15, 101261.	1.7	3
1448	Genomic and molecular features distinguish young adult cancer from later-onset cancer. <i>Cell Reports</i> , 2021, 37, 110005.	2.9	21
1449	Analysis of Multi-Layer RNA Modification Patterns for the Characterization of Tumor Immune Microenvironment in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 761391.	1.8	1

#	ARTICLE	IF	CITATIONS
1450	Prediction of Survival Outcome in Lower-Grade Glioma Using a Prognostic Signature with 33 Immune-Related Gene Pairs. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8149-8160.	0.8	7
1451	Advances in mass cytometry and its applicability to digital pathology in clinical-translational cancer research. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2022, 3, 5-16.	0.1	1
1452	Role of Tumor-Associated Neutrophils in the Molecular Carcinogenesis of the Lung. <i>Cancers</i> , 2021, 13, 5972.	1.7	11
1453	A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 769272.	1.3	23
1454	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 745769.	2.2	3
1455	Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma. <i>BMC Cancer</i> , 2021, 21, 1211.	1.1	7
1456	The current and future applications of <i>in situ</i> hybridization technologies in anatomical pathology. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 5-18.	1.5	5
1457	Neoadjuvant/Perioperative Treatment Affects Spatial Distribution and Densities of Tumor Associated Neutrophils and CD8+ Lymphocytes in Gastric Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 1184.	1.1	4
1459	Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. <i>Frontiers in Genetics</i> , 2021, 12, 717319.	1.1	10
1460	Homeoprotein SIX1 compromises antitumor immunity through TGF- β -mediated regulation of collagens. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2660-2672.	4.8	5
1461	Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 5911.	1.7	1
1462	Identification of CCL4 as an Immune-Related Prognostic Biomarker Associated With Tumor Proliferation and the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 694664.	1.3	4
1463	Degradation-resistant implanted biomaterials establish an immunosuppressive microenvironment that induces T cell exhaustion by recruiting myeloid cells. <i>Fundamental Research</i> , 2022, 2, 648-658.	1.6	4
1464	Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer. <i>Cancers</i> , 2021, 13, 5998.	1.7	8
1465	IL-34, the rationale for its expression in physiological and pathological conditions. <i>Seminars in Immunology</i> , 2021, 54, 101517.	2.7	12
1466	Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 55890-55901.	4.0	16
1467	Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. <i>Cancer Cell</i> , 2021, 39, 1594-1609.e12.	7.7	151
1468	KRAS mutation: from undruggable to druggable in cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 386.	7.1	255

#	ARTICLE	IF	CITATIONS
1469	Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review. <i>Frontiers in Immunology</i> , 2021, 12, 771201.	2.2	14
1470	Myeloid Cell-Derived Oxidized Lipids and Regulation of the Tumor Microenvironment. <i>Cancer Research</i> , 2022, 82, 187-194.	0.4	14
1471	Downregulation of the Coiled-Coil Domain Containing 80 and Its Perspective Mechanisms in Ovarian Carcinoma: A Comprehensive Study. <i>International Journal of Genomics</i> , 2021, 2021, 1-20.	0.8	7
1472	Tumour Microenvironment Stress Promotes the Development of Drug Resistance. <i>Antioxidants</i> , 2021, 10, 1801.	2.2	29
1473	APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2022, 10, 70-86.	1.6	20
1474	CPP Applications in Immune Modulation and Disease Therapy. <i>Methods in Molecular Biology</i> , 2022, 2383, 347-368.	0.4	3
1475	The Role of Decorin and Biglycan Signaling in Tumorigenesis. <i>Frontiers in Oncology</i> , 2021, 11, 801801.	1.3	36
1476	Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. <i>Nature Communications</i> , 2021, 12, 6726.	5.8	101
1477	Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 767466.	1.8	13
1478	Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer. <i>Frontiers in Endocrinology</i> , 2021, 12, 772349.	1.5	11
1479	Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment for optimal cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2022, 237, 1285-1298.	2.0	20
1480	Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies. <i>Seminars in Cancer Biology</i> , 2022, 86, 769-781.	4.3	43
1481	Mad2 Induced Aneuploidy Contributes to Eml4-Alk Driven Lung Cancer by Generating an Immunosuppressive Environment. <i>Cancers</i> , 2021, 13, 6027.	1.7	1
1482	Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 782852.	2.2	19
1483	Immunologically modified enzyme-responsive micelles regulate the tumor microenvironment for cancer immunotherapy. <i>Materials Today Bio</i> , 2022, 13, 100170.	2.6	10
1484	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
1485	Impact of immune cells on the hallmarks of cancer: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103541.	2.0	27
1486	Profiling of immune features to predict immunotherapy efficacy. <i>Innovation(China)</i> , 2021, 3, 100194.	5.2	13

#	ARTICLE	IF	CITATIONS
1487	Cholangiocarcinoma: what are the most valuable therapeutic targets – cancer-associated fibroblasts, immune cells, or beyond T cells?. Expert Opinion on Therapeutic Targets, 2021, 25, 835-845.	1.5	8
1488	Targeting cancer metabolism in the era of precision oncology. Nature Reviews Drug Discovery, 2022, 21, 141-162.	21.5	385
1489	Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. Cancers, 2021, 13, 6052.	1.7	15
1490	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0
1491	Interferon- β Resistance and Immune Evasion in Glioma Develop via Notch-Regulated Co-Evolution of Malignant and Immune Cells. SSRN Electronic Journal, 0, , .	0.4	0
1492	Neutrophil extracellular traps and cancer. Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 665-671.	0.1	0
1493	Ferroptosis-related genes identify tumor immune microenvironment characterization for the prediction of prognosis in cervical cancer. Annals of Translational Medicine, 2022, 10, 123-123.	0.7	16
1494	Analysis of the tumor immune environment identifies an immune gene set-based prognostic signature in non-small cell lung cancer. Annals of Translational Medicine, 2021, 10, 0-0.	0.7	2
1495	MXD1 is a Potential Prognostic Biomarker and Correlated With Specific Molecular Change and Tumor Microenvironment Feature in Esophageal Squamous Cell Carcinoma. Technology in Cancer Research and Treatment, 2021, 20, 153303382110521.	0.8	3
1496	Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy. British Journal of Cancer, 2022, 126, 1570-1580.	2.9	18
1497	Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer. Frontiers in Immunology, 2021, 12, 812713.	2.2	3
1498	A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases. International Journal of General Medicine, 2022, Volume 15, 325-342.	0.8	3
1499	C-Reactive Protein Is an Indicator of the Immunosuppressive Microenvironment Fostered by Myeloid Cells in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 774823.	1.3	5
1500	A size/charge/targeting changeable nano-booster to realize synergistic photodynamic-immunotherapy with high safety. Chemical Engineering Journal, 2022, 434, 134585.	6.6	14
1501	Biomarkers of tumor microenvironment of malignant neoplasms of kidneys, urinary bladder, and prostate gland (literature review). Medical Alphabet, 2022, , 41-46.	0.0	0
1502	A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. Genome Medicine, 2022, 14, 5.	3.6	25
1503	Basics of immunotherapy for epithelial ovarian cancer. Journal of Gynecology Obstetrics and Human Reproduction, 2022, 51, 102283.	0.6	4
1504	Immune evasion mechanisms and therapeutic strategies in gastric cancer. World Journal of Gastrointestinal Oncology, 2022, 14, 216-229.	0.8	7

#	ARTICLE	IF	CITATIONS
1505	Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 342, 210-227.	4.8	16
1506	Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy. <i>Translational Oncology</i> , 2022, 16, 101309.	1.7	5
1507	Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?. <i>Annals of Translational Medicine</i> , 2020, 8, 1112-1112.	0.7	1
1508	Germline mutations and blood malignancy (Review). <i>Oncology Reports</i> , 2020, 45, 49-57.	1.2	2
1509	Multi-omics analysis reveals the genetics and immune landscape of dexamethasone responsive genes in cancer microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1416-1416.	0.7	2
1510	Study on the Changes of Immune Factors in Different Stages of Non-Small Cell Lung Cancer Chemotherapy. <i>Advances in Lung Cancer (Irvine)</i> , 2021, 10, 57-64.	0.2	0
1512	Epstein-Barr Virus-induced Gene 3 as a Novel Biomarker in Metastatic Melanoma With Infiltrating CD8+ T Cells: A Study Based on The Cancer Genome Atlas (TCGA). <i>Anticancer Research</i> , 2022, 42, 511-517.	0.5	2
1513	Chemokine Receptor-Targeted Therapies: Special Case for CCR8. <i>Cancers</i> , 2022, 14, 511.	1.7	16
1514	Shedding light on the hidden human proteome expands immunopeptidome in cancer. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	4
1515	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	33
1516	Pyroptosis-Mediated Molecular Subtypes are Characterized by Distinct Tumor Microenvironment Infiltration Characteristics in Breast Cancer. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 345-362.	1.6	9
1517	Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future. <i>Molecular Imaging and Biology</i> , 2022, 24, 264-279.	1.3	3
1519	Localized Degradation of Neutrophil Extracellular Traps by Photoregulated Enzyme Delivery for Cancer Immunotherapy and Metastasis Suppression. <i>ACS Nano</i> , 2022, 16, 2585-2597.	7.3	41
1520	Methylation-Driven Gene PLAU as a Potential Prognostic Marker for Differential Thyroid Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 819484.	1.8	4
1521	Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe. <i>Frontiers in Immunology</i> , 2022, 13, 836223.	2.2	14
1522	Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy. <i>Cancers</i> , 2022, 14, 226.	1.7	55
1523	Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. <i>OncImmunity</i> , 2022, 11, .	2.1	2
1524	Antiangiogenic agents in the treatment of colorectal, gastric, and gastroesophageal junction adenocarcinoma. , 2022, , 67-78.		0

#	ARTICLE	IF	CITATIONS
1525	Spatio-temporal analysis of nanoparticles in live tumor spheroids impacted by cell origin and density. <i>Journal of Controlled Release</i> , 2022, 341, 661-675.	4.8	12
1526	The B7H4-PDL1 classifier stratifies immuno-phenotype in cervical cancer. <i>Cancer Cell International</i> , 2022, 22, 3.	1.8	2
1527	Fatty Acid Metabolism in Myeloid-Derived Suppressor Cells and Tumor-Associated Macrophages: Key Factor in Cancer Immune Evasion. <i>Cancers</i> , 2022, 14, 250.	1.7	16
1528	Pan-Cancer Analysis Shows Enrichment of Macrophages, Overexpression of Checkpoint Molecules, Inhibitory Cytokines, and Immune Exhaustion Signatures in EMT-High Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 793881.	1.3	12
1529	Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 23.	4.2	32
1530	Identifies Immune Feature Genes for Prediction of Chemotherapy Benefit in Cancer. <i>Journal of Cancer</i> , 2022, 13, 496-507.	1.2	3
1532	Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets. <i>Medicinal Research Reviews</i> , 2022, 42, 1246-1279.	5.0	38
1533	Effective CpG Delivery Using Zwitterion-Functionalized Dendrimer-Entrapped Gold Nanoparticles to Promote T Cell-Mediated Immunotherapy of Cancer Cells. <i>Biosensors</i> , 2022, 12, 71.	2.3	4
1534	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. <i>Cancers</i> , 2022, 14, 644.	1.7	11
1535	Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation. <i>Cancer Cell International</i> , 2022, 22, 33.	1.8	12
1536	The emerging role of Arid5a in cancer: A new target for tumors. <i>Genes and Diseases</i> , 2022, , .	1.5	0
1537	Cell Communication Network factor 4 promotes tumor-induced immunosuppression in melanoma. <i>EMBO Reports</i> , 2022, 23, e54127.	2.0	6
1538	Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy. <i>Theranostics</i> , 2022, 12, 434-458.	4.6	154
1539	Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. <i>Journal of Clinical Oncology</i> , 2022, 40, 598-610.	0.8	94
1541	Dual-Targeted Lipid Nanotherapeutic Boost for Chemotherapy of Cancer. <i>Advanced Materials</i> , 2022, 34, e2106350.	11.1	25
1543	Cellular architecture of human brain metastases. <i>Cell</i> , 2022, 185, 729-745.e20.	13.5	69
1544	Yeast-derived nanoparticles remodel the immunosuppressive microenvironment in tumor and tumor-draining lymph nodes to suppress tumor growth. <i>Nature Communications</i> , 2022, 13, 110.	5.8	49
1545	Molecular Landscape of the Coagulum of Oral Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 460.	1.7	12

#	ARTICLE	IF	CITATIONS
1546	A Systematic Review of Expression and Immunogenicity of Human Endogenous Retroviral Proteins in Cancer and Discussion of Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1330.	1.8	14
1547	Identification of TRPM2 as a Marker Associated With Prognosis and Immune Infiltration in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 774905.	1.6	2
1548	<i>LINC00152</i> acts as a competing endogenous RNA of <i>HMGA1</i> to promote the growth of gastric cancer cells. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24192.	0.9	6
1549	Spatial Metrics of Interaction between CD163-Positive Macrophages and Cancer Cells and Progression-Free Survival in Chemo-Treated Breast Cancer. <i>Cancers</i> , 2022, 14, 308.	1.7	8
1551	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. <i>OncImmunology</i> , 2022, 11, 1993042.	2.1	16
1552	Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications. <i>Cancers</i> , 2022, 14, 280.	1.7	12
1553	Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 773581.	2.2	16
1554	Single-Cell RNA Sequencing in Lung Cancer: Revealing Phenotype Shaping of Stromal Cells in the Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 802080.	2.2	19
1555	N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer. <i>BMC Genomic Data</i> , 2022, 23, 8.	0.7	9
1556	Pan-cancer analysis of GALNTs expression identifies a prognostic of GALNTs feature in low grade glioma. <i>Journal of Leukocyte Biology</i> , 2022, 112, 887-899.	1.5	8
1557	Discovering dominant tumor immune archetypes in a pan-cancer census. <i>Cell</i> , 2022, 185, 184-203.e19.	13.5	70
1559	SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-13.	0.9	5
1560	Identification of the Key Immune-Related Genes in Chronic Obstructive Pulmonary Disease Based on Immune Infiltration Analysis. <i>International Journal of COPD</i> , 2022, Volume 17, 13-24.	0.9	4
1561	CXCR2 Mediates Distinct Neutrophil Behavior in Brain Metastatic Breast Tumor. <i>Cancers</i> , 2022, 14, 515.	1.7	12
1562	The prognostic value of m6A-related lncRNAs in patients with HNSCC: bioinformatics analysis of TCGA database. <i>Scientific Reports</i> , 2022, 12, 579.	1.6	12
1563	Novel Mouse Models for Cancer Immunology. <i>Annual Review of Cancer Biology</i> , 2022, 6, 269-291.	2.3	9
1564	N6-Methyladenosine-Related Gene Expression Signatures for Predicting the Overall Survival and Immune Responses of Patients With Colorectal Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1565	Positive Correlation Between LTA Expression and Overall Immune Activity Suggests an Increased Probability of Survival in Uterine Corpus Endometrial Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 793793.	1.8	2

#	ARTICLE	IF	CITATIONS
1566	Characterization of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration in Ovarian Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 794801.	1.8	4
1568	Metabolic regulation of ferroptosis in the tumor microenvironment. <i>Journal of Biological Chemistry</i> , 2022, 298, 101617.	1.6	44
1569	Orchestrated Yolkâ€“Shell Nanohybrids Regulate Macrophage Polarization and Dendritic Cell Maturation for Oncotherapy with Augmented Antitumor Immunity. <i>Advanced Materials</i> , 2022, 34, e2108263.	11.1	53
1570	Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of VSTM2L in Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 792154.	1.6	3
1571	Adipose-Derived Mesenchymal Stem Cells Responses to Different Doses of Gamma Radiation. <i>Journal of Biomedical Physics and Engineering</i> , 2022, 12, 35-42.	0.5	3
1572	A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity. <i>Journal of Immunology Research</i> , 2022, 2022, 1-17.	0.9	3
1573	Characterization of Interplay Between Autophagy and Ferroptosis and Their Synergistical Roles on Manipulating Immunological Tumor Microenvironment in Squamous Cell Carcinomas. <i>Frontiers in Immunology</i> , 2021, 12, 739039.	2.2	35
1574	Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. , 2022, 235, 108114.		13
1575	Development and Validation of a Three-Gene Prognostic Signature Based on Tumor Microenvironment for Gastric Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 801240.	1.1	5
1576	Role of Circular RNAs in the Regulation of Immune Cells in Response to Cancer Therapies. <i>Frontiers in Genetics</i> , 2022, 13, 823238.	1.1	8
1577	Inflammatory and immune effects on tumor progression. <i>Trends in Immunology</i> , 2022, 43, 93-95.	2.9	1
1578	CAF-derived exosomes deliver LINC01410 to promote epithelial-mesenchymal transition of esophageal squamous cell carcinoma. <i>Experimental Cell Research</i> , 2022, 412, 113033.	1.2	17
1579	Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma. <i>Gene</i> , 2022, 818, 146177.	1.0	9
1580	STK11 Loss: A Novel Mechanism for Melanoma Metastasis with Therapeutic Implications. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1007-1009.	0.3	3
1581	Single-cell transcriptomics reveals a low CD8 ⁺ T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma. , 2022, 10, e004206.		27
1582	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade. <i>Life</i> , 2022, 12, 229.	1.1	15
1583	Treatment Response and Prognosis Evaluation in Highâ€“Grade Glioma: An Imaging Review Based on <sc>MRI</sc>. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 325-340.	1.9	16
1584	Tertiary lymphoid structure and decreased CD8+ Tâ€“cell infiltration in minimally invasive adenocarcinoma. <i>IScience</i> , 2022, 25, 103883.	1.9	3

#	ARTICLE	IF	CITATIONS
1585	CGN Correlates With the Prognosis and Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 758974.	1.6	1
1586	Mesenchymal stromal cells equipped by IFN γ empower T cells with potent anti-tumor immunity. <i>Oncogene</i> , 2022, 41, 1866-1881.	2.6	9
1587	Reshaping the Tumor Immune Microenvironment Based on a Light-Activated Nanoplatfom for Efficient Cancer Therapy. <i>Advanced Materials</i> , 2022, 34, e2108908.	11.1	41
1588	Understanding metabolic reprogramming in tumor microenvironment. <i>Medical Review</i> , 2021, 1, 111-113.	0.3	0
1589	Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy. <i>Pathology Research and Practice</i> , 2022, 232, 153808.	1.0	5
1590	TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression. <i>Cancer Letters</i> , 2022, 532, 215583.	3.2	17
1591	Prognostic value of Dickkopf-1 and β -catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer. <i>Scientific Reports</i> , 2022, 12, 1931.	1.6	2
1592	Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy. <i>Advanced Materials</i> , 2022, 34, e2108167.	11.1	32
1594	Recent advance in nanomaterials for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 435, 134145.	6.6	16
1595	Lactic acid, a driver of tumor-stroma interactions. <i>International Immunopharmacology</i> , 2022, 106, 108597.	1.7	14
1596	Branched Polymer-Based Redox/Enzyme-Activatable Photodynamic Nanoagent to Trigger STING-Dependent Immune Responses for Enhanced Therapeutic Effect. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	59
1597	New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 38-55.	0.9	7
1598	Recent advances in biomaterial-boosted adoptive cell therapy. <i>Chemical Society Reviews</i> , 2022, 51, 1766-1794.	18.7	29
1599	Molecular imprinting of glycoproteins: From preparation to cancer theranostics. <i>Theranostics</i> , 2022, 12, 2406-2426.	4.6	18
1600	Intravenous Vaccination Induces CD8 ⁺ T Cells and Type I IFN-Dependent Remodeling of the Tumor Microenvironment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1601	ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts. <i>Journal of Cancer</i> , 2022, 13, 1933-1944.	1.2	6
1602	Multi-Omics Profiling of the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 283-326.	0.8	6
1603	Target therapy in cancer treatment. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
1604	Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 845923.	2.2	11
1605	Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors. <i>Cancer Management and Research</i> , 2022, Volume 14, 479-498.	0.9	11
1606	Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma. <i>Npj Precision Oncology</i> , 2022, 6, 10.	2.3	23
1607	Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 210-226.	1.3	7
1608	Correlation between Lymphocyte-to-Monocyte Ratio (LMR), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Tumor-Infiltrating Lymphocytes (TILs) in Left-Sided Colorectal Cancer Patients. <i>Biology</i> , 2022, 11, 385.	1.3	17
1609	Molecular Patterns Based on Immunogenomic Signatures Stratify the Prognosis of Colon Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 820092.	2.0	3
1610	Substrate rigidity dictates colorectal tumorigenic cell stemness and metastasis via CRAD-dependent mechanotransduction. <i>Cell Reports</i> , 2022, 38, 110390.	2.9	13
1611	Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2022, 10, 420-436.	1.6	17
1612	Exploring ALDH2 expression and immune infiltration in HNSC and its correlation of prognosis with gender or alcohol intake. <i>Scientific Reports</i> , 2022, 12, 2504.	1.6	5
1613	Correlation between Tumor Microenvironment and Immune Subtypes Based on CD8 T Cells Enhancing Personalized Therapy of Gastric Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-23.	0.6	2
1614	RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. <i>Molecular Cancer</i> , 2022, 21, 58.	7.9	33
1615	Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 62.	3.5	44
1616	Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer. <i>Cells</i> , 2022, 11, 824.	1.8	4
1617	Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma. <i>Frontiers in Immunology</i> , 2022, 13, 819515.	2.2	2
1618	A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	0
1619	Immune Analysis and Small Molecule Drug Prediction of Hepatocellular Carcinoma Based on Single Sample Gene Set Enrichment Analysis. <i>Cell Biochemistry and Biophysics</i> , 2022, 80, 427-434.	0.9	4
1620	Nano-ultrasonic Contrast Agent for Chemoimmunotherapy of Breast Cancer by Immune Metabolism Reprogramming and Tumor Autophagy. <i>ACS Nano</i> , 2022, 16, 3417-3431.	7.3	42
1622	Tumor-Infiltrating PD-L1+ Neutrophils Induced by GM-CSF Suppress T Cell Function in Laryngeal Squamous Cell Carcinoma and Predict Unfavorable Prognosis. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1079-1097.	1.6	10

#	ARTICLE	IF	CITATIONS
1623	Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection. <i>Frontiers in Immunology</i> , 2022, 13, 833310.	2.2	10
1624	Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 1216.	1.7	12
1625	Enhanced antitumor chemo-immunotherapy by local co-delivery of chemotherapeutics, immune checkpoint blocking antibody and <i>IDO</i> inhibitor using an injectable polypeptide hydrogel. <i>Journal of Polymer Science</i> , 2022, 60, 1595-1609.	2.0	9
1626	Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2022, 12, 2817.	1.6	3
1627	The Unfolded Protein Response at the Tumor-Immune Interface. <i>Frontiers in Immunology</i> , 2022, 13, 823157.	2.2	11
1628	Typical and atypical properties of peripheral nerve allografts enable novel strategies to repair segmental-loss injuries. <i>Journal of Neuroinflammation</i> , 2022, 19, 60.	3.1	8
1629	Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment. <i>Exploration of Medicine</i> , 0, , 22-42.	1.5	1
1630	CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 740822.	1.8	3
1631	Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers. <i>Frontiers in Immunology</i> , 2022, 13, 811601.	2.2	3
1632	Ferroptosis in Cancer Immunotherapy—Implications for Hepatocellular Carcinoma. <i>Immuno</i> , 2022, 2, 185-217.	0.6	3
1633	Physical & Chemical Microwave Ablation (MWA) Enabled by Nonionic MWA Nanosensitizers Repress Incomplete MWA-Arised Liver Tumor Recurrence. <i>ACS Nano</i> , 2022, 16, 5704-5718.	7.3	27
1634	Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma. <i>Nature Communications</i> , 2022, 13, 1158.	5.8	29
1635	Engineered nanomaterials for synergistic photo-immunotherapy. <i>Biomaterials</i> , 2022, 282, 121425.	5.7	57
1636	Seed or soil: Tracing the immune subsets in metastatic tumors. <i>Cancer Cell</i> , 2022, 40, 353-355.	7.7	3
1637	Identification of Immune-Related Breast Cancer Chemotherapy Resistance Genes via Bioinformatics Approaches. <i>Frontiers in Oncology</i> , 2022, 12, 772723.	1.3	1
1638	Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity. <i>Nano Letters</i> , 2022, 22, 2217-2227.	4.5	18
1639	The case for cancer-associated fibroblasts: essential elements in cancer drug discovery?. <i>Future Drug Discovery</i> , 0, , .	0.8	3
1640	Glutathione Depletion-Induced Activation of Dimersomes for Potentiating the Ferroptosis and Immunotherapy of Cold-Tumor. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	43

#	ARTICLE	IF	CITATIONS
1642	Nanoengineered Neutrophils as a Cellular Sonosensitizer for Visual Sonodynamic Therapy of Malignant Tumors. <i>Advanced Materials</i> , 2022, 34, e2109969.	11.1	32
1643	Comprehensive Analysis Identified Mutation-Gene Signature Impacts the Prognosis Through Immune Function in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 748557.	1.3	1
1644	Upregulation of MTA1 in Colon Cancer Drives A CD8+ T Cell-Rich But Classical Macrophage-Lacking Immunosuppressive Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2022, 12, 825783.	1.3	4
1645	Spatial CRISPR genomics identifies regulators of the tumor microenvironment. <i>Cell</i> , 2022, 185, 1223-1239.e20.	13.5	79
1646	<i>In Vivo</i> Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes. <i>Current Protocols</i> , 2022, 2, e377.	1.3	1
1647	Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	27
1648	Construction of immune-related lncRNA signature to predict aggressiveness, immune landscape, and drug resistance of colon cancer. <i>BMC Gastroenterology</i> , 2022, 22, 127.	0.8	2
1649	Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands. <i>BiolImpacts</i> , 2022, , .	0.7	4
1650	Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 840198.	2.2	9
1651	Immunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells. <i>Carcinogenesis</i> , 2022, , .	1.3	2
1652	Identification of New m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Landscape that Predict Clinical Outcomes for Papillary Renal Cell Carcinoma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818194.	1.8	1
1653	Ferroptosis Patterns and Tumor Microenvironment Infiltration Characterization in Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 832892.	1.8	17
1654	Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Based on Cytolytic Activity in Skin Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2022, 12, 844666.	1.3	2
1655	T Cell Metabolism in Infection. <i>Frontiers in Immunology</i> , 2022, 13, 840610.	2.2	45
1656	Landscape of T Cells in NK-AML(M4/M5) Revealed by Single-Cell Sequencing. <i>Journal of Leukocyte Biology</i> , 2022, 112, 745-758.	1.5	4
1657	Comprehensive Analysis of the Immune and Prognostic Implication of TRIM8 in Breast Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 835540.	1.1	1
1658	SIRT7 is a Prognostic Biomarker in Kidney Renal Clear Cell Carcinoma That is Correlated with Immune Cell Infiltration. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3167-3182.	0.8	0
1659	A Novel Prognostic Model for Identifying the Risk of Hepatocellular Carcinoma Based on Angiogenesis Factors. <i>Frontiers in Genetics</i> , 2022, 13, 857215.	1.1	8

#	ARTICLE	IF	CITATIONS
1660	Identifying the Potential Role and Prognostic Value of the Platelet-Derived Growth Factor Pathway in Kidney Renal Clear Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
1661	GSDMs are potential therapeutic targets and prognostic biomarkers in clear cell renal cell carcinoma. <i>Aging</i> , 2022, 14, 2758-2774.	1.4	12
1663	Roles of RNA-binding proteins in immune diseases and cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 310-324.	4.3	14
1664	Reproducible, high-dimensional imaging in archival human tissue by multiplexed ion beam imaging by time-of-flight (MIBI-TOF). <i>Laboratory Investigation</i> , 2022, 102, 762-770.	1.7	16
1665	Pyroptosis-related molecular classification and immune microenvironment infiltration in breast cancer: A novel therapeutic target. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2259-2272.	1.6	11
1666	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. <i>Cancers</i> , 2022, 14, 1367.	1.7	10
1667	Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 849759.	2.2	4
1668	Clinical relevance of tumour-associated macrophages. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 402-421.	12.5	250
1669	Development of a Localized Drug Delivery System with a Step-by-Step Cell Internalization Capacity for Cancer Immunotherapy. <i>ACS Nano</i> , 2022, 16, 5778-5794.	7.3	18
1670	Glycolysis-Related Gene Signature Can Predict Survival and Immune Status of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 3963-3976.	0.7	5
1671	Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas. <i>Frontiers in Immunology</i> , 2022, 13, 824586.	2.2	6
1672	MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3003-3030.	0.8	4
1673	Glutathione Depletion-Induced Activation of Dimersomes for Potentiating the Ferroptosis and Immunotherapy of Cold Tumor. <i>Angewandte Chemie</i> , 0, , .	1.6	6
1674	Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration. <i>Frontiers in Immunology</i> , 2022, 13, 854785.	2.2	27
1675	Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 847906.	1.6	6
1676	SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 864156.	2.2	11
1677	Tumor-Mediated Neutrophil Polarization and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3218.	1.8	20
1678	Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas. <i>Scientific Reports</i> , 2022, 12, 5457.	1.6	3

#	ARTICLE	IF	CITATIONS
1679	Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 823812.	1.3	5
1680	Targeting the RNA m6A modification for cancer immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 76.	7.9	78
1681	miR-873 and miR-105-2 May Affect the Tumour Microenvironment and are Potential Biomarkers for Lung Adenocarcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3433-3445.	0.8	4
1682	Role of Prostaglandin E2 in the Progression of Gastrointestinal Cancer. <i>Cancer Prevention Research</i> , 2022, 15, 355-363.	0.7	7
1683	Investigating the Clinico-Molecular and Immunological Evolution of Lung Adenocarcinoma Using Pseudotime Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 828505.	1.3	4
1684	Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine. <i>Cancers</i> , 2022, 14, 1759.	1.7	45
1685	Irradiation immunity interactions. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 519-535.	0.9	2
1686	Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells. <i>Human Gene Therapy</i> , 2022, 33, 649-663.	1.4	5
1687	The Pan-Cancer Crosstalk Between the EFNA Family and Tumor Microenvironment for Prognosis and Immunotherapy of Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 790947.	1.8	7
1688	Cellular vesicles expressing PD-1-blocking scFv reinvigorate T cell immunity against cancer. <i>Nano Research</i> , 2022, 15, 5295-5304.	5.8	11
1689	Sex Differences in Differentiated Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 224-235.	2.4	36
1690	Patterns of Tumor Infiltrating Lymphocytes in Adenoid Cystic Carcinoma of the Head and Neck. <i>Cancers</i> , 2022, 14, 1383.	1.7	5
1691	An Individualized Prognostic Signature for Clinically Predicting the Survival of Patients With Bladder Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 837301.	1.1	2
1692	Immune Infiltration and Clinical Outcome of Super-Enhancer-Associated lncRNAs in Stomach Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 780493.	1.3	6
1693	The AlkB Family: Potential Prognostic Biomarkers and Therapeutic Targets in Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 847821.	1.3	1
1694	In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4077.	1.8	4
1695	Intratumoral genetic and immune microenvironmental heterogeneity in <sc>T4NOM0</sc> (diameterâ€‰%â€‰%â€‰%7Åcm) nonâ€‰small cell lung cancers. <i>Thoracic Cancer</i> , 2022, , .	0.8	2
1697	Deep neural network modeling identifies biomarkers of response to immune-checkpoint therapy. <i>IScience</i> , 2022, 25, 104228.	1.9	4

#	ARTICLE	IF	CITATIONS
1698	Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 1813.	1.7	4
1699	Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 117.	7.1	72
1700	Multifunctional nanomedicines for synergistic photodynamic immunotherapy based on tumor immune microenvironment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 173, 103-120.	2.0	1
1701	Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 872531.	1.3	16
1702	Artificial Intelligenceâ€‘Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Nonâ€‘Small-Cell Lung Cancer. <i>American Journal of Pathology</i> , 2022, 192, 701-711.	1.9	6
1703	Longitudinal shear wave elasticity measurements of millimeter-sized biomaterials using a single-element transducer platform. <i>PLoS ONE</i> , 2022, 17, e0266235.	1.1	2
1704	Comprehensive Analysis of Tumor Immune Microenvironment Characteristics for the Prognostic Prediction and Immunotherapy of Oral Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 788580.	1.1	8
1705	Proteomics approaches to characterize the immune responses in cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119266.	1.9	4
1706	Radiation therapy-induced remodeling of the tumor immune microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 737-747.	4.3	30
1707	CAR-T Cells for the Treatment of Lung Cancer. <i>Life</i> , 2022, 12, 561.	1.1	8
1708	Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma. <i>Translational Oncology</i> , 2022, 18, 101367.	1.7	10
1709	CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity. <i>Nature Communications</i> , 2022, 13, 1899.	5.8	16
1710	Type 1 T Helper Cell-Based Molecular Subtypes and Signature Are Associated with Clinical Outcome in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 839893.	1.8	2
1711	Pinpointing the tumor-specific T cells via TCR clusters. <i>ELife</i> , 2022, 11, .	2.8	15
1712	New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis. , 2022, 10, e003765.		10
1713	Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer. <i>Nature Communications</i> , 2022, 13, 1742.	5.8	213
1714	IL-17â€‘induced HIF1Î± drives resistance to antiâ€‘PD-L1 via fibroblast-mediated immune exclusion. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	21
1715	Analyzing Spatial Transcriptomics Data Using Giotto. <i>Current Protocols</i> , 2022, 2, e405.	1.3	10

#	ARTICLE	IF	CITATIONS
1716	Unmet Needs and Perspectives in Oral Cancer Prevention. <i>Cancers</i> , 2022, 14, 1815.	1.7	14
1717	Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation. <i>Nano Today</i> , 2022, 43, 101425.	6.2	15
1718	Emerging immunotherapy for HCC: A guide for hepatologists. <i>Hepatology</i> , 2022, 75, 1604-1626.	3.6	97
1719	A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA. <i>Journal of Controlled Release</i> , 2022, 345, 354-370.	4.8	14
1720	Engineering complexity in human tissue models of cancer. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114181.	6.6	10
1721	Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside. <i>Life Sciences</i> , 2022, 297, 120466.	2.0	18
1722	Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and opportunities. <i>International Journal of Biological Macromolecules</i> , 2022, 207, 1022-1037.	3.6	9
1723	Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. <i>Journal of Controlled Release</i> , 2022, 345, 200-213.	4.8	13
1724	Identification and validation of Osteopontin and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) for potential immunotherapeutic significance of in lung squamous cell carcinoma. <i>International Immunopharmacology</i> , 2022, 107, 108715.	1.7	6
1725	p70 S6 kinase as a therapeutic target in cancers: More than just an mTOR effector. <i>Cancer Letters</i> , 2022, 535, 215593.	3.2	10
1726	Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis. <i>Healthcare (Switzerland)</i> , 2022, 10, 75.	1.0	5
1727	A Cascade Nanozyme with Amplified Sonodynamic Therapeutic Effects through Comodulation of Hypoxia and Immunosuppression against Cancer. <i>ACS Nano</i> , 2022, 16, 485-501.	7.3	88
1728	Immunosuppressive Traits of the Hybrid Epithelial/Mesenchymal Phenotype. <i>Frontiers in Immunology</i> , 2021, 12, 797261.	2.2	52
1731	Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance. <i>Medical Review</i> , 2021, 1, 222-243.	0.3	4
1732	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. <i>Science Translational Medicine</i> , 2021, 13, eabf8495.	5.8	16
1733	Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 205.	1.7	10
1734	Different Glucose Metabolic Features According to Cancer and Immune Cells in the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 769393.	1.3	3
1735	N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 773570.	2.2	22

#	ARTICLE	IF	CITATIONS
1737	Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. <i>Annual Review of Cancer Biology</i> , 2022, 6, 17-34.	2.3	23
1738	Differentially Expressed Genes in Clear Cell Renal Cell Carcinoma as a Potential Marker for Prognostic and Immune Signatures. <i>Frontiers in Oncology</i> , 2021, 11, 776824.	1.3	7
1739	Identification of m6A Regulator-Associated Methylation Modification Clusters and Immune Profiles in Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 761134.	1.8	6
1740	Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature. <i>BMC Cancer</i> , 2021, 21, 1324.	1.1	8
1741	Epigenetic loss of heterogeneity from low to high grade localized prostate tumours. <i>Nature Communications</i> , 2021, 12, 7292.	5.8	15
1742	Transcriptomic and Metabolomic Profiling in <i>Helicobacter pylori</i> -Induced Gastric Cancer Identified Prognosis- and Immunotherapy-Relevant Gene Signatures. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 769409.	1.8	6
1743	Morphological features of single cells enable accurate automated classification of cancer from non-cancer cell lines. <i>Scientific Reports</i> , 2021, 11, 24375.	1.6	9
1744	Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides. <i>Journal of Translational Medicine</i> , 2021, 19, 526.	1.8	3
1745	Role of the tumor immune microenvironment in tumor immunotherapy (Review). <i>Oncology Letters</i> , 2021, 23, 53.	0.8	17
1747	Confocal Imaging of Single-Cell Signaling in Orthotopic Models of Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2022, 2424, 295-315.	0.4	1
1748	Autophagy and ncRNAs: Dangerous Liaisons in the Crosstalk between the Tumor and Its Microenvironment. <i>Cancers</i> , 2022, 14, 20.	1.7	5
1749	Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry. <i>Journal of Translational Medicine</i> , 2021, 19, 529.	1.8	8
1750	Focus on organoids: cooperation and interconnection with extracellular vesicles – Is this the future of in vitro modeling?. <i>Seminars in Cancer Biology</i> , 2022, 86, 367-381.	4.3	5
1751	Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2022, 2410, 649-670.	0.4	11
1752	Novel Multikernel Trick for Predicting Pan-Cancer Distant Metastatic Sites Using a Feature Extraction Strategy. , 2021, , .		0
1753	CRISPR Screens to Identify Regulators of Tumor Immunity. <i>Annual Review of Cancer Biology</i> , 2022, 6, 103-122.	2.3	5
1754	Characterization of m6A RNA Methylation Regulators Predicts Survival and Immunotherapy in Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 782551.	2.2	7
1755	Biological therapies in patients with liver disease: are they really lifesavers?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 473-490.	1.4	0

#	ARTICLE	IF	CITATIONS
1756	Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy. <i>Molecules</i> , 2022, 27, 137.	1.7	41
1757	Complementing Cancer Photodynamic Therapy with Ferroptosis through Iron Oxide Loaded Porphyrin-Grafted Lipid Nanoparticles. <i>ACS Nano</i> , 2021, 15, 20164-20180.	7.3	69
1758	Mechanism of HBV-positive liver cancer cell exosomal miR-142-3p by inducing ferroptosis of M1 macrophages to promote liver cancer progression. <i>Translational Cancer Research</i> , 2022, 11, 1173-1187.	0.4	12
1759	Assessment of the prognostic value of SPOCK1 in clear cell renal cell carcinoma: a bioinformatics analysis. <i>Translational Andrology and Urology</i> , 2022, 11, 509-518.	0.6	4
1760	Immunotherapies and their moderation. , 2022, , 461-502.		0
1761	Role of m ⁵ C RNA methylation regulators in colorectal cancer prognosis and immune microenvironment. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24303.	0.9	10
1763	Dissection of Immune Profiles in Microsatellite Stable and Low Microsatellite Instability Colon Adenocarcinoma by Multiomics Data Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
1764	LAMP2 as a Biomarker Related to Prognosis and Immune Infiltration in Esophageal Cancer and Other Cancers: A Comprehensive Pan-Cancer Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 884448.	1.3	3
1765	Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes. <i>Journal of Immunology Research</i> , 2022, 2022, 1-16.	0.9	9
1767	Copackaging photosensitizer and PD-L1 siRNA in a nucleic acid nanogel for synergistic cancer photoimmunotherapy. <i>Science Advances</i> , 2022, 8, eabn2941.	4.7	50
1768	STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation. <i>Nano Research</i> , 2022, 15, 6328-6339.	5.8	13
1769	Uncovering N4-Acetylcytidine-Related mRNA Modification Pattern and Landscape of Stemness and Immunity in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 861000.	1.8	9
1770	Tumor-associated macrophages promote intratumoral conversion of conventional CD4 ⁺ T cells into regulatory T cells via PD-1 signalling. <i>Oncolmmunology</i> , 2022, 11, 2063225.	2.1	14
1771	Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 829391.	2.2	5
1772	Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 872932.	1.6	7
1773	The Pan-Cancer Landscape of Crosstalk Between TRP Family and Tumour Microenvironment Relevant to Prognosis and Immunotherapy Response. <i>Frontiers in Immunology</i> , 2022, 13, 837665.	2.2	6
1775	Ultrasound and microbubble-mediated drug delivery and immunotherapy. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, , 1.	0.6	6
1776	Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. <i>Cell</i> , 2022, 185, 1694-1708.e19.	13.5	100

#	ARTICLE	IF	CITATIONS
1777	A novel prognostic model associated with the overall survival in patients with breast cancer based on lipid metabolism-related long noncoding RNAs. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24384.	0.9	17
1778	Subcellular delivery of lipid nanoparticles to endoplasmic reticulum and mitochondria. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1803.	3.3	5
1779	Genetic perturbations go spatial. <i>Cell Genomics</i> , 2022, 2, 100120.	3.0	0
1780	Emerging tumor-on-chips with electrochemical biosensors. <i>TrAC - Trends in Analytical Chemistry</i> , 2022, 153, 116640.	5.8	32
1781	Mapping Breast Cancer Microenvironment Through Single-Cell Omics. <i>Frontiers in Immunology</i> , 2022, 13, 868813.	2.2	18
1782	Triggering Immune System With Nanomaterials for Cancer Immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 878524.	2.0	9
1783	m6A-Related lncRNAs Are Potential Prognostic Biomarkers of Cervical Cancer and Affect Immune Infiltration. <i>Disease Markers</i> , 2022, 2022, 1-22.	0.6	2
1784	Recent Advances of Tumor Therapy Based on the CD47-SIRP α Axis. <i>Molecular Pharmaceutics</i> , 2022, 19, 1273-1293.	2.3	18
1785	Covalent labeling of immune cells. <i>Current Opinion in Chemical Biology</i> , 2022, 68, 102144.	2.8	3
1849	Heterogeneity of the tumor immune microenvironment and its clinical relevance. <i>Experimental Hematology and Oncology</i> , 2022, 11, 24.	2.0	40
1850	Cross talk between RNA modification writers and tumor development as a basis for guiding personalized therapy of gastric cancer. <i>Human Genomics</i> , 2022, 16, 14.	1.4	5
1852	Immune infiltration and a ferroptosis-related gene signature for predicting the prognosis of patients with cholangiocarcinoma.. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 1204-1219.	0.0	0
1853	Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases. <i>Oncologist</i> , 2022, 27, 538-547.	1.9	4
1854	Magnetic nanocluster-mediated photothermal effect and macrophage modulation for synergistic photothermal immunotherapy of cancer. <i>Biomaterials Science</i> , 2022, 10, 3188-3200.	2.6	2
1855	Exploring Tumor Immune Microenvironment and Its Associations With Molecular Characteristics in Melanoma. <i>Frontiers in Oncology</i> , 2022, 12, 821578.	1.3	3
1856	A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 859323.	2.2	25
1857	A Novel TAF-Related Signature Based on ECM Remodeling Genes Predicts Glioma Prognosis. <i>Frontiers in Oncology</i> , 2022, 12, 862723.	1.3	2
1858	The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage IIa-III and metastatic breast cancers. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 65-78.	1.1	10

#	ARTICLE	IF	CITATIONS
1859	Transcriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function. <i>Cell Reports Medicine</i> , 2022, 3, 100621.	3.3	15
1860	A comprehensive characterization of alternative splicing events related to prognosis and the tumor microenvironment in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 479-479.	0.7	2
1861	Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 844013.	1.8	0
1862	Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy. <i>ACS Central Science</i> , 2022, 8, 603-614.	5.3	24
1863	Characterizing the Inflammatory Microenvironment in K14-HPV16 Transgenic Mice: Mast Cell Infiltration and MicroRNA Expression. <i>Cancers</i> , 2022, 14, 2216.	1.7	4
1864	Establishment and Application of a Prognostic Risk Score Model Based on Characteristics of Different Immunophenotypes for Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 850101.	1.1	0
1865	Watsonâ€™Crick Base Pairing-Inspired Laser/GSH Activatable miRNA-Coordination Polymer Nanoplexes for Combined Cancer Chemo-Immuno-Photothermal Therapy. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 20762-20777.	4.0	10
1866	An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 343-355.	1.8	10
1867	A Risk Model of Eight Immune-Related Genes Predicting Prognostic Response to Immune Therapies for Gastric Cancer. <i>Genes</i> , 2022, 13, 720.	1.0	3
1868	Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 802665.	2.2	4
1869	Development of an immune-related prognostic biomarker for triple-negative breast cancer. <i>Annals of Medicine</i> , 2022, 54, 1212-1220.	1.5	6
1870	Identifying Molecular Subtypes and 6-Gene Prognostic Signature Based on Hypoxia for Optimizing Targeted Therapies in Non-Small Cell Lung Cancer. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4417-4432.	0.8	1
1871	m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 888650.	2.2	15
1872	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. <i>Annual Review of Immunology</i> , 2022, 40, 45-74.	9.5	122
1873	Essential m6A Methylation Regulator HNRNPC Serves as a Targetable Biomarker for Papillary Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-29.	0.6	0
1874	Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2749-2758.	2.8	16
1875	Non-Coding RNAs Implicated in the Tumor Microenvironment of Colorectal Cancer: Roles, Mechanisms and Clinical Study. <i>Frontiers in Oncology</i> , 2022, 12, 888276.	1.3	1
1876	Toll-like Receptor 9 Pathway Mediates Schlafen+-MDSC Polarization During Helicobacter-induced Gastric Metaplasias. <i>Gastroenterology</i> , 2022, 163, 411-425.e4.	0.6	13

#	ARTICLE	IF	CITATIONS
1877	Macrophage-Mediated Delivery of Fe ₃ O ₄ -Nanoparticles: A Generalized Strategy to Deliver Iron to Tumor Microenvironment. <i>Current Drug Delivery</i> , 2022, 19, 928-939.	0.8	1
1878	The Landscape of the Tumor-Infiltrating Immune Cell and Prognostic Nomogram in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	4
1879	Albumin nanoparticle containing a PI3K ^{Î³} inhibitor and paclitaxel in combination with Î±-PD1 induces tumor remission of breast cancer in mice. <i>Science Translational Medicine</i> , 2022, 14, eabl3649.	5.8	34
1880	Multimodality imaging of <scp>nanoparticleâ€based</scp> vaccines: Shedding light on immunology. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, , e1807.	3.3	1
1881	Prognostic value and immune characteristics of RUNX gene family in human cancers: a pan-cancer analysis. <i>Aging</i> , 2022, 14, 4014-4035.	1.4	3
1882	Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. <i>EBioMedicine</i> , 2022, 79, 104016.	2.7	12
1883	Association of the tissue infiltrated and peripheral blood immune cell subsets with response to radiotherapy for rectal cancer. <i>BMC Medical Genomics</i> , 2022, 15, 107.	0.7	5
1884	Tumour microenvironment and focal therapy for prostate cancer. <i>Current Opinion in Urology</i> , 2022, 32, 248-253.	0.9	1
1885	Ursolic acid-enriched kudingcha extract enhances the antitumor activity of bacteria-mediated cancer immunotherapy. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, 123.	1.2	1
1887	Expanding therapeutic opportunities for progressive uterine cancer: clinical experience. <i>Opuholi Zenskoj Reproktivnoj Sistemy</i> , 2022, 18, 103-110.	0.1	0
1888	Characterizing the landscape of cervical squamous cell carcinoma immune microenvironment by integrating the singleâ€cell transcriptomics and RNAâ€Seq. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	4
1889	Targeting tumor extracellular matrix activates the tumor-draining lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2957-2968.	2.0	6
1890	Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	15
1891	Attenuated <i>Toxoplasma gondii</i> enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2743-2757.	1.2	6
1892	Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response. <i>Biologics: Targets and Therapy</i> , 2022, Volume 16, 35-45.	3.0	3
1893	Regulating Acidosis and Relieving Hypoxia by Platelet Membrane-Coated Nanoparticle for Enhancing Tumor Chemotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, .	2.0	8
1894	Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
1895	Intratumoral therapies and in-situ vaccination for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1890512.	1.4	8

#	ARTICLE	IF	CITATIONS
1896	High-throughput single-Cell sequencing in cancer research. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 145.	7.1	39
1897	Short-Course But Not Prolonged Treatment With ATR Inhibitor AZD6738 Integrates With Radiotherapy to Generate a Tumor Antigen-Specific CD8 ⁺ T Cell Expansion in the Periphery. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1898	Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma. <i>BMC Endocrine Disorders</i> , 2022, 22, 130.	0.9	3
1899	Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response. <i>Pharmaceuticals</i> , 2022, 15, 605.	1.7	0
1900	The roles of TGF- β 2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. , 2022, 240, 108211.		21
1901	Automated "Mechanical Procedure Compared to Gentle Enzymatic Tissue Dissociation in Cell Function Studies. <i>Biomolecules</i> , 2022, 12, 701.	1.8	7
1902	Immune cell infiltration and immunotherapy in hepatocellular carcinoma. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 7178-7200.	1.0	2
1903	Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	3
1904	Cancer evolution: special focus on the immune aspect of cancer. <i>Seminars in Cancer Biology</i> , 2022, , .	4.3	4
1905	PD-L1 Mediates IFN γ -Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	6
1906	Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
1907	Exosomes and their roles in the chemoresistance of pancreatic cancer. <i>Cancer Medicine</i> , 2022, 11, 4979-4988.	1.3	11
1908	Identifying tumor antigens and immune subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine. <i>Cancer Medicine</i> , 2022, , .	1.3	3
1909	Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients. , 2022, 10, e004239.		6
1910	Cancer Immunoediting in the Era of Immuno-oncology. <i>Clinical Cancer Research</i> , 2022, 28, 3917-3928.	3.2	31
1911	Tissue-Resident Memory CD4 ⁺ T Cells Play a Dominant Role in the Initiation of Antitumor Immunity. <i>Journal of Immunology</i> , 2022, 208, 2837-2846.	0.4	10
1912	Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. <i>International Review of Cell and Molecular Biology</i> , 2022, , 123-147.	1.6	8
1913	Tumor microenvironment manipulation and cancer metastasis (taming the beast). , 2022, , 209-234.		0

#	ARTICLE	IF	CITATIONS
1914	A brain-enriched lncRNA shields cancer cells from immune-mediated killing for metastatic colonization in the brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
1915	Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer. <i>Journal of Pathology Informatics</i> , 2022, 13, 100105.	0.8	9
1916	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1181.	1.4	8
1917	Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2022, 17, e0266620.	1.1	5
1918	Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. <i>Cancer Cell</i> , 2022, 40, 624-638.e9.	7.7	113
1919	Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2549.	1.7	10
1920	Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications. <i>Cytokine</i> , 2022, 156, 155916.	1.4	9
1921	Cascades Catalyzed Lactic Acid Depletion Coordinated with Photothermal Therapy for Enhanced Cancer Immunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1922	DenVar: density-based variation analysis of multiplex imaging data. <i>Bioinformatics Advances</i> , 2022, 2, .	0.9	10
1923	A Radiomic Model to Predict the Expression of Pd-1 and Overall Survival of Patients with Ovary Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1924	Recent advances, patient selection & challenges in managing cancer patients undergoing treatment with immune checkpoint inhibitors. <i>Indian Journal of Medical Research</i> , 2022, .	0.4	0
1925	Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1926	Identification of FCER1G related to Activated Memory CD4+ T Cells Infiltration by Gene Co-expression Network and Construction of a Risk Prediction Module in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1927	Ferroptosis at the crossroads of tumor-host interactions, metastasis, and therapy response. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C95-C103.	2.1	8
1928	Necroptosis-Related lncRNAs Signature and Subtypes for Predicting Prognosis and Revealing the Immune Microenvironment in Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1929	Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. , 2022, 10, e004297.		41
1930	Engineering Bioinspired Nanomedicines to Mitigate the Resistance to Cancer Immunotherapy. <i>Accounts of Materials Research</i> , 2022, 3, 697-708.	5.9	14
1931	SLC6A8 is a Potential Biomarker for Poor Prognosis in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3

#	ARTICLE	IF	CITATIONS
1932	N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma. <i>Cancer Cell International</i> , 2022, 22, .	1.8	7
1933	Development and validation of a computed tomographyâ€‘based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer. <i>European Radiology</i> , 2022, 32, 8726-8736.	2.3	2
1935	Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114365.	6.6	30
1936	Targeting protein kinases benefits cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188738.	3.3	5
1937	Role of thymic stromal lymphopoietin in allergy and beyond. <i>Nature Reviews Immunology</i> , 2023, 23, 24-37.	10.6	54
1939	HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 2769.	1.7	8
1940	Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1941	Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	112
1942	A role for microfluidic systems in precision medicine. <i>Nature Communications</i> , 2022, 13, .	5.8	63
1943	Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	7
1944	Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
1945	Multi-Omics Integrative Analysis of Lung Adenocarcinoma: An in silico Profiling for Precise Medicine. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1946	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. <i>Advanced Science</i> , 2022, 9, .	5.6	140
1950	Bioengineered nanogels for cancer immunotherapy. <i>Chemical Society Reviews</i> , 2022, 51, 5136-5174.	18.7	81
1951	Recent advances in biomedical applications of bacterial outer membrane vesicles. <i>Journal of Materials Chemistry B</i> , 2022, 10, 7384-7396.	2.9	5
1953	Tumor Immune Microenvironment of Soft Tissue Sarcoma. , 2022, , 639-647.		1
1954	Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient. <i>Bulletin Du Cancer</i> , 2022, 109, 2S4-2S18.	0.6	3
1955	Microenvironmental regulation of tumor initiation and development. <i>Scientia Sinica Vitae</i> , 2022, 52, 1377-1390.	0.1	1

#	ARTICLE	IF	CITATIONS
1956	Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. , 2022, 10, e004762.		19
1957	Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. Journal of Immunology Research, 2022, 2022, 1-21.	0.9	6
1958	Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products. Biomedicines, 2022, 10, 1410.	1.4	4
1959	Characterization of Different Subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	7
1960	Identification Of key prognostic genes in ovarian cancer using WGCNA and LASSO analysis. International Journal of Transgender Health, 2022, 15, 728-744.	1.1	2
1961	Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome. British Journal of Cancer, 2022, 127, 1162-1171.	2.9	3
1962	The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective. Frontiers in Medicine, 0, 9, .	1.2	2
1963	Tumor-Infiltrated CD8+ T Cell 10-Gene Signature Related to Clear Cell Renal Cell Carcinoma Prognosis. Frontiers in Immunology, 0, 13, .	2.2	5
1964	Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability. Frontiers in Oncology, 0, 12, .	1.3	4
1965	Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing. Frontiers in Immunology, 0, 13, .	2.2	32
1966	Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer. Journal of Cellular and Molecular Medicine, 0, , .	1.6	1
1967	Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade. Cancer Research, 2022, 82, 2904-2917.	0.4	72
1968	MIAMI: mutual information-based analysis of multiplex imaging data. Bioinformatics, 2022, 38, 3818-3826.	1.8	5
1969	Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. Journal of Hepatology, 2022, 77, 1359-1372.	1.8	30
1970	Emerging Biomaterials Imaging Antitumor Immune Response. Advanced Materials, 2022, 34, .	11.1	22
1971	Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma. Clinical Cancer Research, 2022, 28, 4322-4335.	3.2	2
1972	Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question. Pharmaceuticals, 2022, 14, 1243.	2.0	14
1973	Context-Dependent Effects Explain Divergent Prognostic Roles of Tregs in Cancer. Cancers, 2022, 14, 2991.	1.7	2

#	ARTICLE	IF	CITATIONS
1974	Update on the current knowledge of lymphatic drainage system and its emerging roles in glioma management. <i>Immunology</i> , 2023, 168, 233-247.	2.0	14
1975	Predicting the efficacy of <i>first-line</i> immunotherapy by combining cancer cachexia and tumor burden in advanced <i>non-small cell</i> lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2064-2074.	0.8	7
1976	Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1977	Systematic co-delivery of dual agonists to enhance cancer immunotherapy. <i>Nano Research</i> , 2022, 15, 8326-8335.	5.8	9
1978	m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1979	Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1980	Non-cytotoxic nanoparticles re-educating macrophages achieving both innate and adaptive immune responses for tumor therapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 557-570.	4.3	7
1981	Phage in cancer treatment – Biology of therapeutic phage and screening of tumor targeting peptide. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 873-882.	2.4	12
1982	CLEC1B is a Promising Prognostic Biomarker and Correlated with Immune Infiltration in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 0, Volume 15, 5661-5672.	0.8	3
1983	Time of day as a critical variable in biology. <i>BMC Biology</i> , 2022, 20, .	1.7	18
1984	Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. <i>Nature Biomedical Engineering</i> , 2022, 6, 855-866.	11.6	23
1985	Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
1986	Identification of pyroptosis related subtypes and tumor microenvironment infiltration characteristics in breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
1987	Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	0.9	7
1988	Role of TNFSF9 bidirectional signal transduction in antitumor immunotherapy. <i>European Journal of Pharmacology</i> , 2022, 928, 175097.	1.7	9
1989	Modelling the tumor immune microenvironment for precision immunotherapy. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	16
1990	Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors. <i>Advances in Clinical Medicine</i> , 2022, 12, 5913-5936.	0.0	0
1991	Advancing Tumor Microenvironment Research by Combining Organs-on-Chips and Biosensors. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 171-203.	0.8	3

#	ARTICLE	IF	CITATIONS
1992	The Transcriptional and Immunological Roles of Six2 in Clear Cell Renal Cell Carcinoma. <i>Oncologie</i> , 2022, 24, 261-282.	0.2	2
1993	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1994	Cancer Stem Cell-Associated Immune Microenvironment in Recurrent Glioblastomas. <i>Cells</i> , 2022, 11, 2054.	1.8	8
1995	Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx [®] Digital Spatial Profiler. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	28
1996	Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma. <i>Aging</i> , 2022, 14, 5271-5291.	1.4	3
1997	Computational estimation of quality and clinical relevance of cancer cell lines. <i>Molecular Systems Biology</i> , 2022, 18, .	3.2	12
1998	Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation. <i>OncolImmunology</i> , 2022, 11, .	2.1	14
1999	Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188758.	3.3	14
2001	Immunotherapy of sarcomas with modified T cells. <i>Current Opinion in Oncology</i> , 2022, 34, 362-370.	1.1	5
2002	Interferon- β resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. <i>Developmental Cell</i> , 2022, 57, 1847-1865.e9.	3.1	15
2003	Clinical impact of tumour burden on the efficacy of PD-1 inhibitors plus chemotherapy in non-small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1
2004	RNA N6-methyladenosine modification in regulating cancer stem cells and tumor immune microenvironment and its implication for cancer therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1621-1633.	1.2	5
2005	A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2006	Gallic acid induces T-helper-1-like T _{reg} cells and strengthens immune checkpoint blockade efficacy. , 2022, 10, e004037.		16
2007	A Predictive Model Based on Pyroptosis-Related Gene Features Can Effectively Predict Clear Cell Renal Cell Carcinoma Prognosis and May Be an Underlying Target for Immunotherapy. <i>Disease Markers</i> , 2022, 1-21.	0.6	0
2008	A Novel Prognostic Signature Associated with Immunotherapeutic Response for Hepatocellular Carcinoma. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
2009	Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2010	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13

#	ARTICLE	IF	CITATIONS
2011	Relationship between consolidation tumor ratio and tumor-infiltrating lymphocytes in small-sized lung adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 2134-2141.	0.8	4
2012	Quantifying Spatial Heterogeneity of Tumor-Infiltrating Lymphocytes to Predict Survival of Individual Cancer Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 1113.	1.1	4
2013	Comprehensive Computational Analysis of Honokiol Targets for Cell Cycle Inhibition and Immunotherapy in Metastatic Breast Cancer Stem Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-18.	0.5	1
2014	Identification of Grb2-associated binding protein 3 expression to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. <i>Journal of Biochemical and Molecular Toxicology</i> , 2022, 36, .	1.4	2
2015	Progressing Towards a Human-Centric Approach in Cancer Research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2016	The role of imaging in targeted delivery of nanomedicine for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114447.	6.6	24
2017	Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
2018	AP3S1 is a Novel Prognostic Biomarker and Correlated With an Immunosuppressive Tumor Microenvironment in Pan-Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
2019	Phytochemical based nanomedicine: a panacea for cancer treatment, present status and future prospective. <i>OpenNano</i> , 2022, 7, 100055.	1.8	20
2020	TSLP, IL-33, and IL-25: Not just for allergy and helminth infection. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1302-1313.	1.5	20
2021	JMJD8 Is an M2 Macrophage Biomarker, and It Associates With DNA Damage Repair to Facilitate Stemness Maintenance, Chemoresistance, and Immunosuppression in Pan-Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
2022	Identifying an Immune-Related Gene ST8SIA1 as a Novel Target in Patients With Clear-Cell Renal Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2023	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	58
2024	Cancer Biology and Implications for the Perioperative Period. , 2023, , 24-45.		1
2025	Analysis and prognostic significance of tumour immune infiltrates and immune microenvironment of m6A-related lncRNAs in patients with gastric cancer. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	5
2026	Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 430-439.	0.6	6
2027	CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2028	The Multi-Omics Landscape and Clinical Relevance of the Immunological Signature of Phagocytosis Regulators: Implications for Risk Classification and Frontline Therapies in Skin Cutaneous Melanoma. <i>Cancers</i> , 2022, 14, 3582.	1.7	0

#	ARTICLE	IF	CITATIONS
2029	Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. <i>PLoS Computational Biology</i> , 2022, 18, e1010254.	1.5	17
2030	AURKA is a prognostic potential therapeutic target in skin cutaneous melanoma modulating the tumor microenvironment, apoptosis, and hypoxia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3089-3107.	1.2	3
2032	Apigenin Targets MicroRNA-155, Enhances SHIP-1 Expression, and Augments Anti-Tumor Responses in Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 3613.	1.7	4
2033	Efficient Immunotherapy of Drug-Free Layered Double Hydroxide Nanoparticles via Neutralizing Excess Acid and Blocking Tumor Cell Autophagy. <i>ACS Nano</i> , 2022, 16, 12036-12048.	7.3	39
2034	Role of Cancer-Associated fibroblast in the pathogenesis of ovarian Cancer: Focus on the latest therapeutic approaches. <i>International Immunopharmacology</i> , 2022, 110, 109052.	1.7	6
2035	Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms. <i>Pharmacological Research</i> , 2022, 183, 106364.	3.1	18
2036	Cascades catalyzed lactic acid depletion coordinated with photothermal therapy for enhanced cancer immunotherapy. <i>Materials and Design</i> , 2022, 221, 110961.	3.3	1
2037	SNAIL-expressing fibroblasts and derived-extracellular matrix as mediators of drug resistance in colorectal cancer patients. <i>Toxicology and Applied Pharmacology</i> , 2022, 450, 116171.	1.3	7
2038	Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity. <i>British Journal of Cancer</i> , 2022, 127, 1584-1594.	2.9	21
2039	Immune Cell and Biochemical Biomarkers in Advanced Laryngeal Cancer. <i>Dose-Response</i> , 2022, 20, 155932582211155.	0.7	0
2040	Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2022, 49, 525-538.	0.8	4
2041	Membrane-Coated Biomimetic Nanoparticles: A State-of-the-Art Multifunctional Weapon for Tumor Immunotherapy. <i>Membranes</i> , 2022, 12, 738.	1.4	5
2042	The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2043	Multipeptide supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses. <i>Science Advances</i> , 2022, 8, .	4.7	10
2044	A Novel Immune-Related Gene Signature to Identify the Tumor Microenvironment and Prognose Disease Among Patients With Oral Squamous Cell Carcinoma Patients Using ssGSEA: A Bioinformatics and Biological Validation Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
2045	Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2046	Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies. <i>Cancers</i> , 2022, 14, 3561.	1.7	11
2047	Tumor evolution-targeted nanomedicine<sup>EVT</sup>. <i>Scientia Sinica Chimica</i> , 2022, 52, 2121-2155.	0.2	4

#	ARTICLE	IF	CITATIONS
2048	Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
2049	Crosstalk of three novel types of programmed cell death defines distinct microenvironment characterization and pharmacogenomic landscape in breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2050	Identification and Validation of an Immune Evasion Molecular Subgroup of Patients With Colon Cancer for Implications of Immunotherapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2051	Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy. <i>Advanced Science</i> , 2022, 9, .	5.6	19
2052	Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	10
2053	Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	27
2054	Implication of IL6-positive Cancer-associated Fibroblasts in Merkel Cell Carcinoma Pathogenesis: A Possible Modulator of Immune Microenvironment. <i>Anticancer Research</i> , 2022, 42, 4359-4369.	0.5	1
2055	Identification of Candidate Therapeutic Target Genes and Profiling of Tumor-Infiltrating Immune Cells in Pancreatic Cancer via Integrated Transcriptomic Analysis. <i>Disease Markers</i> , 2022, 2022, 1-14.	0.6	1
2056	CD39 ⁺ tissue-resident memory CD8 ⁺ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. <i>Science Immunology</i> , 2022, 7, .	5.6	23
2057	Secretory co-factors in next-generation cellular therapies for cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2058	The Effects of Tamoxifen on Tolerogenic Cells in Cancer. <i>Biology</i> , 2022, 11, 1225.	1.3	1
2059	Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	5
2060	Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment. <i>Cell Reports</i> , 2022, 40, 111201.	2.9	9
2061	Characterization of Immune-Related Alternative Polyadenylation Events in Cancer Immunotherapy. <i>Cancer Research</i> , 2022, 82, 3474-3485.	0.4	6
2062	Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma. , 2022, 10, e004807.		8
2063	Identification of Potential Prognostic Biomarkers Associated with Monocyte Infiltration in Lung Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2022, 2022, 1-19.	0.9	1
2064	Editorial: Post-translational modifications of proteins in cancer immunity and immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2065	Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects. <i>Current Medicinal Chemistry</i> , 2023, 30, 3215-3237.	1.2	3

#	ARTICLE	IF	CITATIONS
2066	Reduction Sensitive Polymers Delivering Cationic Platinum Drugs as STING Agonists for Enhanced Chemo-immunotherapy. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	29
2068	Exosome-guided direct reprogramming of tumor-associated macrophages from protumorigenic to antitumorigenic to fight cancer. <i>Bioactive Materials</i> , 2023, 25, 527-540.	8.6	11
2069	The role of anti-tumor immunity of focused ultrasound for the malignancies: depended on the different ablation categories. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1543-1553.	1.0	3
2070	m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2071	Deciphering colorectal cancer immune microenvironment transcriptional landscape on single cell resolution – A role for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2072	Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies. <i>Advanced Science</i> , 2022, 9, .	5.6	11
2073	Injectable pH-responsive hydrogel for combinatorial chemoimmunotherapy tailored to the tumor microenvironment. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	14
2074	Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2075	Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. <i>Nature Immunology</i> , 2022, 23, 1309-1316.	7.0	39
2076	A Peritumorally Injected Immunomodulating Adjuvant Elicits Robust and Safe Metalloimmunotherapy against Solid Tumors. <i>Advanced Materials</i> , 2022, 34, .	11.1	55
2077	A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2022, 127, 1691-1700.	2.9	2
2078	Pannexin1 channel-dependent secretome from apoptotic tumor cells shapes immune-escape microenvironment. <i>Biochemical and Biophysical Research Communications</i> , 2022, 628, 116-122.	1.0	5
2079	Novel GIRlncRNA Signature for Predicting the Clinical Outcome and Therapeutic Response in NSCLC. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2080	The epiphany derived from T-cell-inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
2081	Heterogeneous expression of ACE2, TMPRSS2, and FURIN at single-cell resolution in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	4
2082	Functional 2D Iron-Based Nanosheets for Synergistic Immunotherapy, Phototherapy, and Chemotherapy of Tumor. <i>Advanced Healthcare Materials</i> , 2022, 11, .	3.9	8
2083	Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2084	Application of nanotechnology in CAR-T-cell immunotherapy. <i>Chinese Chemical Letters</i> , 2023, 34, 107747.	4.8	5

#	ARTICLE	IF	CITATIONS
2085	m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
2086	Cancer immune therapy using engineered "tail-flipping"™ nanoliposomes targeting alternatively activated macrophages. <i>Nature Communications</i> , 2022, 13, .	5.8	13
2087	BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors. <i>Future Oncology</i> , 2022, 18, 3245-3254.	1.1	6
2088	m6A Regulator-Based Exosomal Gene Methylation Modification Patterns Identify Distinct Microenvironment Characterization and Predict Immunotherapeutic Responses in Colon Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-25.	1.9	1
2089	Sequential acid/reduction response of triblock copolymeric nanomicelles to release camptothecin and toll-like receptor 7/8 agonist for orchestrated chemoimmunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	2
2090	Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
2091	Genetically Engineered Hematopoietic Stem Cells Deliver TGF β Inhibitor to Enhance Bone Metastases Immunotherapy. <i>Advanced Science</i> , 2022, 9, .	5.6	13
2092	Griottes: a generalist tool for network generation from segmented tissue images. <i>BMC Biology</i> , 2022, 20, .	1.7	6
2093	Using CD69 PET Imaging to Monitor Immunotherapy-Induced Immune Activation. <i>Cancer Immunology Research</i> , 2022, 10, 1084-1094.	1.6	11
2094	Glutathione peroxidase 8 expression on cancer cells and cancer-associated fibroblasts facilitates lung cancer metastasis. <i>MedComm</i> , 2022, 3, .	3.1	2
2095	RASA2 ablation in T cells boosts antigen sensitivity and long-term function. <i>Nature</i> , 2022, 609, 174-182.	13.7	65
2096	Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 52.	1.0	4
2097	Influence of PD α 1/PD α L1 on immune microenvironment in oral leukoplakia and oral squamous cell carcinoma. <i>Oral Diseases</i> , 2023, 29, 3268-3277.	1.5	4
2098	Immunotherapeutic targets in non-small cell lung cancer. <i>Immunology</i> , 2023, 168, 256-272.	2.0	5
2099	Solving the puzzle of what makes immunotherapies work. <i>Trends in Cancer</i> , 2022, 8, 890-900.	3.8	7
2100	Temporally restricted activation of IFN γ signaling underlies response to immune checkpoint therapy in mice. <i>Nature Communications</i> , 2022, 13, .	5.8	12
2101	Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
2102	Fast Data Driven Estimation of Cluster Number in Multiplex Images using Embedded Density Outliers. , 2022, , .		1

#	ARTICLE	IF	CITATIONS
2103	scRNA-seq of gastric tumor shows complex intercellular interaction with an alternative T cell exhaustion trajectory. <i>Nature Communications</i> , 2022, 13, .	5.8	32
2104	Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114504.	6.6	36
2105	Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
2106	Immune cellular components and signaling pathways in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 187-201.	4.3	18
2107	Impact of glycoengineering and antidrug antibodies on the anticancer activity of a plantâ€made <sc>lectinâ€Fc</sc> fusion protein. <i>Plant Biotechnology Journal</i> , 2022, 20, 2217-2230.	4.1	1
2108	Fc Fragment of <sc>IgE</sc> Receptor Ig (<sc>FCER1G</sc>) acts as a key gene involved in cancer immune infiltration and tumour microenvironment. <i>Immunology</i> , 2023, 168, 302-319.	2.0	7
2109	Development and validation of a novel fibroblast scoring model for lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2110	Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment. , 0, , .		0
2111	Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2112	Methylation related genes are associated with prognosis of patients with head and neck squamous cell carcinoma via altering tumor immune microenvironment. <i>Journal of Dental Sciences</i> , 2022, , .	1.2	2
2113	Integrative Analysis of Bioinformatics and Machine Learning Algorithms Identifies a Novel Diagnostic Model Based on Costimulatory Molecule for Predicting Immune Microenvironment Status in Lung Adenocarcinoma. <i>American Journal of Pathology</i> , 2022, , .	1.9	1
2114	Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases. <i>Thoracic Cancer</i> , 0, , .	0.8	1
2116	Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy. <i>EBioMedicine</i> , 2022, 83, 104207.	2.7	43
2117	Icaritin and intratumoral injection of CpG treatment synergistically promote T cell infiltration and antitumor immune response in mice. <i>International Immunopharmacology</i> , 2022, 111, 109093.	1.7	6
2118	Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine. <i>Translational Oncology</i> , 2022, 25, 101514.	1.7	11
2119	Bioinformatics Analysis and Structure of Gastric Cancer Prognosis Model Based on Lipid Metabolism and Immune Microenvironment. <i>Genes</i> , 2022, 13, 1581.	1.0	3
2120	Induction of the activating transcription factor-4 in the intratumoral CD8+â€T cells sustains their viability and anti-tumor activities. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 815-826.	2.0	1
2121	Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. <i>ELife</i> , 0, 11, .	2.8	10

#	ARTICLE	IF	CITATIONS
2122	Hypoxia Confers Tumor with a Higher Immune Infiltration but Lower Mutation Burden in Gastrointestinal Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	1
2123	Building a healthy mouse model ecosystem to interrogate cancer biology. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	6
2124	A new personalized vaccine strategy based on inducing the pyroptosis of tumor cells in vivo by transgenic expression of a truncated GSDMD N-terminus. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2125	Prediction of lung squamous cell carcinoma immune microenvironment and immunotherapy efficiency with pyroptosis-derived genes. <i>Medicine (United States)</i> , 2022, 101, e30304.	0.4	1
2126	Intravital microscopy for real-time monitoring of drug delivery and nanobiological processes. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114528.	6.6	6
2127	Tannins in <i>Terminalia bellirica</i> inhibits hepatocellular carcinoma growth via re-educating tumor-associated macrophages and restoring CD8+T cell function. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113543.	2.5	6
2128	Orthotopic and heterotopic triple negative breast cancer preclinical murine models: A tumor microenvironment comparative. <i>Research in Veterinary Science</i> , 2022, 152, 364-371.	0.9	4
2129	Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 11345-11366.	1.0	0
2130	Igniting Hope for Tumor Immunotherapy: Promoting the "Hot and Cold" Tumor Transition. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211207.	0.6	11
2131	Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancer. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5440-5452.	1.9	6
2132	Artificial Intelligence-Assisted Analysis of Tumor Growth Pattern, Tumor-Infiltrating Lymphocytes, And Survival from Colorectal Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2133	New insights into the tumour immune microenvironment of nasopharyngeal carcinoma. <i>Current Research in Immunology</i> , 2022, 3, 222-227.	1.2	7
2134	Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer. , 2022, , .		0
2135	CD47KO/CRT Dual-Bioengineered Cell Membrane-Coated Nanovaccine Combined with Anti-PD-L1 Antibody for Boosting Tumor Immunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2136	The Interface of Cancer, Their Microenvironment and Nanotechnology. <i>Oncologie</i> , 2022, 24, 371-411.	0.2	2
2137	Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, 5, 889-901.	0.9	6
2138	Tumor Microenvironment Remodeling Via Targeted Depletion of M2-Like Tumor-Associated Macrophages for Cancer Immunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2139	Molecular mechanisms associated with the chemoprotective role of protocatechuic acid and its potential benefits in the amelioration of doxorubicin-induced cardiotoxicity: A review. <i>Toxicology Reports</i> , 2022, 9, 1713-1724.	1.6	7

#	ARTICLE	IF	CITATIONS
2140	Gadolinium-based ultra-small nanoparticles augment radiotherapy-induced T-cell response to synergize with checkpoint blockade immunotherapy. <i>Nanoscale</i> , 2022, 14, 11429-11442.	2.8	12
2141	Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. <i>Theranostics</i> , 2022, 12, 6273-6290.	4.6	25
2142	CXCR3 Expression in Regulatory T Cells Drives Interactions With Dendritic Cells in Tumors to Limit CD8 <sup>+</sup> T Cell Tumor Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2143	Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma. <i>Theranostics</i> , 2022, 12, 5877-5887.	4.6	21
2144	European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211188.	1.4	1
2145	Fasting and cancer responses to therapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 107-123.	1.6	2
2146	Polymeric micelles as delivery systems for anticancer immunotherapy. , 2022, , 175-197.		0
2147	Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4390-4401.	1.9	2
2148	New opportunities for immunomodulation of the tumour microenvironment using chemical tools. <i>Chemical Society Reviews</i> , 2022, 51, 7944-7970.	18.7	15
2149	CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy. <i>Bioactive Materials</i> , 2023, 22, 211-224.	8.6	9
2150	Molecular profile reveals immune-associated markers of medulloblastoma for different subtypes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2151	Necroptosis-Related Prognostic Signature and Nomogram Model for Predicting the Overall Survival of Patients with Lung Cancer. <i>Genetical Research</i> , 2022, 2022, 1-15.	0.3	0
2152	The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy. <i>Cancers</i> , 2022, 14, 4255.	1.7	3
2153	Identification and validation of roles of lysyl oxidases in the predictions of prognosis, chemotherapy and immunotherapy in glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2154	Inflammatory Cytokine: An Attractive Target for Cancer Treatment. <i>Biomedicines</i> , 2022, 10, 2116.	1.4	19
2155	The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. <i>Genes</i> , 2022, 13, 1555.	1.0	2
2156	The Ferroptosis Molecular Subtype Reveals Characteristics of the Tumor Microenvironment, Immunotherapeutic Response, and Prognosis in Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9767.	1.8	2
2157	CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance. <i>Cancers</i> , 2022, 14, 4251.	1.7	4

#	ARTICLE	IF	CITATIONS
2158	FABP6 Expression Correlates with Immune Infiltration and Immunogenicity in Colorectal Cancer Cells. <i>Journal of Immunology Research</i> , 2022, 2022, 1-33.	0.9	3
2159	Dissecting a hypoxia-related angiogenic gene signature for predicting prognosis and immune status in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2160	Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2161	Pyroptosis-Related Gene Model Predicts Prognosis and Immune Microenvironment for Non-Small-Cell Lung Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-27.	1.9	3
2162	Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
2163	The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia. <i>Blood</i> , 2023, 141, 369-379.	0.6	4
2164	A comprehensive review of SHP2 and its role in cancer. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 729-753.	2.1	32
2165	Recent advancement of bioinspired nanomaterials and their applications: A review. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	5
2166	The angiogenic genes predict prognosis and immune characteristics in esophageal squamous cell carcinoma: Evidence from multi-omics and experimental verification. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2167	Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
2168	Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy. <i>Seminars in Immunopathology</i> , 2023, 45, 163-186.	2.8	14
2169	Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. <i>Medicina (Lithuania)</i> , 2022, 58, 1298.	0.8	0
2170	Interleukin-17A mRNA Expression is Associated with the Prognosis of Patients with Colorectal Cancer: A Pooled Meta-Analysis. , 2022, 33, 995-1003.		1
2171	Crosstalk between tumor-associated macrophages and tumor cells promotes chemoresistance via CXCL5/PI3K/AKT/mTOR pathway in gastric cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	12
2172	Photothermal Nano-Vaccine Promoting Antigen Presentation and Dendritic Cells Infiltration for Enhanced Immunotherapy of Melanoma via Transdermal Microneedles Delivery. <i>Research</i> , 2022, 2022, .	2.8	6
2173	Immunotherapy of targeting MDSCs in tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
2174	Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2175	Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	8

#	ARTICLE	IF	CITATIONS
2176	Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions. <i>Communications Biology</i> , 2022, 5, .	2.0	1
2177	Identification and analysis of a CD8+ T cell-related prognostic signature for colorectal cancer based on bulk RNA sequencing and scRNA sequencing data: A STROBE-compliant retrospective study. <i>Medicine (United States)</i> , 2022, 101, e30758.	0.4	0
2179	Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2180	USO1 expression is dysregulated in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 1877-1895.	1.3	1
2181	Pyroptosis patterns of colon cancer could aid to estimate prognosis, microenvironment and immunotherapy: evidence from multi-omics analysis. <i>Aging</i> , 2022, 14, 7547-7567.	1.4	1
2182	The Immune Subtypes and Landscape of Advanced-Stage Ovarian Cancer. <i>Vaccines</i> , 2022, 10, 1451.	2.1	1
2183	Targeted Singlet Oxygen Delivery: A Bioorthogonal Metabolic Shunt Linking Hypoxia to Fast Singlet Oxygen Release. <i>Angewandte Chemie</i> , 0, , .	1.6	0
2184	Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4344.	1.7	13
2185	Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2186	Tumor-associated macrophages are shaped by intratumoral high potassium via Kir2.1. <i>Cell Metabolism</i> , 2022, 34, 1843-1859.e11.	7.2	22
2187	Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. <i>Cancer Cell</i> , 2022, 40, 1145-1160.e9.	7.7	30
2188	Salmonella-mediated blood-brain barrier penetration, tumor homing and tumor microenvironment regulation for enhanced chemo/bacterial glioma therapy. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 819-833.	5.7	13
2189	Combination immunotherapy for pancreatic cancer: challenges and future considerations. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1173-1186.	1.3	4
2191	High FLT3 expression indicates favorable prognosis and correlates with clinicopathological parameters and immune infiltration in breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
2192	Targeted Singlet Oxygen Delivery: A Bioorthogonal Metabolic Shunt Linking Hypoxia to Fast Singlet Oxygen Release. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	9
2193	Integrated Analysis of C16orf54 as a Potential Prognostic, Diagnostic, and Immune Marker across Pan-Cancer. <i>Disease Markers</i> , 2022, 2022, 1-25.	0.6	3
2194	Paving the road to make chimeric antigen receptor CAR-T cell therapy effective against solid tumors. <i>Cancer Science</i> , 2022, 113, 4020-4029.	1.7	2
2195	Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 3045-3054.	2.8	9

#	ARTICLE	IF	CITATIONS
2196	Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers. <i>Cancer Research</i> , 2022, 82, 4359-4372.	0.4	23
2197	Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy. <i>Military Medical Research</i> , 2022, 9, .	1.9	19
2198	Identification of prognosis-related hub genes of ovarian cancer through bioinformatics analyses and experimental verification. <i>Medicine (United States)</i> , 2022, 101, e30374.	0.4	3
2199	<scp>BDNF</scp> is a prognostic biomarker involved in immune infiltration of lung adenocarcinoma and is associated with brain metastasis. <i>Immunology</i> , 2023, 168, 320-330.	2.0	3
2200	Epithelial PD‑1 expression at tumor front predicts overall survival in a cohort of oral squamous cell carcinomas from Sudan. <i>Clinical and Experimental Dental Research</i> , 0, , .	0.8	1
2201	Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	11
2202	The regulation and potential roles of m6A modifications in early embryonic development and immune tolerance at the maternal-fetal interface. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2203	The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
2204	Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. <i>British Journal of Cancer</i> , 0, , .	2.9	2
2205	An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
2208	IFN- γ enhances the antitumor activity of attenuated salmonella-mediated cancer immunotherapy by increasing M1 macrophage and CD4 and CD8 T cell counts and decreasing neutrophil counts. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
2209	CT-based radiomics signature to predict CD8+ tumor infiltrating lymphocytes in non-small-cell lung cancer. <i>Acta Radiologica</i> , 2023, 64, 1390-1399.	0.5	2
2210	Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity. <i>Cancer Immunology Research</i> , 2022, 10, 1354-1369.	1.6	20
2211	Microenvironment immune response induced by tumor ferroptosis—the application of nanomedicine. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2213	Histone lysine methylation patterns in prostate cancer microenvironment infiltration: Integrated bioinformatic analysis and histological validation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2214	Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2215	CDCA3 Predicts Poor Prognosis and Affects CD8+ T Cell Infiltration in Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	2
2216	Protein Profiling of Breast Carcinomas Reveals Expression of Immune-Suppressive Factors and Signatures Relevant for Patient Outcome. <i>Cancers</i> , 2022, 14, 4542.	1.7	0

#	ARTICLE	IF	CITATIONS
2217	Manganese-doped mesoporous polydopamine nanoagent for T1â€“T2 magnetic resonance imaging and tumor therapy. <i>Nano Research</i> , 2023, 16, 2991-3003.	5.8	10
2218	Construction of a tumor immune infiltration macrophage signature for predicting prognosis and immunotherapy response in liver cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
2219	Nanocarriers for cancer nano-immunotherapy. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1936-1954.	3.0	17
2220	Immune-related gene risk score predicting the effect of immunotherapy and prognosis in bladder cancer patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2221	NXPH4 Used as a New Prognostic and Immunotherapeutic Marker for Muscle-Invasive Bladder Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-21.	0.6	1
2222	Integrated computer analysis and a self-built Chinese cohort study identified GSTM2 as one survival-relevant gene in human colon cancer potentially regulating immune microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2224	Targeting to Tumor-Harbored Bacteria for Precision Tumor Therapy. <i>ACS Nano</i> , 2022, 16, 17402-17413.	7.3	18
2225	Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2226	When Cancer Cells Become the Enablers of an Antitumor Immune Response. <i>Cancer Discovery</i> , 2022, 12, 2244-2248.	7.7	5
2227	Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2228	Role of AI and digital pathology for colorectal immuno-oncology. <i>British Journal of Cancer</i> , 2023, 128, 3-11.	2.9	7
2229	Tumor microenvironment adrenergic nerves blockade liposomes for cancer therapy. <i>Journal of Controlled Release</i> , 2022, 351, 656-666.	4.8	2
2230	Upregulated YTHDF1 associates with tumor immune microenvironment in head and neck squamous cell carcinomas. <i>Translational Cancer Research</i> , 2022, 11, 3986-3999.	0.4	2
2231	Clinical and Prognostic Value of PPIA, SQSTM1, and CCL20 in Hepatocellular Carcinoma Patients by Single-Cell Transcriptome Analysis. <i>Cells</i> , 2022, 11, 3078.	1.8	7
2232	Immunotherapy for liposarcoma: emerging opportunities and challenges. <i>Future Oncology</i> , 2022, 18, 3449-3461.	1.1	5
2233	Prognostic and Immunological Role of STK38 across Cancers: Friend or Foe?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11590.	1.8	2
2234	Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	7
2235	Development of a Hallmark Pathway-Related Gene Signature Associated with Immune Response for Lower Grade Gliomas. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11971.	1.8	14

#	ARTICLE	IF	CITATIONS
2236	A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
2237	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1109-1125.	1.8	11
2238	Drug Resistance in Cancers: A Free Pass for Bullying. <i>Cells</i> , 2022, 11, 3383.	1.8	12
2240	Current status of immunotherapy for non-small cell lung cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
2241	Chronic inflammation, cancer development and immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	24
2242	CD45RO+TILs: cellular biomarkers for larynx squamous cell carcinoma outcome. <i>Brazilian Journal of Otorhinolaryngology</i> , 2022, 88, S133-S142.	0.4	1
2243	Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis. <i>Lung Cancer</i> , 2022, 174, 71-82.	0.9	3
2244	Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2245	RNA m5C regulator-mediated modification patterns and the cross-talk between tumor microenvironment infiltration in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2246	Oncolytic Vaccinia Virus Carrying Aphyrocallistes vastus Lectin (oncoVV-AVL) Enhances Inflammatory Response in Hepatocellular Carcinoma Cells. <i>Marine Drugs</i> , 2022, 20, 667.	2.2	3
2247	Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	0.6	2
2248	Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. , 2022, 10, e004781.		2
2249	The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy. <i>Medicina (Lithuania)</i> , 2022, 58, 1494.	0.8	2
2251	Automated multimodal fluorescence microscopy for hyperplex spatial-proteomics: Coupling microfluidic-based immunofluorescence to high resolution, high sensitivity, three-dimensional analysis of histological slides. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2252	Nanozymes-Enhanced Cell Therapy. <i>ACS Symposium Series</i> , 0, , 189-209.	0.5	0
2253	SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling. <i>Nature Immunology</i> , 2022, 23, 1588-1599.	7.0	8
2254	Differences of macrophages in the tumor microenvironment as an underlying key factor in glioma patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2255	Targeting tumour-intrinsic N ⁷ -methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy. <i>Gut</i> , 2023, 72, 1555-1567.	6.1	22

#	ARTICLE	IF	CITATIONS
2256	Identification of Key Genes in the HBV-Related HCC Immune Microenvironment Using Integrated Bioinformatics Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	0
2257	Identification of Two Novel Immune Subtypes Characterized by Distinct Prognosis and Tumor Microenvironment in Osteosarcoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-12.	0.9	1
2258	Liquid Biopsy and the Translational Bridge from the TIME to the Clinic. <i>Cells</i> , 2022, 11, 3114.	1.8	0
2259	Immunotherapeutic Implications of Toll-like Receptors Activation in Tumor Microenvironment. <i>Pharmaceutics</i> , 2022, 14, 2285.	2.0	10
2260	A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
2261	Bioinformatic analysis of FOXP3 expression and prognostic value in pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2262	Application of nanomaterials in combined thermal ablation and immunotherapy for liver tumors. <i>World Chinese Journal of Digestology</i> , 2022, 30, 829-837.	0.0	0
2263	Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	17
2264	A novel m7G methylation-related signature associated with chromosome homeostasis in patients with lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
2265	A comprehensive investigation discovered the novel methyltransferase METTL24 as one presumably prognostic gene for kidney renal clear cell carcinoma potentially modulating tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2267	Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2268	Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	6
2269	The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer. <i>Life</i> , 2022, 12, 1640.	1.1	5
2270	Spatial Profiling of the Prostate Cancer Tumor Microenvironment Reveals Multiple Differences in Gene Expression and Correlation with Recurrence Risk. <i>Cancers</i> , 2022, 14, 4923.	1.7	3
2271	Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 4829.	1.7	8
2272	Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer. <i>BMC Medicine</i> , 2022, 20, .	2.3	0
2273	Dissecting the Immunological Profiles in NS3-Amplified LUSC through Integrative Multi-Scale Analyses. <i>Cancers</i> , 2022, 14, 4997.	1.7	3
2274	PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. , 2022, 10, e004590.		12

#	ARTICLE	IF	CITATIONS
2275	Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts. <i>Clinical Cancer Research</i> , 2023, 29, 244-260.	3.2	30
2276	WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	20
2278	The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 694-718.	0.5	4
2279	Comprehensive Analysis and Validation of Solute Carrier Family 25 (SLC25) and Its Correlation with Immune Infiltration in Pan-Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-23.	0.9	3
2280	Distinct tumor microenvironment landscapes of rectal cancer for prognosis and prediction of immunotherapy response. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 1363-1381.	2.1	8
2281	Necroptosis-related lncRNAs: Combination of bulk and single-cell sequencing reveals immune landscape alteration and a novel prognosis stratification approach in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2282	Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. <i>Cell</i> , 2022, 185, 4317-4332.e15.	13.5	71
2285	CAPN8 involves with exhausted, inflamed, and desert immune microenvironment to influence the metastasis of thyroid cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2286	Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 598-629.	0.5	3
2287	Tumor microenvironment: barrier or opportunity towards effective cancer therapy. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	67
2288	What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13217.	1.8	9
2289	Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. <i>Cancer Cell</i> , 2022, 40, 1173-1189.e6.	7.7	10
2290	EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
2291	EV11 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment. <i>Blood Advances</i> , 2023, 7, 1577-1593.	2.5	3
2292	Lipid metabolism characterization in gastric cancer identifies signatures to predict prognostic and therapeutic responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2293	Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2294	Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2295	Supramolecular Polypeptide Self-Assembly Mediated In Situ Elicitation of Robust Innate and Adaptive Immune Responses Boosts Immunogenic Photothermal Therapy toward Cold Tumor. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	2

#	ARTICLE	IF	CITATIONS
2296	Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2022, 10, 1490-1505.	1.6	4
2298	Tillandsia usneoides Extract Decreases the Primary Tumor in a Murine Breast Cancer Model but Not in Melanoma. <i>Cancers</i> , 2022, 14, 5383.	1.7	7
2299	A novel ten-gene prognostic signature for cervical cancer based on CD79B-related immunomodulators. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2300	A prognostic signature model for unveiling tumor progression in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2301	Radiomic model to predict the expression of PD-1 and overall survival of patients with ovarian cancer. <i>International Immunopharmacology</i> , 2022, 113, 109335.	1.7	11
2302	Combination of a cationic complexes loaded with mRNA and β -Galactose ceramide enhances antitumor immunity and affects the tumor immune microenvironment. <i>International Immunopharmacology</i> , 2022, 113, 109254.	1.7	3
2303	Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice. <i>Biomaterials</i> , 2022, 291, 121872.	5.7	12
2304	The main battlefield of mRNA vaccine “ Tumor immune microenvironment. <i>International Immunopharmacology</i> , 2022, 113, 109367.	1.7	4
2305	The emerging roles of exosome-derived noncoding RNAs in the tumor immune microenvironment and their future applications. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113863.	2.5	5
2306	Modeling leukemia with zebrafish (<i>Danio rerio</i>): Towards precision medicine. <i>Experimental Cell Research</i> , 2022, 421, 113401.	1.2	0
2307	Nanomodulators targeting tumor-resident immunosuppressive cells: Mechanisms and recent updates. <i>Nano Today</i> , 2022, 47, 101641.	6.2	7
2308	Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma. <i>Translational Oncology</i> , 2023, 27, 101561.	1.7	1
2309	Tumor microenvironment-activated Nb2C quantum dots/lactate oxidase nanocatalyst mediates lactate consumption and macrophage repolarization for enhanced chemodynamic therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2023, 221, 113005.	2.5	4
2310	Improved antitumor immunity of chemotherapy in OSCC treatment by Gasdermin-E mediated pyroptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2023, 28, 348-361.	2.2	5
2311	Stabilizing RNA Nanovaccines with Transformable Hyaluronan Dynamic Hydrogel for Durable Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2023, 33, .	7.8	17
2312	Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5473.	1.7	4
2313	GZMK ^{high} CD8 ⁺ T effector memory cells are associated with CD15 ^{high} neutrophil abundance in non-metastatic colorectal tumors and predict poor clinical outcome. <i>Nature Communications</i> , 2022, 13, .	5.8	13
2314	CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
2315	Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 17-48.	2.1	28
2316	Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2317	Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2023, 11, 4-12.	1.6	12
2318	Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2319	Understanding the regulation of α -Don TM Eat-Me α signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 511-529.	1.2	2
2321	Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity. <i>Nature Communications</i> , 2022, 13, .	5.8	8
2322	Ferroptosis: a double-edged sword mediating immune tolerance of cancer. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	20
2323	Engineering metal α -phenolic networks for enhancing cancer therapy by tumor microenvironment modulation. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	2
2324	Single-cell transcriptome analysis of tumor immune microenvironment characteristics in colorectal cancer liver metastasis. <i>Annals of Translational Medicine</i> , 2022, 10, 1170-1170.	0.7	7
2325	Stk10 Deficiency in Mice Promotes Tumor Growth by Dysregulating the Tumor Microenvironment. <i>Biology</i> , 2022, 11, 1668.	1.3	0
2326	Overexpression of Pleckstrin Homology Domain-Containing Family A Member 4 Is Correlated with Poor Prognostic Outcomes and Immune Infiltration in Lower-Grade Glioma. <i>Disease Markers</i> , 2022, 1-15.	0.6	3
2327	Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non α -small α -cell lung cancer characterizes the features of response to PD α 1 blockade plus chemotherapy. <i>Cancer Communications</i> , 2022, 42, 1331-1346.	3.7	10
2328	Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13723.	1.8	0
2329	CAR T-cells for colorectal cancer immunotherapy: Ready to go?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
2331	GSK3 α Inhibition Prevents Macrophage Reprogramming by High-Dose Methotrexate. <i>Journal of Innate Immunity</i> , 2023, 15, 283-296.	1.8	1
2332	Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	5
2333	Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach. <i>Cancers</i> , 2022, 14, 5605.	1.7	4
2334	Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. <i>Cells</i> , 2022, 11, 3534.	1.8	1

#	ARTICLE	IF	CITATIONS
2335	Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. <i>Nature</i> , 2022, 612, 141-147.	13.7	177
2336	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. <i>Advances in Clinical Chemistry</i> , 2022, , .	1.8	0
2337	Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges. , 2022, 13, 1615.		21
2338	High expression of prolyl 4-hydroxylase subunit alpha-2 in lung adenocarcinoma indicates poor prognosis. <i>Clinics</i> , 2022, 77, 100123.	0.6	1
2339	Neoantigen-Based Immunotherapy for a Long-Term Survivor With Pancreatic Neuroendocrine Tumor. <i>Pancreas</i> , 2022, 51, e99-e101.	0.5	0
2340	A Novel Immune-Related Gene Prognostic Index (IRGPI) in Pancreatic Adenocarcinoma (PAAD) and Its Implications in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 5652.	1.7	3
2342	Understanding NSCLC, one cell at a time. <i>Cancer Cell</i> , 2022, , .	7.7	2
2345	Pore formingâ€‘mediated intracellular protein delivery for enhanced cancer immunotherapy. <i>Science Advances</i> , 2022, 8, .	4.7	9
2346	NADPH Selective Depletion Nanomedicineâ€‘Mediated Radioâ€‘Immunometabolism Regulation for Strengthening Antiâ€‘PD-L1 Therapy against TNBC. <i>Advanced Science</i> , 2023, 10, .	5.6	13
2347	Molecular subtyping and IMScore based on immune-related pathways, oncogenic pathways, and DNA damage repair pathways for guiding immunotherapy in hepatocellular carcinoma patients. <i>Journal of Gastrointestinal Oncology</i> , 2022, .	0.6	1
2348	Intra-Tumor Cell Heterogeneity: Different Immune Responses for Different Cells. , 2022, , 1-26.		0
2349	Cell delivery devices for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2023, 353, 875-888.	4.8	7
2350	Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review. <i>Current Research in Pharmacology and Drug Discovery</i> , 2023, 4, 100146.	1.7	1
2351	Endotoxin contamination alters macrophage-cancer cell interaction and therapeutic efficacy in pre-clinical 3D in vitro models. , 2023, 144, 213220.		2
2352	Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma. <i>Journal of Bone Oncology</i> , 2023, 38, 100463.	1.0	10
2353	Chapter 13. The Intersection of Biomaterials, Tissue Engineering, and Immuno-oncology. <i>Biomaterials Science Series</i> , 2022, , 342-383.	0.1	0
2354	Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer. <i>Theranostics</i> , 2022, 12, 7884-7902.	4.6	3
2355	Tumor Microenvironment Complexity: A Pathological Milieu that Innately Modulates Cancer Progression. , 2022, , 1-28.		0

#	ARTICLE	IF	CITATIONS
2356	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 131-149.	0.4	3
2357	Prognostic and therapeutic prediction by screening signature combinations from transcriptome-methylome interactions in oral squamous cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
2358	Comprehensive Analysis of Cuproptosis-Related Genes in Prognosis and Immune Infiltration of Hepatocellular Carcinoma Based on Bulk and Single-Cell RNA Sequencing Data. <i>Cancers</i> , 2022, 14, 5713.	1.7	4
2359	Ferroptosis-related molecular patterns reveal immune escape, inflammatory development and lipid metabolism characteristics of the tumor microenvironment in acute myeloid leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
2361	Highly multiplexed spatial profiling with CODEX: bioinformatic analysis and application in human disease. <i>Seminars in Immunopathology</i> , 2023, 45, 145-157.	2.8	11
2362	The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
2363	Cuproptosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	4
2364	LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2365	Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis. <i>Current Oncology</i> , 2022, 29, 9172-9180.	0.9	0
2366	Higher thymocyte selection-associated high mobility group box (TOX) expression predicts poor prognosis in patients with ovarian cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
2367	Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
2368	Cancer associated fibroblast derived gene signature determines cancer subtypes and prognostic model construction in head and neck squamous cell carcinomas. <i>Cancer Medicine</i> , 0, , .	1.3	1
2369	A novel prognostic model for cutaneous melanoma based on an immune-related gene signature and clinical variables. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
2370	Advances in the Lung Cancer Immunotherapy Approaches. <i>Vaccines</i> , 2022, 10, 1963.	2.1	6
2371	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2023, 20, 133-157.	1.9	46
2372	Co-delivery of immunochemotherapeutic by classified targeting based on chitosan and cyclodextrin derivatives. <i>International Journal of Biological Macromolecules</i> , 2023, 226, 1396-1410.	3.6	3
2373	Experimental in vitro, ex vivo and in vivo models in prostate cancer research. <i>Nature Reviews Urology</i> , 2023, 20, 158-178.	1.9	11
2374	Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	1

#	ARTICLE	IF	CITATIONS
2375	Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	33
2376	PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2377	Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
2378	Recent Advances of Organ-on-a-Chip in Cancer Modeling Research. <i>Biosensors</i> , 2022, 12, 1045.	2.3	14
2380	Glimmers of hope for targeting oncogenic KRAS-G12D. <i>Cancer Gene Therapy</i> , 0, , .	2.2	1
2381	Lyophilization-inactivated cancer cells composited Janus scaffold for tumor postoperative immuno-chemotherapy. <i>Chemical Engineering Journal</i> , 2023, 455, 140619.	6.6	11
2382	Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model. <i>Science Advances</i> , 2022, 8, .	4.7	8
2383	Immunotherapeutic effects of intratumorally injected Zymosan-Adenovirus conjugates encoding constant active IRF3 in a melanoma mouse model. <i>Immunologic Research</i> , 2023, 71, 197-212.	1.3	1
2384	Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2386	Tumor Microenvironment-Activable Manganese-Boosted Catalytic Immunotherapy Combined with PD-1 Checkpoint Blockade. <i>ACS Nano</i> , 2022, 16, 20400-20418.	7.3	27
2387	Pheophorbide Aâ€‘Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PDâ€‘L1 Expression. <i>Pharmaceutics</i> , 2022, 14, 2513.	2.0	3
2388	An Apoptotic Bodyâ€‘based Vehicleâ€‘with Navigation for Photothermalâ€‘Immunotherapy by Precise Delivery and Tumor Microenvironment Regulation. <i>Advanced Functional Materials</i> , 2023, 33, .	7.8	18
2389	circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	7
2390	HNRNPC, a predictor of prognosis and immunotherapy response based on bioinformatics analysis, is related to proliferation and invasion of NSCLC cells. <i>Respiratory Research</i> , 2022, 23, .	1.4	4
2391	Harnessing the Potential of Plant Expression System towards the Production of Vaccines for the Prevention of Human Papillomavirus and Cervical Cancer. <i>Vaccines</i> , 2022, 10, 2064.	2.1	6
2392	Emerging Strategies of Engineering and Tracking Dendritic Cells for Cancer Immunotherapy. <i>ACS Applied Bio Materials</i> , 2023, 6, 24-43.	2.3	3
2393	Transcriptional upregulation of <scp>CXCL13</scp> is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma. <i>Cancer Medicine</i> , 2023, 12, 7639-7650.	1.3	3
2394	The Pan-Cancer Multi-Omics Landscape of FOXO Family Relevant to Clinical Outcome and Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15647.	1.8	24

#	ARTICLE	IF	CITATIONS
2395	High eukaryotic initiation factor 5A2 expression predicts poor prognosis and may participate in the SNHG16 / miR-10b-5p / EIF5A2 regulatory axis in head and neck squamous cell carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	0.9	1
2396	What Are the Roles of Proprotein Convertases in the Immune Escape of Tumors?. <i>Biomedicines</i> , 2022, 10, 3292.	1.4	5
2397	m6A RNA methylation regulators predict prognosis and indicate characteristics of tumour microenvironment infiltration in acute myeloid leukaemia. <i>Epigenetics</i> , 0, , 1-20.	1.3	2
2398	Surveying lncRNA-lncRNA cooperations reveals dominant effect on tumor immunity cross cancers. <i>Communications Biology</i> , 2022, 5, .	2.0	4
2399	Single-Cell RNA Sequencing Reveals Heterogeneity in the Tumor Microenvironment between Young-Onset and Old-Onset Colorectal Cancer. <i>Biomolecules</i> , 2022, 12, 1860.	1.8	2
2400	Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model. <i>International Immunopharmacology</i> , 2022, 113, 109470.	1.7	8
2401	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
2402	Cell surface nanotechnology for cancer targeting immunoregulation and precise immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	4
2403	Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF- β /IL-6 pathway in neuroblastoma. <i>OncImmunology</i> , 2022, 11, .	2.1	9
2404	Flexible Skin Patch Enabled Tumor Hybrid Thermophysical Therapy and Adaptive Antitumor Immune Response. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	7
2405	Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model. <i>Cancer Immunology Research</i> , 2023, 11, 217-227.	1.6	4
2406	A novel diagnostic model for predicting immune microenvironment subclass based on costimulatory molecules in lung squamous carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
2407	Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. <i>Cancers</i> , 2022, 14, 6146.	1.7	3
2408	Intratatumoral immune heterogeneity of prostate cancer characterized by typing and hub genes. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 101-112.	1.6	2
2409	Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2410	Environmental exposure and the role of AhR in the tumor microenvironment of breast cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
2411	Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2023, 29, 791-804.	3.2	8
2412	In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	2

#	ARTICLE	IF	CITATIONS
2413	Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2709-2734.	1.2	6
2414	Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment. <i>Current Oncology</i> , 2022, 29, 9833-9854.	0.9	1
2415	SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma. <i>Cells</i> , 2022, 11, 3997.	1.8	2
2416	Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer. <i>British Journal of Cancer</i> , 2023, 128, 568-575.	2.9	3
2417	Pan-cancer analysis identifies NT5E as a novel prognostic biomarker on cancer-associated fibroblasts associated with unique tumor microenvironment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2418	Radiosensitivity is associated with antitumor immunity in estrogen receptor-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 479-488.	1.1	2
2419	Effect of M2-like macrophages of the injured-kidney cortex on kidney cancer progression. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	3
2420	Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 6150.	1.7	3
2421	Microglia and Brain Macrophages as Drivers of Glioma Progression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15612.	1.8	9
2422	Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives. <i>Molecular Biology Reports</i> , 0, , .	1.0	0
2423	Engineered bacteria combined with doxorubicin nanoparticles suppress angiogenesis and metastasis in murine melanoma models. <i>Acta Biomaterialia</i> , 2023, 158, 734-746.	4.1	5
2424	Immunotherapy for Esophageal Cancer. , 2023, , 1-22.		0
2425	ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	0
2426	BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1603-1618.	2.0	6
2427	3D tumor explant as a novel platform to investigate therapeutic pathways and predictive biomarkers in cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2428	PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer. <i>Cancer Research</i> , 2023, 83, 568-581.	0.4	4
2429	Targeting macrophages: a novel treatment strategy in solid tumors. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	14
2430	Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy. <i>Nature Communications</i> , 2022, 13, .	5.8	16

#	ARTICLE	IF	CITATIONS
2431	Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer. <i>Cancer Science</i> , 2023, 114, 1256-1269.	1.7	6
2432	Elimination of 4T1 Mammary Tumor Cells by BALB/cBy UBC-GFP Transgenics following Stable Inheritance of the H-2b MHC Allele. <i>ImmunoHorizons</i> , 2023, 7, 64-70.	0.8	1
2433	Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. <i>Cancer Discovery</i> , 2023, 13, 278-297.	7.7	37
2434	Identifying Immune-Specific Subtypes of Adrenocortical Carcinoma Based on Immunogenomic Profiling. <i>Biomolecules</i> , 2023, 13, 104.	1.8	2
2436	Epigenetics and Metabolism Reprogramming Interplay into Glioblastoma: Novel Insights on Immunosuppressive Mechanisms. <i>Antioxidants</i> , 2023, 12, 220.	2.2	4
2437	Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
2438	Inflammatory Cellâ€Inspired Cascade Nanozyme Induces Intracellular Radical Storm for Enhanced Anticancer Therapy. <i>Small Methods</i> , 2023, 7, .	4.6	6
2439	Review of ferroptosis in colorectal cancer: Friends or foes?. <i>World Journal of Gastroenterology</i> , 0, 29, 469-486.	1.4	1
2440	Combining an adenovirus encoding human endostatin and PDâ€1 blockade enhanced antitumor immune activity. , 2023, 2, .		0
2441	Repurposing nitric oxide donating drugs in cancer therapy through immune modulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	8
2442	Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion. <i>Viruses</i> , 2023, 15, 176.	1.5	4
2443	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0
2444	Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2445	Single-cell RNA sequencing reveals the suppressive effect of PPP1R15A inhibitor Sephin1 in antitumor immunity. <i>IScience</i> , 2023, 26, 105954.	1.9	4
2447	Progress in the application of hydrogels in immunotherapy of gastrointestinal tumors. <i>Drug Delivery</i> , 2023, 30, .	2.5	5
2448	Remodeling the tumor immune microenvironment with oncolytic viruses expressing miRNAs. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2449	Targeted Degradation of PDâ€1 and Activation of the STING Pathway by Carbonâ€Based PROTACs for Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	27
2450	Pyroptosis Provides New Strategies for the Treatment of Cancer. <i>Journal of Cancer</i> , 2023, 14, 140-151.	1.2	12

#	ARTICLE	IF	CITATIONS
2451	Nano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy. <i>Small Methods</i> , 2023, 7, .	4.6	24
2452	Introduction to Tumor Microenvironment. , 2023, , 1-13.		0
2453	Selenadiazole derivative-loaded metal azolate frameworks facilitate NK cell immunotherapy by sensitizing tumor cells and shaping immuno-suppressive microenvironments. <i>Biomaterials Science</i> , 2023, 11, 1517-1529.	2.6	3
2456	PFKFB3 overexpression in monocytes of patients with colon but not rectal cancer programs pro-tumor macrophages and is indicative for higher risk of tumor relapse. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
2457	Editorial: Immune modulation in tumor microenvironment: New perspectives for cancer immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
2458	The mutation in splicing factor genes correlates with unfavorable prognosis, genomic instability, anti-tumor immunosuppression and increased immunotherapy response in pan-cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
2459	Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
2460	Dimorphic glioblastoma with glial and epithelioid phenotypes: Clonal evolution and immune selection. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
2461	Emerging Roles of Hedgehog Signaling in Cancer Immunity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1321.	1.8	8
2462	Thiolated Mesoporous Silica Nanoparticles as an Immunoadjuvant to Enhance Efficacy of Intravesical Chemotherapy for Bladder Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	8
2463	Guidelines for visualization and analysis of DC in tissues using multiparameter fluorescence microscopy imaging methods. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	9
2464	Targeted Degradation of PD-1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	1
2465	Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors. <i>Seminars in Immunopathology</i> , 0, , .	2.8	2
2466	New Tools for Lineage Tracing in Cancer In Vivo. <i>Annual Review of Cancer Biology</i> , 2023, 7, 111-129.	2.3	1
2467	Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	17
2468	Icariside II potentiates the anti-PD-1 antitumor effect by reducing chemotactic infiltration of myeloid-derived suppressor cells into the tumor microenvironment via ROS-mediated inactivation of the SRC/ERK/STAT3 signaling pathways. <i>Phytomedicine</i> , 2023, 110, 154638.	2.3	8
2469	Levels of pretreatment serum lipids predict responses to PD-1 inhibitor treatment in advanced intrahepatic cholangiocarcinoma. <i>International Immunopharmacology</i> , 2023, 115, 109687.	1.7	6
2470	Targeting Tumor-Associated Macrophages for Imaging. <i>Pharmaceutics</i> , 2023, 15, 144.	2.0	1

#	ARTICLE	IF	CITATIONS
2472	Histopathological Growth Pattern in Colorectal Liver Metastasis and The Tumor Immune Microenvironment. <i>Cancers</i> , 2023, 15, 181.	1.7	5
2473	5-Methylcytosine (m5C) Modification Patterns and Tumor Immune Infiltration Characteristics in Clear Cell Renal Cell Carcinoma. <i>Current Oncology</i> , 2023, 30, 559-574.	0.9	2
2474	Comparison of PD-L1 expression in squamous cell cancer of unknown primary and oropharyngeal squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 1991-1997.	0.8	2
2475	Emerging Role of Neutrophil Extracellular Traps in Gastrointestinal Tumors: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 334.	1.8	2
2476	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. <i>Clinics and Practice</i> , 2023, 13, 22-40.	0.6	14
2477	Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity. <i>ImmunoHorizons</i> , 2022, 6, 790-806.	0.8	0
2478	High SERPINH1 expression predicts poor prognosis in lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2022, 14, 4785-4802.	0.6	5
2479	Bioinformatics analysis of the correlation between m6A RNA methylation regulators and the immune infiltration and prognosis of bladder cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 1386-1386.	0.7	3
2480	Bioinformatics analysis identifies PSMB8 as a key gene in the cutaneous malignant melanoma tumor microenvironment. <i>Annals of Translational Medicine</i> , 2022, 10, 1354-1354.	0.7	0
2482	Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction. <i>Annals of Translational Medicine</i> , 2022, 10, 1379-1379.	0.7	0
2483	Deciphering Tumour Microenvironment of Liver Cancer through Deconvolution of Bulk RNA-Seq Data with Single-Cell Atlas. <i>Cancers</i> , 2023, 15, 153.	1.7	2
2484	Role of Noncoding RNAs in the Tumor Immune Microenvironment of Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	0
2485	HPV oncovirus: molecular biology and mechanism of action. , 2023, , 223-225.		0
2486	IFN γ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. <i>Nature Communications</i> , 2023, 14, .	5.8	12
2488	An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	3
2490	Epigenetic Perspective of Immunotherapy for Cancers. <i>Cells</i> , 2023, 12, 365.	1.8	4
2491	Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
2492	One-Dimensional Rod-like Tobacco Mosaic Virus Promotes Macrophage Polarization for a Tumor-Suppressive Microenvironment. <i>Nano Letters</i> , 2023, 23, 2056-2064.	4.5	4

#	ARTICLE	IF	CITATIONS
2493	In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	25
2494	Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. <i>Journal of Biomedical Science</i> , 2023, 30, .	2.6	7
2495	Tumor-infiltrating lymphocyte (TIL) therapy. , 2023, , 133-147.		0
2497	NKT cell: Success and promises in transplantation and immunotherapy. , 2023, , 385-401.		0
2498	Perspective Chapter: Critical Role of Hedgehog in Tumor Microenvironment. , 0, , .		0
2499	The Microbiome-TIME Axis: A Host of Possibilities. <i>Microorganisms</i> , 2023, 11, 288.	1.6	1
2500	Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. <i>Nature Communications</i> , 2023, 14, .	5.8	10
2501	Mechanisms driving the immunoregulatory function of cancer cells. <i>Nature Reviews Cancer</i> , 2023, 23, 193-215.	12.8	40
2502	Biomaterials tools to modulate the tumour microenvironment in immunotherapy. , 2023, 1, 125-138.		34
2503	Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	1
2504	Do macrophages follow the beat of circadian rhythm in TIME (Tumor Immune Microenvironment)??. <i>F1000Research</i> , 0, 12, 101.	0.8	0
2505	Predicting colorectal cancer microsatellite instability with a self-attention-enabled convolutional neural network. <i>Cell Reports Medicine</i> , 2023, 4, 100914.	3.3	4
2506	Nanotheranostics: The Afterglow for Cancer Immunotherapy. , 2023, , 1-43.		0
2507	Expression Pattern and Prognostic Value of Key Regulators for N7-methylguanosine RNA Modification in Prostate Cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, , .	0.9	0
2508	Advancing CAR T cell therapy through the use of multidimensional omics data. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 211-228.	12.5	30
2509	PD-1/PD-L1 and DNA Damage Response in Cancer. <i>Cells</i> , 2023, 12, 530.	1.8	12
2510	Research Progress of miRNA in Gastric Cancer and Colorectal Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 2866-2872.	0.0	0
2511	Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses. <i>Chemical Society Reviews</i> , 2023, 52, 2790-2832.	18.7	28

#	ARTICLE	IF	CITATIONS
2512	Role of Immune Cells in the Tumor Microenvironment. , 2023, , .		0
2513	Clinical Applications of Novel Delivery Routes of Immunotherapy Drugs and Vaccines. , 2023, , 1-25.		0
2514	Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma. Nature Communications, 2023, 14, .	5.8	8
2515	Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	6
2516	ZNF385A and ZNF346 Serve as Prognostic Biomarkers Associated with an Inflamed Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 3155.	1.8	3
2517	KLF4 loss in hepatocellular carcinoma: Improving prognostic prediction and correlating immune infiltrates. Frontiers in Genetics, 0, 14, .	1.1	0
2518	Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGASâ€“STING pathway. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6315-6328.	1.2	2
2519	Development of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes. Frontiers in Genetics, 0, 14, .	1.1	2
2520	Identification of fatty acid metabolism-based molecular subtypes and prognostic signature to predict immune landscape and guide clinical drug treatment in renal clear cell carcinoma. International Immunopharmacology, 2023, 116, 109735.	1.7	4
2521	An integrated bioinformatic analysis of bulk and single-cell sequencing clarifies immune microenvironment and metabolic profiles of lung adenocarcinoma to predict immunotherapy efficacy. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	4
2522	New Therapies on the Horizon. Hematology/Oncology Clinics of North America, 2023, , .	0.9	1
2523	3D cancer models: One step closer to in vitro human studies. Frontiers in Immunology, 0, 14, .	2.2	6
2524	Comprehensive analysis of novel cancer prediction genes and tumor microenvironment infiltration in colon cancer. Clinical and Translational Oncology, 0, , .	1.2	0
2525	Vaccination of TLR7/8 Agonistâ€“Conjugated Antigen Nanoparticles for Cancer Immunotherapy. Advanced Healthcare Materials, 2023, 12, .	3.9	5
2526	Deciphering the tumour immune microenvironment cell by cell. Immuno-Oncology Technology, 2023, 18, 100383.	0.2	1
2527	Engineered drug delivery nanosystems for tumor microenvironment normalization therapy. Nano Today, 2023, 49, 101766.	6.2	5
2528	Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
2529	B cells and tertiary lymphoid structures are associated with survival in papillary thyroid cancer. Journal of Endocrinological Investigation, 0, , .	1.8	1

#	ARTICLE	IF	CITATIONS
2530	Metabolic challenges and interventions in CAR T cell therapy. <i>Science Immunology</i> , 2023, 8, .	5.6	13
2531	Oncolytic virotherapy: basic principles, recent advances and future directions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	30
2532	Tumor tissue derived extracellular vesicles promote diabetic wound healing. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108435.	1.2	5
2533	ICI-based therapies: A new strategy for oral potentially malignant disorders. <i>Oral Oncology</i> , 2023, 140, 106388.	0.8	2
2534	Guanidine-modified nanoparticles as robust BTZ delivery carriers and activators of immune responses. <i>Journal of Controlled Release</i> , 2023, 357, 310-318.	4.8	4
2535	Nanomaterials-involved strategies for reversing the immunosuppressive factors and improving antitumor immunotherapy. <i>Nano Today</i> , 2023, 50, 101831.	6.2	4
2536	Immunosuppressive microenvironment improvement and treatment of aggressive malignancy pancreatic ductal adenocarcinoma based on local administration of injectable hydrogel. <i>Nano Today</i> , 2023, 50, 101832.	6.2	9
2537	An anisotropic photocatalytic agent elicits robust photoimmunotherapy through plasmonic catalysis-mediated tumor microenvironment modulation. <i>Nano Today</i> , 2023, 50, 101827.	6.2	4
2538	Nattokinase-Mediated Regulation of Tumor Physical Microenvironment to Enhance Chemotherapy, Radiotherapy, and CAR-T Therapy of Solid Tumor. <i>ACS Nano</i> , 2023, 17, 7475-7486.	7.3	7
2539	Sterol regulatory element binding transcription factor 1 promotes proliferation and migration in head and neck squamous cell carcinoma. <i>PeerJ</i> , 0, 11, e15203.	0.9	1
2540	The potential role of m6A modifications on immune cells and immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114343.	2.5	5
2545	Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. , 2022, , 1-34.		0
2546	Repeated activation of Trpv1-positive sensory neurons facilitates tumor growth associated with changes in tumor-infiltrating immune cells. <i>Biochemical and Biophysical Research Communications</i> , 2023, 648, 36-43.	1.0	2
2548	On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer. <i>Annual Review of Cancer Biology</i> , 2023, 7, 291-311.	2.3	5
2549	Engineered NanoAlum from aluminum turns cold tumor hot for potentiating cancer metalloimmunotherapy. <i>Journal of Controlled Release</i> , 2023, 354, 770-783.	4.8	9
2550	Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
2551	Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
2553	Single-cell spatial immune landscapes of primary and metastatic brain tumours. <i>Nature</i> , 2023, 614, 555-563.	13.7	80

#	ARTICLE	IF	CITATIONS
2554	Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity. , 2023, 11, e005545.		10
2555	Single-Cell Landscape Highlights Heterogenous Microenvironment, Novel Immune Reaction Patterns, Potential Biomarkers and Unique Therapeutic Strategies of Cervical Squamous Carcinoma, Human Papillomavirus-Associated (HPVA) and Non-HPVA Adenocarcinoma. Advanced Science, 2023, 10, .	5.6	6
2556	The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors. International Journal of Biological Sciences, 2023, 19, 1036-1048.	2.6	2
2557	Highly expressed CENPL is correlated with breast cancer cell proliferation and immune infiltration. Frontiers in Oncology, 0, 13, .	1.3	3
2559	Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images. Oncology Research, 2022, 30, 243-258.	0.6	0
2560	Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance. Cancers, 2023, 15, 971.	1.7	3
2561	Estimation of cell lineages in tumors from spatial transcriptomics data. Nature Communications, 2023, 14, .	5.8	12
2562	Therapeutic targeting of tumour myeloid cells. Nature Reviews Cancer, 2023, 23, 216-237.	12.8	49
2563	The potential role of the thymus in immunotherapies for acute myeloid leukemia. Frontiers in Immunology, 0, 14, .	2.2	4
2564	Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. , 2023, 11, e005691.		9
2565	Boosting Checkpoint Immunotherapy with Biomaterials. ACS Nano, 2023, 17, 3225-3258.	7.3	20
2566	Identification and Biological Validation of a Chemokine/Chemokine Receptor-Based Risk Model for Predicting Immunotherapeutic Response and Prognosis in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2023, 24, 3317.	1.8	0
2567	Identification of Gene Signature-Related Oxidative Stress for Predicting Prognosis of Colorectal Cancer. Oxidative Medicine and Cellular Longevity, 2023, 2023, 1-17.	1.9	1
2568	The oncogenic roles and clinical implications of YAP/TAZ in breast cancer. British Journal of Cancer, 2023, 128, 1611-1624.	2.9	13
2569	IL-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy. Journal of Clinical Investigation, 2023, 133, .	3.9	5
2570	The Landscape of Immunotherapy for Retroperitoneal Sarcoma. Current Oncology, 2023, 30, 2144-2158.	0.9	2
2571	Echinacea purpurea-derived homogeneous polysaccharide exerts anti-tumor efficacy via facilitating M1 macrophage polarization. Innovation(China), 2023, 4, 100391.	5.2	4
2572	Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 3441.	1.8	13

#	ARTICLE	IF	CITATIONS
2573	Harnessing Reconstructed Macrophage Modulation of Infiltration-Excluded Immune Microenvironments To Delineate Glioma Infiltrative Region. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 8811-8823.	4.0	3
2574	Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	19
2575	High-multiplex tissue imaging in routine pathology—are we there yet?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 801-812.	1.4	5
2576	Increased Early Cancer Diagnosis: Unveiling Immune-Cancer Biology to Explain Clinical “Overdiagnosis”. <i>Cancers</i> , 2023, 15, 1139.	1.7	1
2577	The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer—Challenges and opportunities. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	4
2578	Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3493.	1.8	4
2579	Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy. <i>Acta Biomaterialia</i> , 2023, 160, 239-251.	4.1	19
2580	Identification and characterization of a novel molecular classification incorporating oxidative stress and metabolism-related genes for stomach adenocarcinoma in the framework of predictive, preventive, and personalized medicine. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	8
2581	Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
2583	PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. <i>Cancer Letters</i> , 2023, 558, 216095.	3.2	11
2585	Tumor-Specific Photothermal-Therapy-Assisted Immunomodulation via Multiresponsive Adjuvant Nanoparticles. <i>Advanced Materials</i> , 2023, 35, .	11.1	13
2586	Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
2587	Towards multiomic analysis of oral mucosal pathologies. <i>Seminars in Immunopathology</i> , 0, , .	2.8	1
2588	Are charged particles a good match for combination with immunotherapy? Current knowledge and perspectives. <i>International Review of Cell and Molecular Biology</i> , 2023, , 1-36.	1.6	4
2589	Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3941.	1.8	14
2590	CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. <i>Science</i> , 2023, 379, .	6.0	26
2591	Preoperative Fibrinogen Albumin Ratio is an Effective Biomarker for Prognostic Evaluation of Gallbladder Carcinoma After Radical Resection: A 10-Year Retrospective Study at a Single Center. <i>Journal of Inflammation Research</i> , 0, Volume 16, 677-689.	1.6	0
2592	Effect of celecoxib plus standard chemotherapy on cancer prognosis: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	1.7	4

#	ARTICLE	IF	CITATIONS
2593	Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis. <i>Nature Communications</i> , 2023, 14, .	5.8	18
2594	Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
2596	Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. <i>Molecular Cancer</i> , 2023, 22, .	7.9	22
2598	Identification of potential tumor antigens and immune subtypes for lung adenocarcinoma. , 2023, 40, .		2
2599	The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. <i>JCI Insight</i> , 2023, 8, .	2.3	8
2600	Integrative Nomogram of Computed Tomography Radiomics, Clinical, and Tumor Immune Features for Analysis of Disease-Free Survival of NSCLC Patients with Surgery. <i>Journal of Oncology</i> , 2023, 2023, 1-14.	0.6	2
2601	Promises and challenges for targeting the immunological players in the tumor micro-environment â€“ Critical determinants for NP-based therapy. <i>OpenNano</i> , 2023, 10, 100134.	1.8	1
2602	RNA-Seq Analysis of Extradomain A and Extradomain B Fibronectin as Extracellular Matrix Markers for Cancer. <i>Cells</i> , 2023, 12, 685.	1.8	2
2603	Antigen discovery for the development of cancer immunotherapy. <i>Seminars in Immunology</i> , 2023, 66, 101733.	2.7	9
2604	Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. <i>Cancers</i> , 2023, 15, 1412.	1.7	5
2605	Clinical Relevance of Mortalin in Ovarian Cancer Patients. <i>Cells</i> , 2023, 12, 701.	1.8	0
2606	Development of in vitro laboratory models of the tumor immune microenvironment to evaluate quality parameters and specific efficacy of the dendritic cell vaccine. <i>Siberian Journal of Oncology</i> , 2023, 22, 82-94.	0.1	0
2607	Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
2608	Immunotherapy of Osteosarcoma. , 2023, , 1-39.		0
2609	Comparison of direct and indirect low-temperature plasma triggering immunogenic cell death in B16F10 melanoma. <i>Plasma Processes and Polymers</i> , 2023, 20, .	1.6	2
2610	Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. , 2023, 11, e006234.		10
2612	Single-cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophage-targeted strategy in multiple myeloma. <i>British Journal of Haematology</i> , 2023, 201, 917-934.	1.2	3
2613	Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
2614	Reconstituting Fundamentals of Bacteria Mediated Cancer Therapy On A Chip. , 2023, , .		0
2615	Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer. <i>Cancers</i> , 2023, 15, 1532.	1.7	6
2616	Functional states of myeloid cells in cancer. <i>Cancer Cell</i> , 2023, 41, 490-504.	7.7	29
2617	Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4786.	1.8	0
2618	CaCO ₃ based proton nanosponge to potentiate immune checkpoint blockade therapy by synergistically reversing tumor immunosuppression. <i>Chemical Engineering Journal</i> , 2023, 462, 142206.	6.6	6
2619	Seminoma subtypes differ in the organization and functional state of the immune microenvironment. <i>3 Biotech</i> , 2023, 13, .	1.1	5
2620	Tumor-Targeted nano-Adjuvants to synergize photomediated immunotherapy enhanced antitumor immunity. <i>View</i> , 2023, 4, .	2.7	15
2621	Characterization of immature ovarian teratomas through single-cell transcriptome. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
2622	N ⁶ -methyladenosine related gene expression signatures for predicting the overall survival and immune responses of patients with colorectal cancer. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
2623	Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. <i>Genome Medicine</i> , 2023, 15, .	3.6	23
2624	Tea Polyphenol Coordinated with Nanoparticles of ZIF-8 and Coated with Polydopamine and PEG for Immuno-Oncotherapy. <i>ACS Applied Nano Materials</i> , 2023, 6, 4379-4389.	2.4	4
2625	Cancer-associated fibroblasts: Is it a key to an intricate lock of tumorigenesis?. <i>Cell Biology International</i> , 2023, 47, 859-893.	1.4	3
2626	Combining chemotherapy with CAR-T cell therapy in treating solid tumors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10
2627	Introduction to Cancer Immunology. , 2023, , 1-29.		0
2628	Collectin-11 promotes cancer cell proliferation and tumor growth. <i>JCI Insight</i> , 2023, 8, .	2.3	4
2629	Development of an immune-related gene prognostic risk model and identification of an immune infiltration signature in the tumor microenvironment of colon cancer. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	2
2630	Immune microenvironment in high-grade serous ovarian carcinomas: association with molecular profiles and neoadjuvant therapy outcome. <i>Voprosy Onkologii</i> , 2023, 69, 74-81.	0.1	0
2632	A multidimensional pan-cancer analysis of <i>DCAF13</i> and its protumorigenic effect in lung adenocarcinoma. <i>FASEB Journal</i> , 2023, 37, .	0.2	1

#	ARTICLE	IF	CITATIONS
2633	Intercellular hif1 α reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	3
2634	Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. <i>Vaccines</i> , 2023, 11, 614.	2.1	4
2635	Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2023, 164, 1261-1278.	0.6	17
2636	Thermosusceptible Nitric-Oxide-Releasing Nitrogel for Strengthening Antitumor Immune Responses with Tumor Collagen Diminution and Deep Tissue Delivery during NIR Laser-Assisted Photoimmunotherapy. <i>ACS Applied Materials & Interfaces</i> , 0, , .	4.0	1
2637	The unfolding story of dying tumor cells during cancer treatment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
2638	The Roles of Secreted Wnt Ligands in Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5349.	1.8	5
2639	New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
2640	I kappa B kinase interacting protein as a promising biomarker in pan-cancer: A multi-omics analysis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
2641	High expression of centromere protein N as novel biomarkers for gastric adenocarcinoma. <i>Cancer Reports</i> , 2023, 6, .	0.6	1
2642	A Novel Fibromodulin Antagonist Peptide RP4 Exerts Antitumor Effects on Colorectal Cancer. <i>Pharmaceutics</i> , 2023, 15, 944.	2.0	4
2644	Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma. , 2023, 11, e006389.		2
2645	Integrative analysis revealed that distinct cuproptosis patterns reshaped tumor microenvironment and responses to immunotherapy of colorectal cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
2646	Deregulated bile acids may drive hepatocellular carcinoma metastasis by inducing an immunosuppressive microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2647	Development of stimuli responsive polymeric nanomedicines modulating tumor microenvironment for improved cancer therapy. <i>Medical Review</i> , 2023, 3, 4-30.	0.3	3
2648	Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
2649	Identifying ITGB2 as a Potential Prognostic Biomarker in Ovarian Cancer. <i>Diagnostics</i> , 2023, 13, 1169.	1.3	4
2650	Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2023, .	1.3	1
2651	Dual Axl/ MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer. <i>Head and Neck</i> , 2023, 45, 1255-1271.	0.9	0

#	ARTICLE	IF	CITATIONS
2652	A core-satellite micellar system against primary tumors and their lymphatic metastasis through modulation of fatty acid metabolism blockade and tumor-associated macrophages. <i>Nanoscale</i> , 2023, 15, 8320-8336.	2.8	2
2653	Therapeutic potential of <i>Clostridium butyricum</i> anticancer effects in colorectal cancer. <i>Gut Microbes</i> , 2023, 15, .	4.3	11
2654	Single-cell RNA analysis to identify five cytokines signaling in immune-related genes for melanoma survival prognosis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
2655	Neutrophil Extracellular Traps and Cancer: Trapping Our Attention with Their Involvement in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5995.	1.8	6
2656	Spatial proteomics of tumor microenvironments reveal why location matters. <i>Nature Immunology</i> , 2023, 24, 565-566.	7.0	0
2657	Heterostructural Nanoadjuvant CuSe/CoSe ₂ for Potentiating Ferroptosis and Photoimmunotherapy through Intratumoral Blocked Lactate Efflux. <i>Journal of the American Chemical Society</i> , 2023, 145, 7205-7217.	6.6	29
2658	Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. <i>Nature Cancer</i> , 2023, 4, 454-467.	5.7	15
2660	Chemotherapy-Sensitized <i>In Situ</i> Vaccination for Malignant Osteosarcoma Enabled by Bioinspired Calcium Phosphonate Nanoagents. <i>ACS Nano</i> , 2023, 17, 6247-6260.	7.3	4
2662	URB2 as an important marker for glioma prognosis and immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
2663	An Immune-Related Gene Signature for Determining Tumor Prognosis Based on Machine Learning. , 2023, , 1-18.		0
2664	Targeting adipocyte-immune cell crosstalk to control breast cancer progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
2665	High Expression Level of BRD4 Is Associated with a Poor Prognosis and Immune Infiltration in Esophageal Squamous Cell Carcinoma. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	1
2666	Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 7515-7527.	1.2	3
2667	Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. <i>Molecular Cancer</i> , 2023, 22, .	7.9	18
2668	Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma. <i>Cancer Biology and Medicine</i> , 2023, 20, 196-217.	1.4	2
2669	Fibroblasts as Turned Agents in Cancer Progression. <i>Cancers</i> , 2023, 15, 2014.	1.7	13
2670	Potential impact of platelet-to-lymphocyte ratio on prognosis in patients with colorectal cancer: A systematic review and meta-analysis. <i>Frontiers in Surgery</i> , 0, 10, .	0.6	1
2671	APC mutation correlated with poor response of immunotherapy in colon cancer. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	1

#	ARTICLE	IF	CITATIONS
2672	An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
2673	Spatial Transcriptomics in Inflammation: Dissecting the Immune Response in 3D in Complex Tissues. , 2023, , 243-279.		0
2674	RNF31 promotes tumorigenesis via inhibiting RIPK1 kinase-dependent apoptosis. <i>Oncogene</i> , 0, , .	2.6	1
2675	Inferring spatial transcriptomics markers from whole slide images to characterize metastasis-related spatial heterogeneity of colorectal tumors: A pilot study. <i>Journal of Pathology Informatics</i> , 2023, 14, 100308.	0.8	6
2676	Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Current Medical Science</i> , 0, , .	0.7	0
2677	Programmed Cell Death Ligand 1 Expression on Immune Cells and Survival in Patients With Nonmetastatic Head and Neck Cancer. <i>JAMA Network Open</i> , 2023, 6, e236324.	2.8	0
2678	Integrating single-cell and bulk RNA sequencing to develop a cancer-associated fibroblast-related signature for immune infiltration prediction and prognosis in lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2023, 15, 1406-1425.	0.6	6
2679	Hydrogel-enabled, local administration and combinatorial delivery of immunotherapies for cancer treatment. <i>Materials Today</i> , 2023, 65, 227-243.	8.3	9
2680	CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
2682	Integrative bioinformatics approaches to establish potential prognostic immune-related genes signature and drugs in the non-small cell lung cancer microenvironment. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
2683	<scp>COL19A1</scp> is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy. <i>Thoracic Cancer</i> , 2023, 14, 1294-1305.	0.8	2
2686	Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers. <i>Biomarkers</i> , 0, , 1-15.	0.9	1
2687	T _{STEM}-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	20
2689	C4orf47 is a Novel Prognostic Biomarker and Correlates with Infiltrating Immune Cells in Hepatocellular Carcinoma. <i>Biomedical Science Letters</i> , 2023, 29, 11-25.	0.0	3
2691	Tumor-Infiltrating B Lymphocytes: Promising Immunotherapeutic Targets for Primary Liver Cancer Treatment. <i>Cancers</i> , 2023, 15, 2182.	1.7	2
2692	Positron emission tomography imaging sheds new light on hypoxia and antitumor therapies. , 2023, 1, .		8
2693	In situ forming pH/ROS-responsive niche-like hydrogel for ultrasound-mediated multiple therapy in synergy with potentiating anti-tumor immunity. <i>Materials Today</i> , 2023, 65, 62-77.	8.3	16
2695	MYC activation impairs cell-intrinsic IFN γ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. <i>Cell Reports Medicine</i> , 2023, 4, 101006.	3.3	3

#	ARTICLE	IF	CITATIONS
2696	Light-activated arginine-rich peptide-modified nanoparticles for deep-penetrating chemo-photo-immunotherapy of solid tumor. <i>Nano Research</i> , 2023, 16, 9804-9814.	5.8	0
2697	The neural addiction of cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 317-334.	12.8	13
2698	Development of an antibody-ligand fusion protein scFvCD16A-sc4-1BBL in <i>Komagataella phaffii</i> with stimulatory activity for Natural Killer cells. <i>Microbial Cell Factories</i> , 2023, 22, .	1.9	0
2699	A tumor microenvironment-based prognostic index for osteosarcoma. <i>Journal of Biomedical Science</i> , 2023, 30, .	2.6	6
2700	Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?. <i>Cancers</i> , 2023, 15, 2273.	1.7	2
2701	Poly Ethylene Glycol (PEG)-Based Hydrogels for Drug Delivery in Cancer Therapy: A Comprehensive Review. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	18
2703	Investigation of Diagnostic and Prognostic Value of CLEC4M of Non-Small Cell Lung Carcinoma Associated with Immune Microenvironment. <i>International Journal of General Medicine</i> , 0, Volume 16, 1317-1332.	0.8	0
2704	New Treatment Options in Metastatic Pancreatic Cancer. <i>Cancers</i> , 2023, 15, 2327.	1.7	4
2706	Multi-View Radiomics Feature Fusion Reveals Distinct Immuno-Oncological Characteristics and Clinical Prognoses in Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 2338.	1.7	4
2707	Proteolytically degradable PEG hydrogel matrix mimicking tumor immune microenvironment for 3D co-culture of lung adenocarcinoma cells and macrophages. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2023, 34, 1981-1999.	1.9	1
2708	FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma. <i>Aging</i> , 0, , .	1.4	0
2709	Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. <i>Science Advances</i> , 2023, 9, .	4.7	9
2710	Epigenetic regulation of stem cells in lung cancer oncogenesis and therapy resistance. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	4
2711	Integrative learning in developing an immunologic lncRNA signature as a consensus risk-stratification tool for lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2023, .	0.6	0
2712	Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication. <i>Journal of Controlled Release</i> , 2023, 357, 460-471.	4.8	7
2714	Dissecting the single-cell transcriptome network of macrophage and identifies a signature to predict prognosis in lung adenocarcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 1351-1368.	2.1	2
2715	Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma. <i>Cancers</i> , 2023, 15, 2379.	1.7	4
2716	Six-Transmembrane Epithelial Antigen of Prostate 4: An Indicator of Prognosis and Tumor Immunity in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 643-658.	1.8	1

#	ARTICLE	IF	CITATIONS
2717	Innate lymphoid cells and innate-like T cells in cancer“ at the crossroads of innate and adaptive immunity. <i>Nature Reviews Cancer</i> , 2023, 23, 351-371.	12.8	15
2718	Uncover DNA damage and repair-related gene signature and risk score model for glioma. <i>Annals of Medicine</i> , 2023, 55, .	1.5	1
2719	Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2023, 396, 2427-2447.	1.4	1
2764	New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine. , 2023, 20, 739-776.		5
2770	The role of the complement system in cancer etiology and management. , 2024, , 41-60.e10.		0
2779	Armored modified vaccinia Ankara in cancer immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	0
2784	Tumor Microenvironment: a Therapeutic Aid in Cancer. <i>Indian Journal of Surgery</i> , 0, , .	0.2	1
2819	Next-generation deconvolution of transcriptomic data to investigate the tumor microenvironment. <i>International Review of Cell and Molecular Biology</i> , 2024, , 103-143.	1.6	1
2851	Probiotics Based Anticancer Immunity In Stomach Cancer. , 2023, , 162-188.		0
2870	Editorial: The immunosuppressive tumor microenvironment and strategies to revert its immune regulatory milieu for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
2894	Application of three-dimensional cell culture technology in screening anticancer drugs. <i>Biotechnology Letters</i> , 0, , .	1.1	0
2897	Roles of macrophages in tumor development: a spatiotemporal perspective. , 2023, 20, 983-992.		16
2918	Local Onco-Sphere: Tumor“Immune Cells Interactions. , 2023, , 51-76.		0
2924	Multiparametric analysis of tumor infiltrating lymphocytes in solid tumors. <i>Methods in Cell Biology</i> , 2023, , .	0.5	0
2929	Tumor-responsive dynamic nanoassemblies for boosted photoimmunotherapy. <i>Nano Research</i> , 2023, 16, 11125-11138.	5.8	0
2930	Neural Influence on Cancer Invasion and Metastasis. , 2023, , 51-68.		0
2939	Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 959-1020.	2.7	1
2957	Spatial transcriptomics in human biomedical research and clinical application. , 2023, 2, .		2

#	ARTICLE	IF	CITATIONS
2986	Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies. Lab on A Chip, 2023, 23, 3906-3935.	3.1	2
2999	Heterogeneity of the tumor immune microenvironment and clinical interventions. Frontiers of Medicine, 2023, 17, 617-648.	1.5	0
3031	(B)On(e)-cohistones and the epigenetic alterations at the root of bone cancer. Cell Death and Differentiation, 0, , .	5.0	0
3050	Cancer Immunotherapy. , 2023, , 121-154.		0
3069	The role of ion channels in the relationship between the immune system and cancer. Current Topics in Membranes, 2023, , .	0.5	0
3107	Advances in Local Ablative Techniques for Breast Cancer. , 2023, , .		0
3121	Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Experimental and Molecular Medicine, 2023, 55, 2308-2319.	3.2	2
3136	Development of nano-immunotherapy for cancer treatment: achievements and scopes. Journal of Pharmaceutical Investigation, 2023, 53, 827-844.	2.7	0
3137	Personalizing adjuvant therapy for patients with colorectal cancer. Nature Reviews Clinical Oncology, 2024, 21, 67-79.	12.5	1
3159	Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes. Naunyn-Schmiedeberg's Archives of Pharmacology, 0, , .	1.4	1
3161	Systemic Onco-sphere: Host Adaptive Immune System. , 2023, , 443-468.		0
3168	A Nanodroplet Probe with Magnetic Response for Acoustic Droplet Vaporization Therapy and Molecular Imaging Evaluation. , 2023, , .		0
3246	Understanding organotropism in cancer metastasis using microphysiological systems. Lab on A Chip, 2024, 24, 1542-1556.	3.1	0
3273	Immunomodulatory hydrogels. , 2024, , 241-267.		0
3275	Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition. , 2024, 41, .		0
3279	The role of stromal cells in epithelialâ€mesenchymal plasticity and its therapeutic potential. Discover Oncology, 2024, 15, .	0.8	0
3283	Fabrication of protein-based nanomaterials as photonanomedicine agents. , 2024, , 93-122.		0
3293	Silk protein: an emerging biomaterial for tumor modeling. , 2024, , 629-652.		0

#	ARTICLE	IF	CITATIONS
3299	Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies. <i>Oncology and Therapy</i> , 2024, 12, 31-55.	1.0	0
3308	SRSA-Net: Separable ResUnit and Self-attention Optimized Network for Simultaneous Nuclei Segmentation and Classification in Histology Images. <i>IFMBE Proceedings</i> , 2024, , 105-112.	0.2	0
3315	Interrogating the roles of lymph node metastasis in systemic immune surveillance. <i>Clinical and Experimental Metastasis</i> , 0, , .	1.7	0
3326	Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	0
3363	Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options. <i>Advances in Experimental Medicine and Biology</i> , 2024, , 221-242.	0.8	0